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Preface 
 
 
The use of biotechnology in agriculture is an important topic of research, as illustrated by a 
number of research reports from the AERU. Recent reports have presented findings from 
survey and focus-group research on New Zealanders’ perceptions and interpretations of 
applications of biotechnology. Prior research, such as that conducted for the Ministry for the 
Environment, focused specifically on the technology of genetic modification; several 
research reports have considered growers’ and consumers’ intentions regarding genetically 
modified products as well as potential trade impacts of adopting this technology. That 
research explored the potential or possible impacts of biotechnology on New Zealand and its 
agriculture: it was forward-looking. 
 
By contrast, this report is the result of a Government initiative to assess quantitatively the 
current economic contribution of biotechnology to primary sector industries in New Zealand. 
It was initially envisaged that a study would assess the current impacts of modern 
biotechnology across all the industries in the primary sector. After consideration of the 
breadth of technologies and the industries, this initial expectation was modified. The Steering 
Group for the project concluded that it would be preferable to measure the impact of a 
selection of biotechnologies across the primary sector in sufficient detail to inform policy 
development.  
 
This approach enables comparisons across industries in the primary sector and across specific 
biotechnologies. It is also conceptually simpler for non-specialists to engage with. While 
using a comprehensive ‘value chain’ approach is attractive to assess impacts, it then becomes 
difficult to determine the boundaries for the primary sector. Biotechnologies can and are 
being used at most stages of the chain and thus in areas, such as waste treatment, that are not 
normally considered as primary sector industries. This study has concentrated on use of 
biotechnologies only in production and early stage processing of primary products. Results 
should be of value to anyone concerned about or interested in the economic contribution of 
the modern use of biotechnology to New Zealand primary production. 
 
It must be emphasised that the naming of products or firms in this report is not intended as 
endorsement nor should it be construed as such. 
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Definition of Biotechnology 
 
 
The OECD defines biotechnology as the “application of scientific and engineering principles 
to the processing of materials by biological agents to provide goods and services” 
(Organisation for Economic Co-operation and Development, 2005). 
They provide an indicative, but not exhaustive, list of biotechnologies as an interpretative 
guideline: 
• DNA (the coding): genomics, pharmaco-genetics, gene probes, DNA 
sequencing/synthesis/amplification, genetic engineering; 
• Proteins and molecules (the functional blocks): protein/peptide sequencing/synthesis, 
lipid/protein glyco-engineering, proteomics, hormones, and growth factors, cell 
receptors/signalling/pheromones; 
• Cell and tissue culture and engineering: cell/tissue culture, tissue engineering, 
hybridisation, cellular fusion, vaccine/immune stimulants, embryo manipulation; 
• Process biotechnologies: bioreactors, fermentation, bioprocessing, bioleaching, bio-
pulping, bio-bleaching, biodesulphurization, bioremediation, and biofiltration; 
• Sub-cellular organisms: gene therapy, viral vectors; and 
• Other. 
Biotechnology might then be better described as a cluster of related technologies. Modern 
biotechnology is generally regarded as comprising techniques coming into widespread 
commercial usage after about 1980, when the understanding of biology was such that 
production processes could begin to use the smallest parts of organisms, their cells and 
biological molecules, in addition to using whole organisms. 
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Glossary of terms and abbreviations 
 
 
Biocontrol: Pest control by biological means. Any process using deliberately introduced 
living organisms to restrain the growth and development of other organisms, such as the 
introduction of predatory insects to control an insect pest (Zaid, Hughes, Porceddu, & 
Nicholas, 1999). 
CBA: cost-benefit analysis. 
Cell culture: The in vitro growth of cells isolated from multi-cellular organisms (Zaid et al., 
1999). 
Clone: 1. A group of cells or individual organisms that are genetically identical as a result of 
asexual reproduction, breeding of completely inbred organisms, or forming genetically 
identical organisms by nuclear transplantation. 2. Group of plants genetically identical in 
which all are derived from one selected individual by vegetative propagation. 3. Verb: to 
clone. To insert a DNA segment into a vector or host chromosome (Zaid et al., 1999). 
Clonal propagation: Asexual propagation of many new plants (ramets) from an individual 
(ortet); all have the same genotype (Zaid et al., 1999). 
Embryo culture: The culture of embryos on nutrient media (Zaid et al., 1999). 
Embryo rescue: A sequence of tissue culture techniques utilized to enable a fertilized 
immature embryo resulting from an interspecific cross to continue growth and development, 
until it can be regenerated into an adult plant (Zaid et al., 1999). 
Enzyme: A protein which, even in very low concentration, catalyses specific chemical 
reactions but is not used up in the reaction. Enzymes are classified into six major groups (1-
6), according to the type of reaction they catalyse: 1. oxidoreductases; 2. transferases; 3. 
hydrolases; 4. lyases; 5. isomerases; 6. ligases. Generally enzymes are named by the addition 
of the suffix -ase to the name of their substrate, and are classified by a standard numerical 
system: the Enzyme Commission (EC) number (Zaid et al., 1999). 
Gross margin: Total revenue less variable or operating expenses. When production changes, 
both revenue and variable expenses can change. Gross margin is used in this research to 
measure changes to net returns to producers after variable expenses. 
LTEM: Lincoln Trade and Environment Model, the trade model used in this research for 
analysing the trade impacts of biotechnology. 
MAF: Ministry of Agriculture and Forestry. 
Marker-assisted selection (Abbreviation: MAS). The use of DNA markers to improve 
response to selection in a population. The markers will be closely linked to one or more target 
loci, which may often be quantitative trait loci (QTL) (Zaid et al., 1999). 
MoRST: Ministry of Research, Science and Technology. 
Opportunity cost: The theoretical value of productive resources when used for some other 
(second-best) purpose. 
Protoplast fusion: The induced or spontaneous coalescence of two or more protoplasts (cells 
that have had their cell walls removed) of the same or different species origin. Where fused 
protoplasts can be regenerated into whole plants, the opportunity exists for the creation of 
novel genomic combinations (Zaid et al., 1999). 
QTL: Quantitative trait loci. A quantitative trait is a measurable trait that shows continuous 
variation (e.g. height, weight, colour intensity, etc.), so that the population cannot be 
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classified into a few discrete classes. A QTL is a locus where allelic variation is associated 
with variation in a quantitative trait (Zaid et al., 1999). 
Somatic cell embryogenesis: The process of differentiation of somatic embryos either from 
explant cells (direct embryogenesis), or from callus generated from explants (indirect 
embryogenesis) (Zaid et al., 1999). 
Somatic hybridization: Naturally occurring or induced fusion of somatic protoplasts or cells 
of two genetically different parents. The difference may be as wide as interspecific. Wide 
synthetic hybrids formed in this way (i.e. not via gametic fusion) are known as cybrids. Not 
all cybrids contain the full genetic information (nuclear and non-nuclear) of both parents 
(Zaid et al., 1999). 
Tetraploid: An organism, or a tissue whose cells contain four haploid sets of chromosomes 
(Zaid et al., 1999). 
Tissue culture: The in vitro culture of cells, tissues or organs in a nutrient medium under 
sterile conditions (Zaid et al., 1999). 
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Executive Summary 
 
 
Developments in biotechnology, that is, the use of biological systems, living organisms or 
parts of them to make or modify products or processes, have contributed significantly to New 
Zealand’s primary sector. The New Zealand economy is strongly reliant on its primary sector. 
The agribusiness and forestry sectors contribute an estimated 20 per cent of real GDP, 65 
percent of merchandise exports, and around 47 per cent of total exports. Key examples of 
biotechnology developed in NZ for the primary industry include marker assisted breeding to 
combat footrot in sheep, clonal propagation of pine trees, soil additives to eliminate nitrate 
leaching into rivers and lakes, and vaccines which increase lambing yield. 
 
Although the economic benefits to the primary sector of biotechnology are recognised, they 
have not to date been measured. This report begins to fill this gap in our understanding by 
estimating the economic contribution of biotechnology to the primary sector in New Zealand. 
 
The research focused on commercialised applications of four biotechnologies across the 
whole primary sector. Data were collected through surveying key informants about the 
production impacts of the technology, the available alternatives to biotechnological 
innovations, and the rates at which innovations had been adopted by primary producers.  
 
The major quantitative findings are given in the table below, which shows the contribution of 
each biotechnology under the assumption that prices for primary products remain constant. 
The total estimated net benefit of these innovations to the primary sector is currently $266 
million per year, assuming constant prices. Clonal propagation/cell manipulation represents 
the largest contributor to that total, by virtue of its widespread and relatively long-term use. 
Biocontrol agents had a smaller economic impact, and the impact of enzyme manipulation 
was smaller still. The least-commercialised biotechnology was marker-assisted selection, 
with only one innovation currently contributing to the economic performance of the primary 
sector at a value of less than one million dollars. 
 
The contribution of these biotechnologies to the different subsectors is also apparent in these 
calculations. Dairy production benefited the most from these innovations, even without 
calculations of the contributions from enzymes used in dairy processing. This result is not 
surprising, given that dairy production is the largest of the subsectors. Other pastoral 
agriculture also benefited, with impacts on sheep production larger than those on beef and 
veal production. The horticulture subsector showed significant benefits, with some crops 
heavily reliant on biotechnology and other barely affected. The dollar value of impacts in 
arable crops was relatively small, but this was a function of the size of the subsector. Finally, 
impacts were relatively small for forestry as only one of the biotechnologies had commercial 
application, and they were nil for seafood production. 
 
Estimates of the non-economic impacts were not possible. This research found that non-
economic benefits have in general not been specified or measured. While there were 
suggestions in the literature and in discussions with key informants about possible non-
economic benefits, such as environmental improvements, there is essentially no information 
about the exact impacts. If non-economic benefits are considered an important contribution of 
biotechnology, then this is clearly a significant gap in the research. 
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Additionally, the survey yielded qualitative findings, two of which are noted below. 
 
• The economic success of biotechnological innovations is not inevitable, but requires a 
combination of scientific expertise and commercial acumen. 
• Product development takes time, with present commercial applications typically being 
the result of long term research.  
 
 
The effect on prices for agricultural commodities and thus on the net contribution to the NZ 
economy was assessed with the Lincoln Trade and Environment Model (LTEM). Results 
suggested that if the innovations were adopted by all countries in the model, the direct 
economic impacts of biotechnology fell to about one-tenth of the original estimate as a result 
of lower prices for agricultural commodities. If, on the other hand, some innovations affected 
production only in New Zealand, the direct economic impacts were again reduced but were 
90 per cent of the original constant price estimate. 
 
The macroeconomic impact was estimated by calculating the indirect and induced impacts on 
the New Zealand economy, using the direct impacts described above. Thus the total annual 
value-added contribution of the four biotechnologies as applied in the primary sector (current 
year), is calculated to be $453 million, based on the constant price estimate. The two trade 
scenarios led to estimates of the macroeconomic impact of biotechnology of about ten per 
cent (Scenario 1) and about 90 per cent (Scenario 2) of the original constant price estimate. 
Summary of direct impacts of four biotechnologies 
Subsector 
Value of clonal 
propagation/ 
cell 
manipulation 
($000’s) 
Value of 
biocontrol 
agents 
($000’s) 
Value of 
enzyme 
manipulations 
($000’s) 
Value of 
marker 
assisted 
selection 
($000’s) 
Total 
($000’s) 
Dairy 74,914 19,893 3,791 nil 98,598 
Beef and veal 20,890 772 nil nil 21,662 
Sheep (meat 
and wool) 35,287 41,353 nil 770 77,410 
Forestry 16,976 nil nil nil 16,976 
Horticulture and 
floriculture 32,995 small value 9,960 nil 42,955 
Arable crops 8,220 nil nil nil 8,220 
Seafood nil nil nil nil nil 
Total 189,282 62,018 13,751 770 265,821 
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Further analysis of the agricultural sector revealed that the sector has seen significant 
increases in multifactor productivity over the last ten to 15 years. The productivity increases 
were much larger than the estimated impacts of the four biotechnologies. In this context of 
the trend output figure, the impacts of the four biotechnologies considered in this report have 
had a positive, but not dominant, role in the primary sector. 
 
The report also outlines several areas that would benefit from further investigation. One such 
area is a survey of biotechnologies and their uses across the whole New Zealand economy. A 
second area is the dairy industry, as the present research was unable to account fully for the 
uses and impacts of biotechnology in this industry. One topic that was found to be little-
understood was the economic value of non-marketed impacts of biotechnology. Finally, the 
present research did not examine proprietary control of technology or Intellectual Property 
Rights (IPRs), which are important in the development of innovations. 
 
 xx 
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Chapter 1  
Introduction: The Biotechnologies and Primary  
Commodities Investigated 
 
1.1 Introduction 
This study had two principal aims: 
 
• To develop and demonstrate robust and effective methodologies to assess the economic 
impact of biotechnologies in the primary sector in New Zealand, and 
• To measure the current economic impact of four selected biotechnologies to the New 
Zealand economy. 
 
The first aim was important to develop a method that could serve not only this research 
project but also future research. Using a common method for separate research projects allows 
the results to be compared directly, increasing the usefulness of both present and future 
results. 
 
This report thus presents not only the results of the research, but also detailed descriptions of 
the methodology. The first step was to define the biotechnologies to study and the boundaries 
of the primary sector. The next step, as discussed in Chapter 2, was to identify and interview 
key people throughout the biotechnology industry and the primary sector. The information 
they provided was the basis for a cost-benefit analysis, as reported in Chapter 4. The results of 
the cost-benefit analysis then in turn became inputs for two macro-economic analyses, the 
trade analysis reported in Chapter 5 and the domestic macro-economic analysis presented in 
Chapter 6. Using this process, the research identified the specific impacts of biotechnology on 
specific parts of the primary sector, and then aggregated those impacts to assess the overall 
effect on New Zealand trade and economic performance. 
 
The second aim was to quantify the economic impact of specific biotechnologies. In order to 
do this, several aspects of the research needed to be defined specifically. One aspect to define 
was the biotechnologies to study, which are described in the next section of this chapter. It is 
important to note that this study is not restricted to New Zealand discoveries or innovations. 
Instead it ignores the derivation of the technique or application, and concentrates on whether 
it is currently making a contribution to the New Zealand economy. A second aspect to define 
was the primary sector. This study concentrates on use of biotechnologies only in primary 
production and early-stage processing of primary products. For ease of research, the primary 
sector was divided into seven subsectors, which are also described below. 
 
Another aspect that required specific definition was the stage of commercialisation of the 
technique, process or application. Many firms and other organisations are involved in 
biotechnology at the research stage and/or have revenues from research contracts or 
technology licensing. For the present research, the biotechnology product or process needed 
to be commercially used in primary sector production. 
 
The rest of this introductory chapter describes and defines the key parameters of this study. It 
starts with descriptions of the four biotechnologies, and then goes on to descriptions of the 
subsectors in the primary sector in New Zealand. 
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1.2 Descriptions of the four biotechnologies 
 
Biotechnology is an example of a horizontal enabling technology (Ministry for Economic 
Development, 2003), a technology that may have wide application across many businesses 
and industries and may underpin a number of specific innovations. It is not itself one single 
technology, but a cluster of related technologies and techniques that may be applied to living 
organisms or their parts. This research examined specific technologies in order to understand 
better the impact of biotechnology as a whole. 
 
A key task was thus to choose a set of biotechnologies that were relevant to the primary sector 
in New Zealand and were also reasonably representative of the biotechnologies utilised. In the 
choice of specific biotechnologies, this research relied on expert advice to identify examples 
of biotechnologies that represent a range in terms of the length of time they have been used, 
the degree of specialisation in their use and the industries in which they are used. It was 
desirable to consider older, more established biotechnologies as well as newer ones, and to 
consider generic technologies that could enable many specific commercial innovations. The 
four biotechnologies chosen were: 
 
• Clonal propagation/cell manipulation, 
• Bio-control agents, 
• Enzyme manipulations, and 
• Marker-assisted selection. 
 
Technical terms used in these biotechnologies are defined according to the FAO Glossary of 
biotechnology for food and agriculture (Zaid et al., 1999) and are included in the glossary for 
this report. A brief description of each biotechnology follows. 
 
1.2.1 Clonal propagation/cell manipulation 
 
In vitro cell and tissue culture have many direct and indirect commercial applications. Among 
techniques used in plant breeding programmes and commercial production systems are 
meristem and bud culture, culture of cells, anthers, ovules and embryos, protoplast isolation 
and fusion, and cell selection. Applications of plant cell and tissue culture include: 
 
• Clonal propagation using meristem and shoot culture to produce large numbers of 
identical individuals; 
• Removal of viruses by heat treatment and propagation from meristematic tissues; 
• Doubling chromosome numbers of cells to enable wide crosses, to attain homozygous 
lines more rapidly in breeding programmes, or to produce polyploid plants for sale; 
• Crossing distantly related species, rescuing the embryo and regeneration of the novel 
hybrid; 
• Screening cells, rather than plants for advantageous characters; and 
• Growing plant cells in liquid culture as a source of secondary products. 
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1.2.2 Bio-control agents 
 
Biological control can be broadly classified into: 
• Conventional biocontrol of pest animals, weeds and diseases using the deliberate release 
of natural enemies, such as predators or parasites, into the environment; and 
• The production of bio pesticides derived from organisms, such as insecticides based the 
bacterium Bacillus thuringiensis. 
 
Effective biocontrol needs sufficient understanding of agro-ecological systems so that 
introduction of biocontrol agents can be successful. It also needs sufficient inoculum of the 
agent to attain control. Biotechnological techniques, particularly isolation and multiplication 
under sterile conditions, are important in producing quantities of some biocontrol agents, for 
example using fungal formulations for weed control or to control crop pathogens and using 
viruses and nematodes for insect control.  
 
Classical biocontrol was not included in the present research. Classical biocontrol seeks 
control of a pest at the ecosystem level and is therefore of general benefit to all primary sector 
producers1 (Auld, 1998). Classical biocontrol has been practiced for decades and does not 
necessarily include modern biotechnology. 
 
1.2.3 Enzyme manipulation 
 
Enzymes are proteins that can, at low concentrations, catalyse reactions. They are the basis of 
biological reactions and are ubiquitous in nature. Basic studies in cell biology have improved 
knowledge of enzyme properties so that now their activity can be harnessed to perform a 
number of functions, including some that were previously undertaken using harsh chemicals. 
 
Enzymes are being used internationally in a number of primary industries on farms and in 
processing in a huge range of activities including feed quality, waste management, food 
processing, textile manufacture and bleaching of wood pulp. 
 
1.2.4 Marker-assisted selection/breeding 
 
Selection to improve the performance of economically valuable species of animals and plants 
has been carried out for centuries on the basis of the phenotype or physical appearance of 
individuals. Marker-assisted selection (MAS) provides the possibility of selecting organisms 
according to their genotypes or genetic constitution. Genetic linkage maps can be used to 
locate genes, including those affecting quantitative traits of economic importance in plants or 
animals. By using molecular markers or identifiable DNA sequences closely linked to 
particular genes, or located within one or more QTL, information at the DNA-level can be 
used for early selection of organisms. This allows selection at the genotype level in a similar 
fashion for genes of major phenotypic effect. 
 
The potential benefits of MAS are greatest for traits that are difficult, time-consuming or 
expensive to measure or can only be measured after reproduction has been completed (Dreher 
et al., 2002; Hayes & Goddard, 2003; Moreau, Lemarie, Charcosset, & Gallais, 2000; 
Tartarini, 2003; Yu, Park, & Poysa, 2000). Mapping and MAS tend to be used mainly in 
                                                 
1 In the language of economists, classical biocontrol is a ‘public good’ (Auld, 1998). It is non-exclusive (specific 
individuals cannot be excluded from benefiting) and it is non-rival (the benefits that one individual receives are 
not reduced by the benefits that another individual receives). 
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species of high economic value and have most potential in clonal breeding programmes, 
where additional genetic gains can be rapidly multiplied. 
1.3 The New Zealand primary sector 
 
The primary sector is an important contributor to the New Zealand economy, both to Gross 
Domestic Product (GDP) and to export earnings. Together, agriculture and forestry contribute 
16 per cent of the country’s GDP (Ministry of Agriculture and Forestry (MAF), 2004c). An 
estimated 53 per cent of New Zealand merchandise exports are agricultural products, and 
forestry adds another 11 per cent to that number (Ministry of Agriculture and Forestry 
(MAF), 2004c). Given merchandise exports in 2003 of $28.2 billion (Statistics New Zealand, 
2004), seafood’s $1.2 billion (Ministry of Fisheries, 2004) accounts for 4.3 per cent of 
merchandise exports. The total contribution of the primary sector is thus 68 per cent of 
merchandise exports. 
 
The primary sector in New Zealand is not subsidised (Ministry of Agriculture and Forestry 
(MAF), 2004c), so that producers are directly tied to international markets. For this reason, 
exchanges rates can be an important determinant of revenues to the sector, regardless of other 
trends. This situation is in stark contrast with agriculture in other areas, such as the EU and 
the US, where New Zealand faces quotas, tariffs and duties on its exports. 
 
What follows is a brief description of several parts of the primary sector in New Zealand. The 
intent is to provide an indication of the magnitude of production and the relative sizes of 
different primary commodities. 
 
1.3.1 Dairy 
 
The dairy industry’s 12,000 milk suppliers and their 5.11 million dairy cattle produced 1.2 
billion kilograms of milksolids in the 2003/04 season (Ministry of Agriculture and Forestry 
(MAF), 2004c). About four per cent of production was used to produce fresh milk for the 
domestic market; the other 96 per cent was processed in milk powder, cheese, butter, casein, 
and other products. The dairy industry is centrally organised, with Fonterra processing 96 per 
cent of New Zealand’s milk. Over 90 per cent of milk products are exported, making the 
industry highly reliant on international markets. In addition, dairy products accounted for 20.3 
per cent of New Zealand’s merchandise exports in the year to June 2004, which amounted to 
$5.826 billion (Statistics New Zealand, 2004). 
 
1.3.2 Beef and veal 
 
According to MAF (2004c), the national beef cattle herd was 4.64 million head in 2004. 
Production of beef and veal is estimated in Chapter 4 of this report to be $1.30 billion per 
year. Of this amount, only about three per cent is veal (Ministry of Agriculture and Forestry 
(MAF), 2004c). Exports were 612,000 tonnes of meat, earning the country $1.92 billion. 
About one-half of that goes to the US, with South Korea, Japan and Taiwan the next most 
important export markets.  
 
1.3.3 Sheep 
 
In 2004, New Zealand had 39.7 million head of sheep. Meat production was 107,000 tonnes 
of mutton and 411,000 tonnes of lamb, carcass weight equivalent (cwe). Exports of mutton 
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were 87,900 tonnes cwe for earnings of $255 million, while exports of lamb were 358,000 
tonnes cwe or $1.97 billion. The EU imports about one-half of the total volume of meat 
exports, paying above average prices for it. The US market is growing, particularly after 
lifting the tariff rate quota (TRQ) in November 2001. 
 
Eighty per cent of New Zealand wool is produced along with meat from dual-purpose 
animals. Only about five per cent of the country’s wool is fine merino wool from specialty 
flocks. Production in 2004 was 165,000 tonnes of wool. Of this, 140,000 tonnes were 
exported for earnings of $740,000 million. The largest market for New Zealand wool is the 
People’s Republic of China (PRC), with the UK and Italy also significant importers. 
 
Statistics on this subsector were taken from MAF (2004c). Total value of production is 
estimated in Chapter 4 of this report at $2.8 billion. 
 
1.3.4 Forestry 
 
The forestry industry in New Zealand, including pulp and paper product manufacturing, 
accounted for 3.3 per cent of the New Zealand economy in 2004. Forestry exports represent 
ten per cent of New Zealand's total merchandise exports and were valued at NZ$3,226 million 
for the year ended March 2004. Approximately 90 per cent of the commercial forest in New 
Zealand is radiata pine (Ministry of Foreign Affairs and Trade, 2004)). 
 
Table 1.1  The forestry industry 
 2001 2002 2003 2004p 
Estimated roundwood removals from New 
Zealand forests (000 cubic metres)a 
(hectares)b 
19,287 
(46,700) 
20,940 
(49,400) 
22,451  
(50,300) 
20,888 
(n/a) 
Area planted (hectares)c 76,200 62,200 58,000 n/a 
Total Exports ($000)d 3,606,005 3,694,742 3,506,017 3,226,272 
Total output (GDP in 1995/1996 prices; 
million dollars))e 3,586 3,557 3,880 3,887 
-Forestry and logging 1,396 1,488 1,568 1,505 
-Wood and paper product manufacturing 2,190 2,069 2,312 2,382 
a  (Ministry of Agriculture and Forestry (MAF), 2004a) 
b (Statistics New Zealand, 2005a) 
c (Statistics New Zealand, 2005a) 
d Exports of Forestry Products from New Zealand for Years Ended 30 June 
(Ministry of Agriculture and Forestry (MAF), 2004b) 
e Gross Domestic Product by Industry, 1995/96 prices, year ended 31st of March (Statistics New Zealand, 2005b)
 
1.3.5 Horticulture 
 
The horticulture subsector, including floriculture, accounted for about $4.5 billion dollars in 
domestic spending and export revenues in 2002/03 (HortResearch, 2003). Of this total, about 
$2.1 billion is exported (Ministry of Agriculture and Forestry (MAF), 2003). Total area in 
horticulture in New Zealand is about 110,000 hectares, spread throughout the country. Major 
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crops by area in 2002 are wine grapes (17,500 ha), apples (12,500 ha), kiwifruit (12,200 ha), 
potatoes (10,600) and onions (5,680) (Burtt, 2004; Ministry of Agriculture and Forestry 
(MAF), 2003). The major exports are kiwifruit ($618 million), processed vegetables ($260 
million) and wine ($249 million) (Ministry of Agriculture and Forestry (MAF), 2003). The 
top markets for these exports are the EU, Japan and the US, with Japan an important market 
for flowers, onions and squash and the UK an important market for wine (HortResearch, 
2003). Floriculture accounts for about $40 to $50 million in exports per year, including 
orchids, callas, sandersonia, and proteacea (Ministry of Agriculture and Forestry (MAF), 
2003). Domestic sales of cut flowers are estimated to be $70 million (HortResearch, 2003). 
 
1.3.6 Arable crops 
 
The arable subsector contains a number of different crops. Statistics on production, prices and 
trends are provided in MAF’s Situation and outlook for New Zealand agriculture and forestry  
(2003). The cereal crops of barley, wheat and maize accounted for about 136,000 hectares in 
2003/04, with barley accounting for nearly half of that area. Cereal production amounted to 
about 856,000 tonnes in that year. Small seeds, such as ryegrass and clover seeds, are grown 
on about 33,000 hectares, and field peas account for another 10,000 hectares of production. A 
small but growing part of the arable subsector is vegetable seed growing, which earned $25 
million in 2003/04. Total exports of arable crops was $111 million, mainly grass seed, field 
peas, and vegetable seeds. Total production is estimated in Chapter 4 of this report at $389 
million. 
 
1.3.7 Seafood 
 
The seafood subsector is the purview of the Ministry of Fisheries, whose information 
(Ministry of Fisheries, 2004) forms the basis of the following industry description. Being an 
island nation, New Zealand has a large Exclusive Economic Zone (EEZ) from which to 
harvest seafood. The 1.3 million square nautical miles in the EEZ provide such economically 
important species as hoki, mussels, rock lobster, orange roughy, squid and snapper. Total 
annual harvest is approximately 750,000 tonnes of seafood, of which ten per cent to 15 per 
cent is produced through aquaculture. The Ministry reports that from 88 per cent to over 90 
per cent of the total harvest is exported, depending on prices in export markets. Exports in 
2003 were $1.2 billion, down from the $1.5 billion exported in 2002. The main export 
markets are the EU, the US and Japan. Domestic demand for seafood is a relatively constant 
$140 million per year. The industry has total direct employment of about 10,000 people, with 
employment concentrated in certain areas. 
 
1.3.8 Summary of primary sector 
 
The above description is summarised in Table 1.2. Each subsector is described by some 
indicator of physical production, by an estimate of the value of production, and by an estimate 
of the value of exports. These values are explained in the descriptions above or in the cost 
benefit analysis in Chapter 4. The values of production are indicative of the relative sizes of 
the subsectors, but are not directly comparable. They use data from different time periods 
between 2002 and 2004, and some are farmgate revenues while others are product sales. 
Nevertheless, they are useful for understanding the magnitude of the primary sector and its 
constituent parts. 
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Table 1.2  New Zealand’s primary sector 
Subsector Physical measure of production 
Value of 
productiona 
($ million) 
Value of  
exportsb 
($ million) 
Dairy 
5.11 million head, 
1.2 billion kgs of 
milksolids 
5,300 5,800 
Beef and veal 4.64 million head 1,300 1,900 
Sheep (meat & wool) 39.7 million head 2,800 3,000 
Horticulture 110,000 hectares 4,500 2,100 
Forestry 20,888,000 m3 3,900 3,200 
Arable over 179,000 hectares 389 111 
Seafood 750,000 tonnes 1,340 1,200 
a Figures for each subsector are not directly comparable with each other, but are only representative.
See text above for details. 
b Value of exports can exceed value of production due to processing of raw products. 
 
1.4 Conclusion 
 
The rest of this report is divided into several chapters. The next chapter describes the method 
for identifying key people in biotechnology and in the primary sector in order to gather 
information on uses of biotechnology in production. Chapter 3 presents qualitative 
information from the interviews, information that is important for understanding the impacts 
of biotechnological innovations but that was not part of the quantitative analysis. The 
quantitative analysis begins in Chapter 4, which provides estimates of the current economic 
impact of each innovation. Chapter 5 extends this analysis to include trade impacts, which can 
influence the prices the New Zealand producers receive for their products. The domestic 
macro-economic impacts are then analysed in Chapter 6. The final chapter summarises and 
concludes this report. 
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Chapter 2  
Method: Interviews with Key Informants 
 
2.1 Introduction 
This project assessed the economic impact of the current commercial use in the primary sector 
of biotechnology, broken down into four types. This information is not available in official 
statistics or from other sources, thus to obtain information on current biotechnology use, it 
was necessary to talk to people in biotechnology and primary production to get their views, 
opinions and experiences with biotechnology. They have the knowledge and experience to 
describe the current usage and impacts. These interviews are the first stage in the assessment 
of economic impacts of biotechnology.  
 
This chapter therefore describes the method used for the survey. It describes how the industry 
was scoped and how the key informants were identified. The chapter goes on to describe the 
economic information that was sought from key informants and the rationale for requesting 
information. It concludes with a discussion of the interviewing itself. 
 
2.2 Scoping the industry 
 
To obtain as complete a picture as possible of current use of biotechnology, it was important 
to gather information from a wide pool of informants. Biotechnology is commercialised 
through the efforts of research scientists, applied scientists, product developers and business 
people. Thus, this research identified potential key informants across science and industry to 
get as wide as possible coverage of the use of biotechnology. 
 
The first step in scoping the industry was to identify people and organisations involved in 
biotechnology and in the primary sector. A very good first source of information was the list 
of biotechnology firms and organisation that is maintained by New Zealand Trade & 
Enterprise on the New Zealand Biosphere Website (http://www.biospherenz.com/). This is a 
list of over 400 people, companies, organisations, and research institutions involved in 
agribiotechnology and biotechnology. MoRST also provided a list of potential key informants 
and the organisation to which they belong. These lists, along with Web searches, reviews of 
reports on the biotechnology sector in New Zealand, and researchers’ prior experience in this 
area formed the basis of the sample. Also added to this list were the key producer 
organisations in the primary sector. The list was circulated to people in MoRST, MAF, and 
Treasury to get feedback on its coverage and further people to contact. Finally, as key 
informants were interviewed, they often suggested other people, companies, or organisations 
to contact. The result of this process was a comprehensive list of contacts working in 
biotechnology as it relates to the primary sector, either as producers of biotechnology 
products or as their users in the primary industries. The full list of contacts contained names 
of 115 people in 78 organisations. 
 
Broadly speaking, key informants tended to fall into one of three groups. One group could 
explain the science involved and how the biotechnology contributed in a physical or scientific 
way. Another group could explain the specific commercial or economic benefit of specific 
biotechnologies. Often, these were informants involved in commercial firms. The third group 
provided context or overall industry information. 
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Over several iterations, this research created a comprehensive list of the primary-sector, 
commercial applications of the four biotechnologies in New Zealand. Products of 
biotechnology were identified based on several criteria. This research focused on commercial 
applications, uses of biotechnology that were used in production agriculture, forestry and 
fisheries. Products and processes were limited to the four biotechnologies describes above, 
and medical and human health products were not included in the analysis. Thus, the uses of 
biotechnology were identified across the primary sector, by the following subsectors: 
 
• Dairy, 
• Beef and veal, 
• Sheep (meat and wool), 
• Forestry, 
• Horticulture, 
• Arable crops, and 
• Seafood. 
 
2.3 Determining farm-gate economic impacts 
 
Once the use of biotechnology throughout the primary sector was scoped and the products and 
processes of biotechnology were identified, the next step was to determine their value. 
Researchers conducted interviews of key informants to determine the perceived economic 
contribution of the identified biotechnologies. 
 
This project is focused on benefits to the primary sector and thus on production impacts. The 
primary intent of the interviews was to understand the impacts at the level of the primary 
producer – the farm or similar production unit – and the changes to return at the farmgate. For 
each product or application the information needed to address four aspects that affect the 
impact the biotechnologies have on production: 
 
• Technology impact on product and production, 
• Adoption pattern, 
• Market characteristics, and 
• Upstream and downstream impacts. 
Each of these aspects is explained below. 
 
2.3.1 Technology impact on product and production 
 
A key factor of interest is whether biotechnology affects the quantity or quality of the primary 
product. If the biotechnology provides a productivity gain, its use leads to a cost-based 
competitive advantage. If the effect is on the product attributes, competitive advantage can be 
based on differentiation (Porter, 1991). The interviews thus sought to gather data on the 
following: 
 
• Productivity gain ($ per unit of output or per cent change) 
• Premium ($ per unit of output or per cent change) 
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The gains in productivity and/or premiums are of course the result of changes in production. 
Changes in production can impact in two major ways. Firstly any change will impact on the 
cost per unit of output through changes in direct variable inputs and yield, and secondly the 
changes can affect the configuration of input factors (Barney, 1986) and/or the activity 
structure (Porter, 1991) of the production. Changes in direct variable input, such as fertilisers 
or veterinary costs, are likely to have their major impacts on a particular step/part in the value 
system, e.g. on the farm, and thus are more easily obtained and quantified. Changes in 
resource configuration and/or activity structure are more likely to have larger down- and 
upstream impacts, as well as structural impacts on the industry. Assessing these types of 
impacts is more assumptions-based. 
 
Interviews thus raised a number of questions regarding the technologies, as listed below. 
 
• Does the technology affect the use of inputs? 
• What will be the technology fee, the cost to producers for using the technology? 
• How are capital costs, such as machinery costs, affected? For example, is new 
machinery required? 
• What will be the impact on labour? 
• Will changes in labour requirements affect labour availability – with it improve or 
exacerbate labour bottlenecks? 
 
2.3.2 Adoption pattern 
 
The extent of the economic impact of a biotechnology innovation is directly related to its 
uptake in the primary sector. Uptake can be influenced by many factors, most notably by 
expectations of the innovation’s profitability. Interviews thus sought to identify uptake rates, 
such as: 
 
• Percentage of producers or production volume or value using the innovation 
• Number of hectares affected by or incorporating the innovation 
• Uneven impacts of the innovation over the industry 
 
2.3.3 Characteristics of markets 
 
The relationship between the market and type of technology impact – productivity gains or 
quality gains – is a major determinant of the economic benefits to New Zealand. Prior 
research indicates that New Zealand benefits most either from technologies or techniques that 
affect product attributes or qualities, or from productivity increase that only New Zealand can 
adopt. Productivity gains may also be necessary for competitive parity in the main commodity 
markets. In markets where New Zealand has very low market share productivity, gains may 
be essential. Interviews thus sought to establish New Zealand’s position with to respect to the 
particular application. Key questions were: 
 
• What market share does NZ have, and how might this be affected? 
• What are NZ’s competitors doing, and what impacts could they have? 
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• What limits market access in a country: tariffs, quotas, tariff-rate quotas (TRQs), and 
non-tariff requirements such as technical barriers to trade? 
• What are practices overseas for producing these products? 
 
2.3.4 Upstream and downstream impacts 
 
Innovations in production systems can have simple effects, as in the case of substitution of 
one input for another, or complex effects that entirely change the methods of production. The 
more complex the effects on production of a specific commodity, the greater the ripple 
effects, both on upstream suppliers and on downstream purchasers and end-users. 
 
Key informants were surveyed about the impacts of biotechnology products on production 
processes, with particular attention to these upstream and downstream impacts. Some of the 
information collected was: 
 
• Do biotechnology products directly substitute for other inputs? 
• How has the use of other inputs changed? 
• Do production processes need to change in order to use biotechnology products? 
• Has the use of biotechnology products led to spontaneous production changes? 
• How have purchasers reacted to the use of biotechnology? 
• Have purchasers or end-users noticed any difference in the primary product? 
• Have there been any market changes or price changes as a result? 
 
2.3.5 Developing the counterfactual 
 
A key consideration in the research was the counterfactual. This is the situation that would 
have prevailed in the absence of the biotechnological innovation. To gather information about 
the possible counterfactual, key informants were asked how production might occur if the 
innovation had not been developed. The idea and impact of the counterfactual will be 
described in more detail in Chapter 4 as part of the methodology for economic valuation. In 
order to gather the information for developing these counterfactuals, key informants were 
asked about the following: 
 
• How has biotechnology changed production? 
• How would production happen without biotechnology? 
• Are there alternative methods of production in use today? 
• Are alternative methods possible, and how would they work? 
 
2.4 Survey administration 
 
The considerations described above guided the development of a survey instrument. A further 
consideration was the necessity of approaching industry and research contacts without 
preconceived notion of the products and processes in use in the primary sector or their 
contributions to economic performance. Informants could and did provide unexpected 
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information and insights. The interview format therefore needed to be fairly flexible to allow 
for a range of responses.  
 
Because this research was as concerned with scoping impacts of biotechnology as it was with 
gathering specific economic data, the survey was a series of semi-structured interviews. The 
interviewees are listed in Appendix 1. The survey instrument served as ‘talking points’ to 
guide interviews, and also served as a reminder to researchers of the main information needed 
for the later analysis. For this research, it was more important to understand the context of 
each specific example of biotechnology, where each company was in the process of 
commercialisation, and how the key informant saw the economic impacts, than it was to fill in 
boxes on a form. The questionnaire is contained in Appendix 2. 
 
Interviews took place in April, May and June 2005 and took many forms. Some were face-to-
face meetings with people who collectively gave many hours of their time to inform the 
research about their products and their uses of biotechnology. Some were telephone 
interviews of various lengths, some quite short and others lasting up to an hour. Email was 
also used to contact people and to provide them with background information. Some key 
informants also provided answers to research questions via emails, so that entire interviews 
took place on-line. Many people had pre-prepared documents – articles, reports, brochures, 
analyses – and generously provided these. All of this information was combined to produce 
the estimates of economic impact developed below. 
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Chapter 3  
Qualitative Results of Survey 
 
3.1 Introduction 
The semi-structured nature of discussion with key informants meant that they provided 
researchers with much more than the figures used to calculate economic impacts. Many 
informants were very generous with their time and were only too happy to explain how their 
innovations were developed, how they have been commercialised in the primary sector, what 
some of the issues were in development or marketing, and what their plans were for future 
changes. 
 
To make this information available, this chapter organises and summarises qualitative results 
from the survey. This discussion establishes the context for the next chapter, which provides 
the calculations of economic impacts. Although the main goal of this research was 
establishing the economic value of current commercial applications of selected 
biotechnologies, these qualitative results form an important part of the research output. 
 
These results and a discussion of them are organised into a three topics. The first topic is a 
summary of the use of these four biotechnologies in the primary sector, and includes a 
discussion of an important issue: the nil results. Many times in exploring a technology or a 
subsector, no commercial benefits had yet been realised. The second topic is 
commercialisation of biotechnology: what leads to success? Many informants, some with 
highly successful products and others who were still yet to commercialise the technology, had 
strong views on this topic. The third topic is the embeddedness of these biotechnologies, 
which affects both their use and the estimation of economic values. 
 
3.2 Use of the four biotechnologies 
 
The innovations identified in this research affected both the efficiency of production and the 
qualities of the products produced. Particularly in livestock, the innovations that generated the 
greatest return were input-oriented. These innovations changed an input to make production 
better, but left the final product unchanged. Other innovations were output-oriented and 
changed the final product; these were more common in arable and vegetable crops. 
 
Where there have been product improvements, the value of the improvements is sometimes 
uncertain. A good example is crop improvements in wheat. Wheat breeding programmes have 
worked to improve the milling quality of New Zealand wheat. The economic value of these 
traits and the extent to which the value can be attributed to biotechnology are both uncertain. 
 
The four biotechnologies have had quite different impacts on the primary sector. Clonal 
propagation/cell manipulation (a set of techniques that are core to plant breeding 
programmes) has had by far the largest economic impact. However, their impact can only be 
measured at the level of a crop, rather than on a cultivar-by-cultivar basis. Furthermore, the 
value of these techniques comes from the steady improvement to primary sector performance 
over time. The use of biocontrol agents is much more on a case-by-case basis. This is a much 
newer field, thus represented by specific products in this category. Biocontrol agents are also 
an additional input to a production system, whereas clonal propagation/cell manipulation 
change an input – the seed used – but are not itself a separate input. Valuation of biocontrol 
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agents was therefore valued here through a case study approach. Enzyme manipulations are 
little used in producing raw products, being much more important in transforming raw goods 
into products for retail sale. In that context, enzyme use is extensive but its valuation 
sometimes beyond the scope of this project. Finally, marker-assisted breeding is another 
technology with wide application across the primary sector. However, it has produced few 
commercial products. Thus, although it is subject of research, the value of this technology so 
far is represented by a few discrete products. 
 
There are three issues that are treated separately as important issues regarding the use of 
biotechnology. These are: the nil results, the extent of contributions of biotechnology, and the 
value of innovations. 
 
3.2.1 Nil results 
 
An important qualitative result of this study was what is referred to here as the nil results. 
These are biotechnologies which did not currently yield significant commercialised returns 
and were still under development or yielding only small revenues. This was often to the 
surprise of not only researchers but also those involved in the sector.  
 
The nil results are important for two reasons. First, this report can be seen as establishing a 
baseline for the economic impact of the four biotechnologies. Whilst of course those 
technologies yielding positive returns are vital for this baseline so are those which do not. 
Future research may be able to use these results as a baseline against which to measure 
progress towards commercialisation. The second reason that these nil results are important is 
that they provide important information to the sector as well as policy makers. Many people 
who seemed to be well informed about the biotechnology sector were not fully aware of 
which companies had actual sales of commercial products and which were surviving but still 
had products yet to be commercialised. 
 
Of the four biotechnology types used in this report the most significant giving nil results was 
marker-assisted breeding. This biotechnology has been described for years as the way of the 
future, the approach to breeding that will allow precise selection of desirable traits and 
introduction of new varieties in a fraction of the time that traditional breeding requires. 
However, key informants only identified three examples of commercialised marker-assisted 
breeding in the primary sector in New Zealand. Two are for sheep, and only one of these is 
currently boosting production (the other is too new to have had an impact). The third, a 
disease-resistant field pea, may be producing benefits in New Zealand, but the scale of the 
benefits was entirely unclear. For other arable crops, vegetables crops, fruit growing, dairy 
and meat cattle, etc., marker-assisted breeding has not yet increased production or improved 
products. 
 
Two subsectors also produced nil results. The seafood industry was not using any of the four 
biotechnologies in production. In part, this nil result came from the boundaries of the project. 
The industry used enzymes to produce processed seafood products and also used them to 
clean equipment, but these uses were not considered directly involved with production. None 
of the other biotechnologies was applied to the seafood sector. The other subsector was ‘new 
industries’, a loose category that was expected to contain residual innovations that could not 
be otherwise categorised. In fact, there were no such innovations. Activities that are typically 
included under ‘new industries’, such as biofuels, were heavily dependent on technologies 
and production processes that are not biotechnology. 
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The intent of this research was to identify and evaluate biotechnological innovations. 
Researchers thus did not give up searching for examples the first time a key informant said 
that a biotechnology was not used in a specific subsector. Multiple informants were 
interviewed for each subsector and each technology, and areas in which nil results were 
identified were probed even more. Some informants were contacted more than once, just to be 
certain of the information they had provided. These nil results do not demonstrate a lack of 
evidence of commercialised products, but rather evidence that commercial products based on 
these biotechnologies are not in use in certain subsectors. 
 
3.2.2 Extent of contributions of biotechnology 
 
As stated above some of the four biotechnologies have had marginal impacts on primary 
production. This statement is not meant to disparage the contributions of biotechnology and 
the obvious gains that have been made, as the following sections will show. However, the 
qualitative survey results did stress the importance of other factors in increasing returns from 
the primary sector. These factors include natural resources – land, fresh water, marine 
environments – in combination with management effort, human labour, and machinery. A 
significant proportion of the growth in the primary sector has been by adding more of these 
inputs, as when irrigation is added to land, and by being more efficient in their use, as when 
information and experience improve farm management. Thus the current use of 
biotechnologies has tended to make improvements at the margin. 
 
Nowhere is this more apparent than with biocontrol agents. It is perhaps the nature of such 
products that they contribute only at the margin. It seemed particularly true of the biocontrol 
agents identified in this research. They seemed to contribute a bit per hectare or a bit to 
overall production, but in many instances the contribution was hardly measurable. 
 
A further reason for the marginal nature of biotechnology is the volatile nature of primary 
production. A good example comes from the apple industry. Although the industry uses an 
integrated pest management programme that makes use of bioinsecticides and biocontrol 
agents, their impact was overwhelmed by trade patterns, exchange rate fluctuations, and 
market trends in the industry. Disentangling the impacts of what amounts to a minor input to 
production from all the other factors affecting the industry was not possible given information 
available; in any case, these impacts were highly unlikely to be significant. 
 
3.2.3 Value of innovations 
 
In general, few respondents knew about the value of specific biotechnological innovations. 
For many innovations, it seemed that commercial considerations were minor factors in the 
process of commercialisation. Biotechnology research appeared to focus on problems that 
could be solved, rather than examining whether the problems were worth solving from a 
financial point of view. This was of course not universally true. Many key informants could 
provide detailed information about production impacts and their values.  
 
As a result of this focus on the technically possible, an innovation might be quite effective 
against a specific pest or disease. It could be difficult to determine, however, the extent of that 
pest or disease in New Zealand. The economic benefit might not be immediately clear or 
readily available, and instead further research was required to uncover exactly what the 
economic impacts were. 
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It was also difficult to obtain from respondents what the alternatives were in the absence of 
the biotechnology, information important to assess correctly the economic value. Again, an 
innovation might be effective, but consideration was not always given to alternative methods 
or inputs that could yield similar results. From an economic point of view, allocating 
resources amongst competing uses is a key consideration. Thus, a central question always is, 
‘what is the alternative?’ 
This research bridged these gaps by examining the specific innovations, the economic value 
of the ‘problem’ they solved, and the possible alternative solutions. 
 
3.3 Commercialisation of biotechnology 
 
In the interviews with key informants from firms that were selling the products of 
biotechnology, one of the main topics of discussion was the commercialisation process. 
Commercialisation was discussed as a difficult, uncertain affair that required proper 
management; it did not just happen. Because the same ideas came up in several discussions, 
they are highlighted here. 
 
Many key informants drew distinctions between the fundamental science of biotechnology, 
biology and agricultural production on the one hand, and commercial application of this 
knowledge on the other. Fundamental scientific research is increasing knowledge of the 
biology of plants and animals, often in the context of agriculture. It is also creating technically 
feasible applications of biotechnology. Although such research expands scientific 
understanding, it is not the same as creating commercially viable applications of 
biotechnology. 
 
One element of the difference between the two that was apparent from this research was the 
tremendous time lag between the initial scientific findings and their eventual commercial 
applications. In conversation, one person involved with biocontrol agents mentioned that the 
initial discovery underpinning the Ballance grass grub biocontrol agent was 40 years old. 
Similarly, the AR1 ryegrass has been on the market for about three years, but it was the result 
of initial observations about ryegrass staggers that were made in 1980. 
 
Another element that was important in converting the fundamental science into 
commercialised innovations was the mechanism for delivering the innovation to users. For 
many innovations, this is a minor issue. Breeding programmes that introduced improved traits 
into plants still deliver those traits via seeds and seedlings that are similar to the non-
improved seeds and seedlings. The biotechnology, in those cases, happens in the background. 
For other innovations, there is some change to the production process. Providing the 
innovation in a convenient package is important for successful commercialisation. For 
example, eco-n from Ravensdown requires specialised equipment for its application. The 
company charges a per-hectare price for the product that includes application costs. Thus, 
rather than expecting farmers to obtain new, specialised equipment, the company provides an 
easy-to-use package. 
 
A further aspect of commercialisation that arose in interviews was the importance of 
involving commercially-minded people in the process. The technical or scientific performance 
of an innovation is only one consideration. It is not enough to demonstrate that, for example, a 
vaccine is effective against a specific pathogen. It is also important to demonstrate the value 
of the innovation to primary production. For successful commercialisation, end users need to 
perceive that the innovation will improve the performance of the farm, forest or marine 
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enterprise. ‘Selling’ the innovation to end users requires that sales and marketing staff are 
involved in the commercialisation process. 
 
The other side of the commercial transaction is the biotechnology firm’s revenues. For the 
viability of these firms and the continued income stream that can finance further 
commercialisation, biotechnology firms need to be recompensed appropriately for the 
innovations they provide. The present research focused on the value of biotechnology 
innovations to the primary sector. Because this value is net of any direct technology payments 
(such as increased seed prices or costs of vaccines), this value represents potential revenues 
for biotechnology firms. If biotechnology firms are to capture enough of the extra value that 
their innovations produce to remain viable, then they need smart sales and marketing 
personnel who understand the value proposition of their innovations. 
 
Biotechnological innovations produce extra sales revenue for the primary sector. These extra 
gross revenues are then split between the firm that provides the innovation and the primary 
sector itself. This element of innovation produces an important tension between cooperation 
and proprietary control of the technology. Cooperation between the government, CRIs, 
innovating firms, and primary producers can lead to impressive gains for the primary sector. 
Given the expense of research and the long lead times required for commercialisation, 
cooperation can be invaluable for producing innovations. The gains from an innovation are 
spread throughout the sector and across all the organisations involved in innovating. Thus, 
total gains might be large, but gains to any one person or organisation are likely to be 
proportionally small. Proprietary control of technology, on the other hand, can be quite 
important for stimulating private firms to pursue innovations. Unless these firms can be 
assured that they own the rights to the innovations and its profits, they may be unwilling to 
invest the funds necessary to convert the fundamental science into a commercial product. 
However, while proprietary control increases the returns to the individual firm, it can ration 
use of an innovation, limiting its uptake in the primary sector. It can also reduce the net value 
of an innovation to an individual farmer, forester or fisher. There is thus a fundamental 
tension between the economic interests of the primary sector and those of biotechnology 
firms. 
 
This research did not attempt to assess the economic value of proprietary control of 
technology. First and foremost, the topic was not in the brief for the project. Secondly, the 
available resources were insufficient for the additional research required to do justice to the 
topic. Intellectual Property Rights (IPRs) are an important consideration for biotechnology 
firms and for international trade relations, and there is a significant and complex body of 
literature considering the impacts of IPRs. The current research focuses on impacts on the 
primary sector; further research will be required to consider impacts on the producers of 
biotechnology. 
 
3.4 Embeddedness of biotechnology 
 
A final recurring theme from the interviews was how the four biotechnologies were 
embedded in primary production. This embeddedness took several specific forms. 
 
One symptom of the embeddedness was that some key informants were unsure of the 
technical details of the use of biotechnology in producing specific innovations. For example, 
tissue culture is widely used in plant breeding, but there was no information available on 
which cultivars had been produced using tissue culture or whether it had been used for 
specific cultivars or traits. There was even the occasional difference of opinion between key 
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informants over whether biotechnology had been used at all in producing a specific 
innovation. Thus, some of these techniques are so ubiquitous and even taken for granted that 
their use is hardly noticed. 
 
Biotechnological innovations do not occur in a vacuum. The environment in which these 
innovations occur can be divided into the physical environment and the technological 
environment. The physical environment is an important consideration because the 
environment factors that currently affect agricultural production are different from the factors 
that affected production in years past. The pressures from pathogens are different, and 
biotechnology has bred crops in response to these evolving pressures. In determining the 
economic value of biotechnology, this research needed to examine how production would 
occur in the absence of biotechnology. This is not a simple case of taking 40-year-old 
cultivars and dropping then into the modern environment, however, because the environment 
has changed. A key question that arose in the research is whether plant breeding could have 
responded as successfully to evolving pressures if it had not had these biotechnologies. 
 
The other environment in which biotechnology innovations are developed and 
commercialised is the technological environment. Biotechnology, particular when it is defined 
as four specific biotechnologies, is one element in a larger picture of technological and 
scientific development. For example, producing more raw milk on more efficient dairy farms 
is of little use if that milk cannot be shipped to a processing plant and then exported overseas 
as butter or milk powder. One specific example that demonstrates the dependence of 
successful commercialisation of one innovation on a suite of developments is the experience 
of AgVax with its ToxoVax vaccine. The vaccine reduces the incidence of spontaneous 
abortion in sheep. AgVax found that the increased use of scanning for sheep increased 
demand for their product. With scanning, sheep farmers gained information about the number 
of pregnancies and therefore the expected number of lambs. When farmers discovered that 
they had fewer live lambs than they expected from scanning results, they had an indication of 
the incidence of abortions. This information then created greater demand for a product that 
reduced abortions. 
 
3.5 Conclusion 
 
The discussions with key informants yielded valuable insights beyond the dollars-and-cents 
information that was required for the economic valuation described in the next chapter. They 
provided important information on the development of commercialised biotechnological 
innovations. In particular, they emphasised that individual innovations are the products of 
long-term, fundamental research. The nil results discussed above can easily be viewed in this 
context: the fundamental science is being worked out but there is still work to be done before 
it yields commercial innovations. The scientific success of the research is only one element. 
Commercialisation is the result of a combination of technology, science, and management 
producing usable, convenient innovations within the context of an industry or a production 
system. Furthermore, profiting from commercialisation requires business expertise, such as 
marketing, sales and farm management, in addition to technological proficiency. 
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Chapter 4  
Quantitative Analysis of Survey Results 
 
4.1 Introduction 
This chapter firstly outlines the method used to calculate the economic benefits of the current 
biotechnology, by sector or case study as appropriate, and then reports the actual calculations 
of these costs and benefits. A key output of this research is an estimate of the economic 
contribution of biotechnology to the primary sector in New Zealand. Such an estimate is not 
readily available from prior research on agricultural productivity or biotechnology. The 
question of the impact of biotechnology on the primary sector has been examined in several 
ways, but an estimate of its annual financial contribution to the primary sector has not been 
made. 
 
The estimates provided here rely on important considerations of the types of impacts that 
biotechnology can have. As has been recognised elsewhere, different biotechnology 
applications have different types of impacts. As such, these impacts need to be carefully 
assessed in order to evaluate their economic benefit to the primary sector. The 
biotechnologies identified in this research demonstrate some of these different types of 
impacts. This chapter therefore builds upon Chapter 3 in discussing the different potential 
impacts, the appropriate methods for determining their economic values and then estimating 
the net benefit to the primary sector. 
 
The first section of this chapter provides a brief discussion of Cost Benefit Analysis (CBA) 
methodology and its application in this research. The second section combines information 
from the interviews of key informants with data from government sources and results of prior 
research to estimate the economic impacts of specific examples of biotechnology. In the 
concluding section, the results are summarised and discussed. 
 
4.2 Method: Cost Benefit Analysis 
 
CBA compares the cost and benefits of policies or projects. These may include social, 
cultural, environmental and economic costs and benefits. This project focused on the 
economic costs and benefits, but included other types of costs and benefits where appropriate 
and feasible. It also focused largely on the direct costs and benefits of the biotechnology 
products. This analysis was based on the assumptions below and those given by respondents. 
Other impacts, including indirect and induced impacts, are examined in the international trade 
and macro-economic analyses in Chapters 5 and 6. The stages in a CBA are defined and 
discussed below. 
 
4.2.1 Stage 1: Definition of impacts 
 
The first stage in any cost-benefit analysis is identifying the options and their impacts. This 
project relies on a number of sources to identify and estimate the impacts of biotechnology on 
the primary sector. Ideally when identifying these impacts, information on production inputs 
and outputs, processes, services, and methods resulting from the four biotechnologies will be 
included. Some of these will be market impacts, while others may be non-market impacts, 
such as environmental impacts. However, this information was not always available and use 
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had to be made of secondary sources or assumptions relating to the impact of the technology, 
which are described on a case by case basis below. 
The next stage in determining the impact of the technology was to assess the alternative 
option: the scenario in the absence of the biotechnology as the counterfactual. The value of 
biotechnology in primary production will be measured as the difference between these two 
options: what is currently being done, and what would have been done had biotechnology not 
generated the products, processes, services, and methodologies that are currently in use. 
 
Researching the issue of what the industry would do without biotechnology led to interesting 
discussions with key informants and required close examination of the literature. Information 
on the counterfactual derived from essentially two sources. The first source was historical: 
how did production occur before biotechnology was introduced? An interesting example of an 
historical perspective was potato production. Nearly the whole industry relies on seed 
potatoes produced through heat treatment and tissue culture and then clonal propagation, a 
process that provides cleaner, more uniform potato tubers. Whilst the technology has been in 
use since the early 1980s, there is good information (and personal reminiscences) on earlier 
production practices from which the counterfactual could be determined. The second source 
of information for the counterfactual was variation in present-day production. For many 
products, only some producers use the biotechnological innovations that are profiled below. 
Other producers do not use the innovations. This enabled good comparisons to be made to 
demonstrate the impacts of biotechnology. 
 
The counterfactual is important to calculate economic benefits. It is against the counterfactual 
that the impact of a biotechnology is measured. If a counterfactual contains too high an 
estimate of productivity or profits, then the impact of the biotechnology application is 
understated. On the other hand, a low estimate for the counterfactual overstates the impact of 
the biotechnology. In every case, this research has sought the most realistic picture of 
production in the absence of these four biotechnologies, based on a review of the literature, 
analysis of production practices, and the interviews with key informants. 
 
4.2.2 Stage 2: Identification and estimation of impacts 
 
This stage of the analysis takes the information from stage one regarding the physical impacts 
and calculates the costs and benefits of the technology for the primary sector. Regardless of 
the types of innovation, the estimation of economic impacts for every biotechnology 
application had two main considerations:  
 
• What is the impact of biotechnology on production? 
• What are the opportunity costs of the resources used in production? 
 
The first question, ‘What is the impact of biotechnology on production?’ is relatively 
straightforward. This is the current state, the present method of production. In this study 
information was primarily obtained from interview participants, who were able to describe 
production as it happens and the contributions that biotechnology made. This was 
supplemented with information from product end-users and secondary sources of data, such 
as data about current production that is included in official statistics and farm-level research.  
 
To estimate the cost to the primary sector of using the biotechnology product ideally requires 
information on a range of factors. The ERMA report, ‘Evaluation of benefits, market access, 
and demand issues for applications for commercial release of genetically modified organisms’ 
(Kaye-Blake & Saunders, 2003), detailed the direct use costs that should be considered in 
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evaluating new technology. These include technology fees, changes in variable input costs, 
changes in capital use and costs, impacts on agricultural labour demands, and impacts on use 
of natural resources such as water. To the extent that they are known and can be assessed or 
estimated, these cost changes were included in the CBA.  
 
One of the main reasons for pursuing interviews with key informants was to understand 
exactly how the biotechnology applications that were identified affected production. This is a 
multi-faceted issue. Innovations can affect the inputs to production or the outputs, and can 
affect either the quantity or the quality. The economic impact calculations took into account 
the different types of impacts that biotechnology could have. 
 
One example is AR1 ryegrass, which contains a endophyte that does not cause ryegrass 
staggers in livestock. The physical seed is identical to seed containing a wild-type endophyte 
that does cause staggers. It is handled in exactly the same way. The output from pasture using 
AR1 ryegrass – the meat, milk or wool – is also identical to output from another type of 
ryegrass. However, the AR1 endophyte improves animal productivity in measurable ways, so 
that the farmer has more production from the same land area. This is an example of a 
technology in which the input is improved, but farm-level production system is largely 
unchanged, as is the physical characteristics of the output.  
 
For an innovation like AR1 ryegrass, the economic calculations focused on the increased cost 
of the input and the increased amount of output. Calculations of changes to production 
systems were unnecessary, and considerations of price or marketing changes were also 
unnecessary. 
 
Another example is the use of clonal propagation to produce improved tubers for floriculture. 
Larger tubers are more productive and command higher prices. Tubers are both an input to 
floriculture and an output, so price impacts had to be considered for both sides of the 
production system. On the input side, larger, clonally propagated tubers cost more. On the 
output side, they can result in more stems and premium tubers, both of which are export 
products.  
 
For this sort of innovation, the economic calculation had to account for the increased costs of 
production as well as the changes to quantity produced and export prices. These calculations 
were thus more complex. 
 
The second consideration that runs through all of the calculations below is the opportunity 
cost of resources used in production. Opportunity cost is an economic concept that recognises 
that productive resources have alternative uses. In valuing the costs (and benefits) of the new 
technology it is the opportunity costs which are relevant, that is, the cost (or benefit) of the 
next best alternative. This requires information on the counterfactual as discussed in stage one 
above. It also requires information on the next best use of resources which have been changed 
in use due to the technology, for example, the cost of alternative treatments or methods for 
achieving results similar to the results of the biotechnology product. The primary source of 
this information was the interviews, and this information was supplemented by the literature 
and secondary sources of data. 
 
The resources used in producing one crop are resources that could have been used in 
producing another. If biotechnology makes one crop more profitable to produce, that change 
will pull resources out of other uses. The improvement due to biotechnology is thus the 
increased returns, over what the resources could earn in alternative uses or employment. The 
improvement is not, strictly speaking, simply the value of production. 
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To capture the opportunity cost of resources used in production, the economic analysis relies 
on calculations of gross margin from the 2004 Financial Budget Manual (Burtt, 2004). This 
publication contains production budgets for the main agricultural products of New Zealand. 
Production budgets detail income by source and expenditure by category, and they are widely 
used in applied economic analysis and practical farm management. The gross margin is the 
total of income less variable expenditures. Variable expenditures are those that would be 
affected by increases in production. For example, if a biotechnology increases the amount of a 
crop that can be harvested per hectare, this increased production also leads to increased costs 
for harvest labour. Gross margin calculations do not included imputed rent values for land and 
exclude many fixed costs, such as machinery, capital costs and farmer’s labour. 
 
Using gross margins is a good approximation of the increased value of many biotechnologies. 
The particulars for each biotechnology or each crop may be slightly different, so gross 
margins will only be an approximation. In addition, the use of gross margin neglects some 
expenditure, such as land rents, that should be attributed to production. Furthermore, one 
should expect such fixed assets to increase in value as their products yield more profits. On 
the other hand, gross margin calculation can understate the impact of a biotechnology. A 
biotechnology that increases product quality can lead to increased value being produced at the 
same cost. A simple gross margin calculation can therefore overstate the cost of production. 
The use of gross margins for this analysis thus has the potential to either understate or 
overstate the impact of a biotechnology, with no clear expectation of the direction of the 
impact. However, a key consideration in the economic analysis is evaluating opportunity cost. 
Gross margin calculations provide a good estimate of opportunity cost in the absence of 
primary data from the surveys. 
 
The benefits of the biotechnology products were analysed using interviews with key 
informants as the first source of information. The informants were asked for data regarding 
the positive impacts of their products in terms of cost savings, improved productivity, 
enhanced product attributes and increased market premiums (Kaye-Blake & Saunders, 2003). 
Combined with these primary data were secondary data from the literature, governmental and 
industry sources to ascertain the contribution of products to overall industry returns. Where 
necessary, this research also relied on industry estimates of price premiums for differentiated 
products, such as premiums to organically-produced food, price margins for higher quality 
designations, and willingness to pay estimates generated by stated preference research.  
 
The research also considered market-level benefits of the biotechnology products, assessing 
the impacts of differential rates of uptake as well as market trends. Some of the market-level 
issues previously identified are the intended markets for the commodity, New Zealand’s 
market shares in those countries, the sensitivity of those markets to price changes, and the 
policies that affect market access (Kaye-Blake & Saunders, 2003). However, the wider 
economic implications of the uptake of technology are assessed in more detail in Chapter 5 
and 6. 
 
By using this information, the CBA estimated the actual first stage net benefits of the 
biotechnology products from the microeconomic perspective. This initial analysis was based 
on the assumption of perfectly elastic demand for primary sector products; that is, it assumed 
that New Zealand could sell as much as it produced without affecting world prices. Following 
chapters relax this assumption, taking into account New Zealand’s relative importance in 
certain international commodity markets. 
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4.2.3 Stage 3: Which impacts are relevant? 
 
In collating and assessing the costs and benefits of the biotechnologies, the relevance and 
significance of the impacts were assessed with a number of criteria, as detailed below. 
 
• Impacts on prices and quantities. Are these impacts large enough to make a difference 
to producers? Are they large enough to affect the market?  
• Impacts on marketed and non-marketed goods and services. Generally the impact on 
marketed goods and services are covered in a CBA but the coverage of non-marketed 
effects may require consideration. Assessing their value is often costly and difficult, so 
it is thus beyond the scope of the proposed research to quantify these impacts. However, 
where the biotechnology products have been shown to have environmental impacts, 
these may also be considered in the analysis using secondary sources of estimates of 
non-market valuations. 
• Direct, indirect and induced impacts. The CBA will consider the direct impacts of the 
products. The indirect and induced impacts will be estimated using secondary data 
sources. 
• Current and future impacts. The proposed research is focussing on currently 
commercialised biotechnology products. However, in the case of forestry there are cost 
and benefit streams into the future, which are included as they represent real 
improvement in capital stock. Thus, in this case future net benefit streams will be 
discounted to express them in current dollars. 
• Certain and uncertain impacts (risk and probability). Because the focus is on current 
products, the uncertainty surrounding the commercialisation of biotechnology products 
is not relevant to this study. The main uncertainty in this study is the quality of data and 
information available from the primary sector. This includes information on uptake 
rates in the primary sector, interactions between the technologies and the production 
environments in which they are used, and market conditions. Moreover, the actual costs 
and benefits do vary according to environmental and market conditions. Whilst the 
study does undertake to account for this uncertainty through the use of averages there 
are cases where information is not available on the variability and this is not possible. 
Discussions with the key informants on this project helped identify key areas of 
uncertainty. For example, the benefits from a programme to reduce footrot in sheep are 
greater when climatic conditions are conducive to developing the condition, and 
conversely are less when conditions are not conducive. Market conditions are another 
source of uncertainty.  
 
In the course of this research, a few biotechnological innovations were identified but not 
subsequently valued. There were two reasons not to calculate precise values for them. The 
first reason was that the innovation was outside the bounds of this research. Some products 
are clearly the result of biotechnology but did not belong to the categories used in this 
research. An example is AndroVax, a vaccine from AgVax that enhance sheep fertility. While 
vaccines are included below, these were included under the heading of ‘Biocontrol agents’. 
As AndroVax is not aimed at controlling a pest, it did not fall into that category. 
 
The second reason is that when estimating the net benefits to the sector particular attention 
was paid to those biotechnologies which had significant effects. In some cases there were 
biotechnologies for which information was not available and the small size of their 
contribution made estimates from secondary sources either impossible or insignificant. Thus 
there may be cases where specific economic calculations were not made for an innovation 
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which, while successful, did not contribute materially to the primary sector as a whole. The 
primary sector is worth tens of billions of dollars, and the overall contribution of 
biotechnology is in the hundreds of millions. This aspect of the research is not intended to 
impugn any products, processes, or producers.  
 
4.2.4 Stage 4: Discounting of cost and benefit flows 
 
As stated above, the production options may involve both costs and benefits over time, 
especially with forestry. These may need to be discounted to a net present value (this allows 
for the fact that generally goods and services available now are more highly valued than those 
available in the future). For each time period, benefits and costs were assessed and the net 
benefit determined. The present value of the net benefit was then calculated using a discount 
rate or a rate of interest. The discounted values of the net benefits for all periods were 
summed to give a total net present value. 
 
( )1
t t
t
t
Benefits CostsCBA NPV
r
−= = +∑  
NPV = Net Present Value 
r = rate of interest (generally the market rate is used here) 
t = time period 
 
4.2.5 Stage 5: Apply the net present value test 
 
From the data and information available, it was possible to calculate a Net Present Value 
(NPV) for the biotechnologies. The NPV Test assesses whether the sum of discounted 
benefits exceed the sum of discounted costs. If so, the technologies can be shown to be a net 
improvement to the primary sector in New Zealand, given the information generated in the 
CBA. 
 
Another use of this test is to determine the relative impacts of different production options. 
This would be particularly appropriate if there are a number of products or production 
methods that can achieve similar results. The Cost Benefit ratio is calculated by dividing the 
discounted benefits by the discounted costs for each project. The resulting ratios are then 
compared. 
 
4.2.6 The indirect and induced contributions 
 
The above direct contribution of biotechnologies is only part of their total contribution to the 
New Zealand economy. There are also indirect and induced contributions, which are 
differentiated below. 
 
1. Direct contributions. These are a result of direct finance and employment injected into 
the economy. 
2. Indirect contributions. These are a result of upstream and downstream finance and 
employment created to service the biotechnology firms. 
3. Induced contributions. These are the effect of the above two contributions on further 
household spending which generates finance and employment such as increases in the 
purchases of household goods and services.  
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Thus, this stage of the analysis calculated the indirect and induced contributions to assess the 
total impact of the biotechnologies on the economy. To estimate the indirect impacts (for both 
output and employment) it is usual to include two levels of upstream and downstream effects. 
The first level is from those who supply the industry directly, such as component suppliers. 
Ideally this should be estimated from primary data. The second level is the output and 
employment effect generated by these firms supplying the industry directly. The survey did 
include questions to try and elicit this first level of indirect impact for output/expenditure by 
providing data on the inputs into biotech firms by type. However, data were not generally 
available so secondary sources of data have been used. The indirect and induced contributions 
are calculated and discussed in Chapter 6. 
 
4.3 Analysis and results 
 
This section reports the results of the cost benefit analysis by product sector or case study as 
appropriate. As outlined in Chapter 3, the application of the technology varies considerably 
by type, impact, and coverage. Moreover, the information available also varies considerably 
as does the availability of secondary sources of data to confirm industry sources or to obtain 
estimates on its impact. Therefore, in the analysis various assumptions have had to be made. 
In addition, whilst in some sectors it has been possible to calculate or estimate impacts of 
technology to the whole sector, in others it has been necessary to rely on case studies. These 
issues are discussed in more detail below. 
 
4.3.1 Direct impacts: Clonal propagation/cell manipulation 
 
Clonal propagation/cell manipulation is a broad category of biotechnology that encompasses a 
number of specific techniques, such as tissue culture, protoplast fusion, in vitro cloning, 
tetraploidy, etc. Not specifically included in this category are genetic manipulation and 
transgenics, but this is not a material omission as these techniques have not yielded 
commercial products in New Zealand. The definition of clonal propagation also does not 
include garden-variety cloning, such as rooting plant cuttings, done without the aid of 
laboratory facilities. 
 
Of the four biotechnologies in this report, clonal propagation/cell manipulation has 
contributed the most value to the primary sector. There are several reasons for its relative 
importance. First, it is a relatively mature, well-established group of techniques. Because it 
has produced effects over time, those impacts have grown and compounded. Secondly, its 
impacts are widespread across the primary sector. Finally, it has proved quite important for 
some products of economic significance to NZ. These factors have all contributed to the 
importance of clonal propagation and cell manipulation. 
 
These same characteristics do complicate the economic assessment of the value of clonal 
propagation and cell manipulation. Because it is a widespread technology, some of its impacts 
need to be estimated at an aggregated level. Also, because some important impacts have been 
localised – for example in potatoes and floriculture – the exact nature and value of the impacts 
are commercially sensitive. The following analysis contends with these issues to calculate the 
contribution of this biotechnology to the primary sector. The sector is divided into five types 
of crops or production systems for the analysis. 
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4.3.1.1  Arable crops 
 
Agronomic research on staple crops led to important increases in production in the second 
half of the 20th century. These increases have been well-documented and studied. Abeledo, 
Calderini, & Slafer (2002) summarise research on genetic gains in barley. Genetic yield gains 
in barley vary by study, but they are 0.3 per cent to 0.4 per cent per year for the whole 20th 
century. Gains achieved in the second half and the last quarter of the century were higher than 
those in the earlier periods. For example, plant breeding has increased the genetic grain yield 
by more than 0.5 per cent per year since the 1940s. In the same chapter, Abeledo, et al. (2002) 
note that genetic gains from wheat have been slightly higher than those for barley, about 0.5 
per cent per year. However, it is possible that yield increases have declined over time in New 
Zealand, as they have in Mexico (Traxler, Falck-Zepeda, Ortiz-Monasterio, & Sayre, 1995) 
and across developing countries (R. E. Evenson, 2003; R.E. Evenson & Gollin, 2003). For 
maize, Duvick & Cooper (2004) demonstrated a clear linear trend in yields per hectare since 
1930. Interestingly, potential yield per plant had not increased from 1930 to the mid-1990s. 
Instead, newer varieties performed better for harvest index and under stress and crop density, 
leading to increased yields per hectare over time. An implication of their linear trend in yields 
is that the percentage yield increase per year has been falling over time, as the same additional 
production is added to larger base yields. At total yield of six tonnes per hectare, which was 
achieved in 1955 according to the regression line and in about 1940 according to the data 
points, an annual increase of 68 kgs represented a 1.1 per cent increase. Yield in 2000 was 
estimated to be nine tonnes per hectare, so that 68 kg represented only a 0.76 per cent 
increase. Importantly, the authors did not separate the genetic yield increase from other 
factors. 
 
Biotechnology through clonal propagation/cell manipulation has contributed to the genetic 
component of the increase in yields reported above. However, the exact contribution is not 
known. The research into gains in yield reviewed above has found that genetic improvements 
vary by crop and country and over time. Certainly, biotechnology was used to generate some 
of these gains but it was also reported in interviews and in the literature that some of these 
gains could have been achieved through traditional breeding. However, there is a view 
expressed in the literature that the ‘easy gains’ from traditional breeding techniques had 
already been achieved and that further gains are harder to achieve and thus require more 
powerful technologies such as biotechnology (Bajaj, 1990). The studies above imply a base 
crop genetic improvement figure of 0.5 per cent per year in yield for arable crops. In this 
study, after consultation with key informants, it was assumed that one-half the base crop 
genetic improvement can be attributed to clonal propagation/cell manipulation. By this 
assumption, the implicit counterfactual is that crop genetic improvement would have been 
one-half its current level if clonal propagation/cell manipulation had not been available. 
 
Thus it is estimated that arable crops have been increasing in productivity by 0.25 per cent per 
year as a result of biotechnology. Writing in 1990, Bajaj (1990) reported that modern 
biotechnology was increasingly incorporated into breeding programmes during the 1980s. 
Attributing some value to biotechnology starting from 20 years ago therefore seems 
appropriate. Compounding the annual gain of 0.25 per cent over a period of 20 years results in 
an estimate of the total gain from the use of biotechnology. Thus, current production is 
estimated to be 5.1 per cent greater than it would be in the absence of clonal propagation/cell 
manipulation. It would be desirable in future economic research to estimate the specific 
contribution of biotechnology to each commodity, but this figure of 5.1 per cent represents the 
best estimate with the available data. Table 4.1 presents calculations of the value to New 
Zealand producers of this increase in yield. This shows that with a 5.1 per cent increase in 
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yield the increase in revenue is nearly $20 million, however to calculate the net returns to NZ 
the gross margin is used giving net benefits of $8.2 million. 
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Table 4.1  Economic contribution of clonal propagation/cell manipulation to the arable crop subsector 
Arable crops Area (hectares) 
Revenue per 
hectarea 
($) 
Revenue  
($000’s) 
Current production due to 
biotechnology from 
0.25% annual increase 
(%) 
Increased 
production 
($000’s) 
Gross margina 
($ per $ of 
revenue) 
Value of clonal 
propagation/cell 
manipulation ($000’s) 
Barleyb 64,700 1,725 111,608 5.1 5,692 0.45 2,561 
Field peasc 10,000 2,320 23,200 5.1 1,183 0.54 639 
Maized 14,166 3,497 49,539 5.1 2,526 0.36 910 
Small seeds*c 33,000 2,376 78,408 5.1 3,999 0.42 1,679 
Veg seedsc 3,000  25,000 n/a n/a n/a n/a 
Wheate 40,900 2,480 101,432 5.1 5,173 0.47 2,431 
Total arable   389,187  18,579  8,220 
* Gross margin is the unweighted average of clover, ryegrass, and fescue gross margins. 
a Burtt, E. (Ed). (2004). Financial Budget Manual. Canterbury: Farm Management Group, Lincoln University. 
b Area data: Ministry of Agriculture and Forestry Website, Total Barley - Area Harvested and Quantity Produced, 2003. 
c Area data: Ministry of Agriculture and Forestry, (2004), Situation and Outlook for New Zealand Agriculture and Forestry (SONZAF). 
d Area data: Ministry of Agriculture and Forestry Website, Grain and Seed Crops by Farm Type (ANZSIC), 2002. 
e Area data: Ministry of Agriculture and Forestry Website, Total Wheat - area harvested and quantity produced, 2004. 
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4.3.1.2  Floriculture 
 
One example of an industry in which this biotechnology is important is the flower industry. 
Some firms, such as Multiflora Ltd and Lifetech, are specialists in tissue culture on contract. 
They reproduce plant matter – bulbs, corms, tubers, and other plant material – for the 
floriculture industry. The industry then sells cut flowers and bulbs to the consumer. Tissue 
culture allows for quicker propagation and better form resulting in larger tubers and earlier 
flowers, resulting in premium prices for growers. 
 
The flower industry can be broken down into several components. One division is between 
the domestic market and the export market. The domestic market for cut flowers is estimated 
to be $70 million (HortResearch, 2003), and the export market for cut flowers, live plants, 
foliage, and bulbs, tubers, and corms totals $76.6 million. MAF suggests that the domestic 
market is potentially oversupplied and that returns are marginal (Ministry of Agriculture and 
Forestry (MAF), 2003). This analysis thus concentrates on values in the export market. 
 
In order to calculate impacts on the gross margin, this analysis uses the production budget for 
export calla lilies (Zantedeschia) (Burtt, 2004) as representative for the whole industry. The 
ratios and margins were calculated from this production budget, and were then applied to 
industry earnings as a whole. The industry on average per holding earns a revenue of $16,750 
of which when variable inputs are removed leaves a gross margin of $5,221, however it 
should be stressed here that the gross margin excludes the cost of the tubers which are 
counted as capital stock. This implies a gross margin ratio to total revenue of 31.2 per cent. If 
this ratio is applied to the total industry export earnings of $76.6 million then $23.9 million 
represents the gross margin for the industry. 
 
Given the widespread adoption of the biotechnology in the industry, no actual estimates could 
be made of the counterfactual. Thus, the study assumed that in the absence of the technology 
the gross margin would be lower. An average was taken of the lowest gross margin estimate 
of a loss of $2,921.19 and the current average of (a gain of) $5,221.25, a value of $1,150. This 
is taken as the counterfactual gross margin, what the flower grower would have earned in the 
absence of tissue culture-derived plantstock. The gross margin for the total industry, instead 
of being $23.9 million, would have been $5.26 million. The gross benefit to the industry is the 
difference between these two figures, or $18.6 million. 
 
This benefit however excludes the cost of the tubers as capital stock which would have been 
produced using biotechnologies; these would cost more when starting up a floriculture 
operation. The prices for different-sized tubers are presented in the Farm Budget Manual, and 
range from $0.70 per tuber to $2.10 per tuber. Given this price spread, one-half the original 
cost of the tuber stock was ascribed to the improved stock. The cost of the stock for the 
production budget was estimated as the interest on the capital invested in tuber stock. This 
was estimated at 7.61 per cent of total income, or $5.83 million for the industry. In the 
counterfactual, growers would be producing less but also spending less on their tuber stock. 
This spending was estimated to be $2.91 million less than actual industry spending, and 
represents the cost of the plant material improved through biotechnology. 
 
The total impact of tissue culture on floriculture was thus estimated to be a benefit of $18.6 
million at a cost of $2.91 million, for a net benefit of $15.7 million. 
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Table 4.2  Economic contribution of clonal propagation/cell manipulation to the 
floriculture subsector 
 With biotechnology Without biotechnology 
Export earnings $76,600,000  
Gross margin (%) 31.2%  
Gross margin ($) $23,899,000 $5,264,000 
Cost of investment in 
plantstock $5,829,000 $2,914,000 
Gross margin net of 
plantstock costs $18,070,000 $2,350,000 
Value of clonal 
propagation/cell 
manipulation 
 $15,720,000 
 
4.3.1.3  Forestry 
 
Clonal propagation is increasingly adopted in commercial radiata pine forests. Trees of a 
clone are genetically identical and can be improved in both growth and wood quality. For the 
purpose of this study, a distinction was made between vegetatively propagated trees and 
clones developed with modern cell technology. The former approach is very common; about a 
third of all radiata pine planted is derived from cuttings from control pollinated families. 
These cuttings are taken from a single mother stool plant, perhaps one hundred over a three- 
to four-year period. When deployed as cuttings in a forest, the common genetic identity of 
such plants is not tracked and thus can and will be mixed with other genotypes. These trees do 
not constitute products of clonal forestry as defined in this study.  
 
The first clonal forestry in NZ based on tissue cultures techniques was commercialised in 
1986. Nowadays, cloning of radiata pine is not only technically feasible but also practised on 
a substantial commercial scale. The two techniques used are tissue culture (organogenesis) 
and somatic embroyogenesis, with the first one being the original and the second one the most 
commonly used at the time of writing (Sorenson & Shelbourne, 2004). 
 
About nine per cent of the 30 million genetically improved trees sold annually in New 
Zealand are made up of clonal planting stock. An estimated total of 14.63 million clonal 
plants have been sold commercially as of 2004 (2.63 million in 2004 alone). The price of a 
single commercial clone was around $1.08 according to Sorenson & Shelbourne (2004), 
which was three times that of control-pollinated trees and five times that of open pollinated 
plants. This cost reflected the higher value of clones as well as the higher cost of production. 
As of June 2005 the premium paid for a clonal treestocks was 60 cents, according to industry 
sources. 
 
Given that the first commercial clonal forest was planted in 1986 and assuming a 27 year 
rotation, any clonally propagated trees have yet to be harvested. They thus do not contribute 
to revenue earned by the New Zealand primary sector. However, there is substantial equity in 
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the 14.63 million clonally propagated trees planted in New Zealand. Given the long 
investment period in forestry (a 27-year rotation), it is appropriate to value this equity as an 
unrealised economic contribution of clonally propagated forestry to the New Zealand 
economy. 
 
The calculations were based on several variables: the initial cost of a clonal tree, the premium 
at the time of harvest, the estimated number of trees planted each year, and an average post-
tax discount rate of 8.3 per cent (Manley, 2003). The cost of management was assumed to be 
equal to the counterfactual of control pollinated trees. Thus, the only cash flows that differed 
were the initial cost for a planting and the final premium received for the harvested trees, 
which are detailed below. 
 
As mentioned above, the initial cost of a planting was in 2004 around $1.08, which is three 
times that of control pollinated trees. Thus the additional investment at the time of planting 
was $0.72; this figure was used for calculating the impacts of clonal propagation. This cost 
was slightly more than the current increased cost for a clonal tree of $0.60, because the 
appropriate figure was the cost per tree at the time of planting. The lower figure reflected 
economies of scale for the technology that have only recently taken effect. 
 
The premium at the time of harvest was harder to estimate as there are a number of aspects of 
clonal forestry that impact on the premium, including better traits and less variance. The best 
way to estimate the premium was to take the average price of the counterfactual forest, which 
in this case would be a control pollinated forest, and compare it with a cloned forest block. 
The graph below shows the quarterly log prices for the quality classification P1, and the high, 
low, and average prices within that quality classification. A calculated premium is also 
included in the graph.  
 
Figure 4.1  P.1 quarterly log prices (NZD/tonne) 
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Source: Ministry of Agriculture and Forestry (MAF) (2005) 
 
There are two important observations about the above figure. The first is that the differences 
between high, low, and average have been relatively stable for the last five years. The second 
is that the difference between high and average price serves as an approximation of the 
premium rewarded to a harvest based on a clonally propagated forest. The table below shows 
the average premium (high minus average) of the last five years (March 2000 to March 2005) 
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for several different quality classifications. The average premium of the five quality levels in 
the table below is $14. However, this premium constitutes a best-case average scenario. The 
range may be from a loss of $100 to a gain of $60 per cubic metre, depending on the success 
of a specific project. Thus a more conservative average premium, corroborated by industry, of 
$10 (pre tax) was used in the calculations. A tax rate of 33 per cent was used. 
 
Table 4.3  Premium for high grade logs over average grade 
Classification Five-year average premium (NZD/tonne) 
P1 $14 
P2 $26 
S1 $8 
S2 $9 
L1 & L2 $11 
Total average $14 
Source: Ministry of Agriculture and Forestry (MAF) (2005) 
 
The growth in the number of clonal trees planted each year is estimated as a logarithmic 
curve. The data available were that 14.63 million clonal trees have been planted since 1986 
and 2.63 million clonal trees were planted in 2004. A logarithmic curve fit these data well. 
Further research may be able to determine the exact numbers of clonal trees planted per year. 
The curve is shown in Figure 4.2. 
 
Figure 4.2  Estimated number of clonal trees planted per year 
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These data are combined in Table 4.4 to estimate the unrealised capital gain from clonal 
plantings. This estimated gain is based on the premium calculated above, the logarithmic 
uptake rate, and an industry-specific discount rate of 8.3 per cent. In addition, the harvest rate 
is set to 90 per cent, and the each tree provides 2.41 cubic meters of wood, of which 2.06 
cubic metres (pruned logs and sawlogs) receive the $10 premium (Forestry Insights, 2005; 
New Zealand Forest Owners Association, New Zealand Forest Industries Council, & Ministry 
of Agriculture and Forestry, 2005). 
 35 
 
 
Table 4.4  Economic contribution of clonal propagation/cell manipulation to the  
forestry subsector 
Year 
Number of  trees 
planted 
NPV of premium 
per tree 
NPV of initial 
investment per tree 
NPV of clonal 
forestry 
1986 76,163 $6.73 -$3.02 $254,292 
1987 92,769 $6.22 -$2.79 $285,998 
1988 112,996 $5.74 -$2.58 $321,658 
1989 137,633 $5.30 -$2.38 $361,765 
1990 167,642 $4.90 -$2.20 $406,871 
1991 204,194 $4.52 -$2.03 $457,603 
1992 248,715 $4.17 -$1.87 $514,659 
1993 302,944 $3.85 -$1.73 $578,830 
1994 368,996 $3.56 -$1.60 $651,002 
1995 449,450 $3.29 -$1.48 $732,172 
1996 547,445 $3.03 -$1.36 $823,464 
1997 666,807 $2.80 -$1.26 $926,138 
1998 812,194 $2.59 -$1.16 $1,041,614 
1999 989,281 $2.39 -$1.07 $1,171,489 
2000 1,204,979 $2.21 -$0.99 $1,317,557 
2001 1,467,706 $2.04 -$0.91 $1,481,837 
2002 1,787,717 $1.88 -$0.84 $1,666,601 
2003 2,177,501 $1.74 -$0.78 $1,874,403 
2004 2,652,272 $1.60 -$0.72 $2,108,114 
Total 14,467,403   $16,976,067 
 
4.3.1.4  Horticulture (except floriculture) 
 
Hops 
The entire hops industry in New Zealand is based on biotechnology, which has produced 
triploid hops with good agronomic and brewing qualities. According to information obtained 
in this research, the hops industry would not exist in New Zealand without biotechnology. 
 
New Zealand Hops Limited provided confidential data that allowed calculation of total 
farmgate value of production, per hectare gross margins, and total industry gross margins. The 
total gross margin for the industry was calculated to be $1,919,000. If the entire industry 
would not exist without biotechnology, then this entire amount could be attributed to 
biotechnology. 
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The exact portion of this amount to attribute to biotechnology is a complex matter; 
unfortunately, there were insufficient resources to devote to the question. One concern is 
consistency with other parts of this analysis in how clonal propagation/cell manipulation is 
defined. Some currently commercial cultivars were released in the early- to mid-1970s, before 
the time period considered in other parts of this research. In addition, although New Zealand 
hops production is based on triploid cultivars, diploid cultivars are commercially significant 
in other hops-growing regions. Exactly how the industry could have developed in New 
Zealand without access to biotechnology is important for developing an appropriate 
counterfactual, but is also a complex and speculative matter. Given that the estimated industry 
gross margins were less than two million dollars, and given the information available, the 
entire amount can be attributed to biotechnology without materially affecting the overall 
results of the research. 
 
Potatoes 
Another crop whose production is significantly improved by tissue culture is potatoes. Tissue 
culture is used after heat treatment to propagate the initial generations of plants, which are 
then used to produce seed potatoes. The resulting potatoes are planted to produce the retail 
crop. Most of New Zealand’s seed potatoes are produced by this process, which produces 
virus-free, uniform seed potatoes and does so more quickly than older methods of 
propagation. The industry depends to such an extent on tissue culture that one key informant 
suggested the potato industry would disappear without it, while other informants suggested 
that production would fall by two-thirds to three-quarters.  
 
There are several benefits to tissue culture (Ovenden, no date; Ovenden, Anderson, 
Armstrong, & Mitchel, 1985; Ovenden & Martin, 1981). First, the final product is larger and 
more uniform, attracting a higher price. Secondly, the crop has fewer problems with 
pathogens, leading to greater productivity. Thirdly, the potato skin is smoother, making the 
tubers easier to clean and more marketable. 
 
The value of biotechnology to potato production is significant in one sense. From the 
accounts of key informants, biotechnology allows the industry to exist in its present form. 
Given the estimated crop volume of 470,000 tonnes (HortResearch, 2003) and a farmgate 
price for fresh potatoes in 2003 of $300 per tonne (Ministry of Agriculture and Forestry 
(MAF), 2003), the value of production is significant at $141 million. 
 
It is important to note, however, that gross margins in the potato sector are variable and on 
average fairly low as a percentage of total revenue. Gross margins for several years are given 
in Table 4.5. An average of the last five years’ gross margins was $1,438.40 per hectare. 
Aggregating this to the approximately 10,600 hectares in production (HortResearch, 2003), 
gross margins were $15.2 million, or 10.8 per cent of total revenue. 
 
Table 4.5  Historical gross margins for potatoes 
Year 2003 2002 2001 2000 1999 
Gross margin 
per hectare $4,050 $1,150 $950 <-$57> $1,099 
Source: (Burtt, 2004)    
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The value of tissue culture could be expressed in two different ways. The first method would 
be to take three-quarters of total gross margins and value biotechnology at $11.4 million. This 
would imply a much smaller industry producing a much smaller crop, but still earning profits. 
The other method would be to assign the industry’s entire gross margins to biotechnology, as 
was suggested by one informant. However, given that there are some growers who do not buy 
tubers from off-farm and assuming that alternative techniques would have arisen in the 
absence of biotechnology, this is probably an unrealistic counterfactual. The first approach is 
a more realistic assessment of the value of biotechnology and is used in this report. Table 4.8 
presents the calculations for potatoes along with calculation for other vegetable crops, and 
follows the discussion of other vegetable crops below. 
 
Assorted horticultural crops 
As has already been discussed, the exact impact of clonal propagation/cell manipulation on 
the horticultural subsector is difficult to determine. This is true for a number of reasons. First, 
data on so-called ‘minor crops’ is not nearly as detailed or consistently available as data on 
more economically important crops. For example, figures on per-hectare productivity of 
silverbeet were not available. Secondly, each crop and even different cultivars within each 
crop have been affected by breeding programmes in different ways. In vegetable crops, 
changes have included greater uniformity in size, form, and harvest date, impacts on size of 
the marketed portion of the plant, frost hardiness, heat tolerance, pest tolerance, and simple 
productivity-per-hectare increases. The impacts of these qualitative and quantitative changes 
are complex to document and catalogue. Thirdly, the extent to which biotechnology was 
responsible for these changes is difficult to determine. Despite a number of interviews it was 
not possible to determine whether a specific change was due to biotechnology. Furthermore, 
knowledge of the specific phenotypic changes is only part of the story. It is also important to 
know the economic value of those changes – how much more does a farmer receive for 
broccoli with a mounded, symmetric shape and the right shade of green? 
 
At the same time, it would be disingenuous to suggest that decades of plant tissue and cell 
manipulation have had no impacts on horticultural crops. The problem simply is knowing the 
economic value of the changes. 
 
The solution pursued here was to assign a representative value to the use of clonal 
propagation/cell manipulation in horticulture. This value was based on several pieces of 
information. For example, these biotechnological techniques have had commercial success in 
arable crops. Furthermore, clonal propagation/cell manipulation did not appear to have led to 
commercially successful results in several horticultural crops, such as apples, kiwifruit, and 
grapes. This finding was based on discussions with key informants, and was confirmed by the 
literature. For example, commercially viable genetic improvement to apples are difficult 
because of scientific and marketing challenges (Brown & Maloney, 2003). The calculations of 
economic value of the contribution of biotechnology thus excluded these crops and focused 
instead on vegetable crops. Calculations began with data on the number of hectares of 
vegetable crops in New Zealand from the 2003 Horticulture Monitoring report and then 
excluded potato acreage, which was treated separately. Gross margin numbers were from 
Burtt (2004). This publication provided values for certain crops, and these were taken as 
indicative of the subsector. Finally, the portion of gross margins attributed to biotechnology 
was calculated at the same rate as in arable crops. 
 
The final calculation of the contribution of clonal propagation/cell manipulation in 
horticulture was thus the product of hectares in vegetables other than potatoes (Table 4.6), 
gross margin per hectare (Table  4.7), and per cent contribution of the biotechnology. The 
figures are provided below. 
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Table 4.6  Vegetable crop production hectares in New Zealand 
District Vegetable hectares 
Northland 1,407 
Auckland 4,752 
Waikato 5,957 
Bay of Plenty 0 
Gisborne 4,593 
Hawkes Bay 7,484 
Manawatu-Wanganui 6,667 
Wellington 447 
Nelson/Tasman 421 
Marlborough 1,976 
Canterbury 13,120 
Otago 749 
Total 47,573 
Less, potato area -10,600 
Total, other vegetables 36,973 
Source: MAF (2003) 
 
Table 4.7  Gross margins for main crop vegetables 
Gross margin by year ($ per hectare) Crop Hectares 
1999 2000 2001 2002 2003 
Average 
Onions 5,680 3,124 -1,353 1,035 405 5,800 1,802 
Cabbage 780 3,223 3,211 3,060 2,380 2,630 2,901 
Cauliflower 1,181 3,762 3,672 3,250 2,490 2,750 3,185 
Broccoli 1,786 2,677 2,545 -250 840 695 1,301 
Lettuce 1,287 2,454 2,673 3,695 2,600 3,010 2,886 
Total average (weighted by acreage) 2,081 
Total average (unweighted) 2,415 
Source: Burtt (2004) 
 
 39 
 
Table 4.8  Economic contribution of clonal propagation/cell manipulation to the horticulture subsectora 
Horticultural 
crops 
Area 
(hectares) 
Revenue  
($000’s) 
Current production 
due to biotechnology 
(%) 
Increased production 
($000’s) 
Gross margin 
($ per ha)b 
Value of clonal 
propagation/cell manipulation 
($000’s) 
Hops 406  100   1,919 
Potatoes 10,600 141,000 75.0 141,000 1,438 11,432 
Other 
vegetables 36,973  5.1  2,081 3,924 
Total      17,275 
a Source: see text and tables above. 
b Burtt (2004) 
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4.3.1.5  Pasture 
 
The use of tissue culture, protoplast fusion, and other cellular techniques in pasture 
plant breeding goes back to the 1970s, but with increased uptake in the 1980s (Van 
Heeswijck, Hutchinson, Kaul, McDonald, & Woodward, 1994). It was unclear exactly 
when these techniques began to affect the commercially planted pasture varieties. 
This application of biotechnology has improved forage quality through changes to 
digestibility, intake rate, and metabolisable energy content (Woodfield & Easton, 
2004). Improved animal health has resulted from decreased incidence of ryegrass 
staggers, fescue toxicosis, bloat, infertility, and nutrient deficiencies (Woodfield & 
Easton, 2004). For this assessment of the value of clonal propagation/cell 
manipulation, reduction of ryegrass staggers was excluded; it is considered separately 
with biocontrol agents. 
 
There were indications in the literature of the genetic gains in pasture plants and their 
impacts on animal production. Over the last 50 to 60 years, genetic improvements in 
forage grasses have led to 0.25 per cent to 1.5 per cent annual gains in dry matter 
yields, while in forage legumes, the gains have been 0.2 per cent to 4.0 per cent 
(Woodfield, 1999; Woodfield & Easton, 2004). These gains have led to improved 
animal performance of 0.3 per cent to 1.4 per cent (Woodfield & Easton, 2004) 
overall, while deselection of a trait that impaired fertility raised annual gains to 2.8 
per cent (Woodfield, 1999). A major source of overall gains, especially since 1985, 
has been in breeding for specific environments (Woodfield, 1999). Sanderson & 
Leung-Wai ((2005) also examined improved animal performance, and calculated a 
growth rate in dairy output from 1975 to 2000 of 1.3 per cent per year. Part of this 
gain was attributed to the 0.5 per cent per year genetic gain in dairy cattle, while the 
remaining 0.8 per cent was attributed to several factors, including nutritive value of 
feed. 
 
Using this research as a basis, this analysis attributed a 0.5 per cent annual gain in 
animal performance to improved forage plant genetics. The implicit counterfactual is 
thus that the growth rate in dairy output would have been 0.8 per cent per annum 
without the biotechnology instead of 1.3 per cent with the technology. As with arable 
crops, it was difficult to determine the portion of that gain that was due to clonal 
propagation/cell manipulation, although it was clear that such techniques were 
important. For example, the development of tetraploid ryegrass required 
biotechnology. This 0.5 per cent annual gain was compounded over a 20-year period 
to estimate the current benefit to New Zealand pastoral production from this 
biotechnology. Note that these gains were only applied to ‘improved’ pasturage, that 
is, pasturage that was sown with improved varieties. Interviews with key informants 
suggested that approximately 30 per cent to 40 per cent of New Zealand pasturage is 
‘improved’. Improvements to pastures affect production in dairy, beef, and sheep 
subsectors. The economic impact of these improvements are broken out by subsector 
and presented in Table 4.9.  
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Table 4.9  Economic contribution of clonal propagation/cell manipulation to pastoral production 
Product Amount of productiona 
Revenue per 
unitb 
Revenue  
($000’s) 
Production 
affected 
Current production due 
to biotechnology from 
0.25% annual increase 
(%) 
Increased 
production 
($000’s) 
Gross 
marginc 
($ per $ of 
revenue) 
Value of clonal 
propagation/cell 
manipulation  
($000’s) 
Dairy 1,250,000 t 4250 5,312,500 0.35 5.1 94,828 0.79 74,914 
Beef and veal 4,644,000 hd 280 1,300,320 0.35 5.1 23,211 0.90 20,890 
Sheep farming        
   Lamb 434,000 t 3790 1,644,860 0.35 5.1 29,361   
   Mutton 113,000 t 2000 226,000 0.35 5.1 4,034   
   Wool 173,000 t 5510 953,230 0.35 5.1 17,015   
Total sheep farming  2,824,090   50,410 0.70 35,287 
Total pastoral production  9,436,910   168,449  131,091 
a MAF (2004c). Figures are from 2003 because some 2004 figures in the report are estimates. 
b For Dairy, this is the 2003/04 payout of $4.25 per kg. For Beef and veal, this is farm income per head of overwintered cattle (Burtt, 2004). For Lamb, Mutton and Wool, prices 
are average baseline prices (MAF, 2004c). 
c Burtt, (2004).For Dairy and Beef and veal, gross margin is adjusted to account for the cost of winter feed. Sheep farming gross margins are the weighted average of three budgets 
(Burtt, 2004). Merino sheep numbers taken from Greer (2005). 
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4.3.1.6  Summary: Clonal propagation/cell manipulation 
 
This specific biotechnology is the most widely used of the four biotechnologies examined in 
this report. For decades, it has been used in plant research and breeding. Our approach here 
has been to examine the scientific and economic literature and combine those findings with 
information from key informants to estimate the current impact on the primary sector. 
 
Because the technology has been in use for many years and is so widely used – that is, it is a 
good example of a horizontal enabling technology – the impacts are quite large compared to 
the other biotechnologies. The findings from each subsector are summarised in Table 4.10. 
The total contribution of clonal propagation/cell manipulation to the primary sector is 
estimated to be $189,282,000. 
 
Table 4.10  Summary of economic contributions of clonal  
propagation/cell manipulation 
Subsector 
Value of clonal propagation/cell 
manipulation 
($000’s) 
Dairy 74,914 
Beef and veal 20,890 
Sheep (meat and wool) 35,287 
Forestry 16,976 
Horticulture and 
floriculture 32,995 
Arable crops 8,220 
Seafood nil 
Total 189,282 
 
4.3.2 Direct impacts: Biocontrol agents 
 
This research identified several specific biocontrol agents in use in New Zealand. They affect 
or have the potential to affect production across the land-based primary sector. Innovations in 
this category of biotechnology were assessed on a case-by-case basis. Each of the specific 
examples identified is discussed in turn below. 
 
4.3.2.1  BVDV vaccines 
 
Bovine virus diarrhoea virus (BVDV) is a disease known to be present in New Zealand cattle 
herds, but whose exact impacts are uncertain. The potential effects of BVDV are known: 
abortions, poor foetal development, and failure to thrive. It is also understood that some three-
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quarters of cattle in New Zealand have been exposed. However, what is uncertain is the 
number of exposed cattle that have experienced symptoms, and what economic losses are 
being sustained as a result. Overseas research estimates economic impacts in other national 
herds of anywhere from less than US$2 million to as high as US$57 million per million 
calvings, with most estimates falling in the range of US$10 million to US$40 million and 
clustered in the low end of that range (Houe, 2003). New Zealand research suggests that the 
value of lost production could be NZ$60 million (Sanderson & Leung-Wai, 2005). 
 
The increased gross margins to New Zealand beef and dairy farmers were estimated to be 
$772,000 and $2,523,000 respectively, net of control costs, for a total of $3,295,000. This 
estimate relies on commercially sensitive information from key informants, so the 
calculations are not included in the main report. These estimates are based on beef and dairy 
herd estimates from MAF (SONZAF 2004), loss per million calvings of $10 million (Houe, 
2003), a NZ$/US$ exchange rate of 0.70, and a combined gross margin of 0.81 for beef and 
dairy farms. 
 
4.3.2.2  Trichoderma products 
 
Trichoderma is a beneficial, naturally occurring fungus. It has two basic modes of operation; 
as a bio-fertiliser and/or as a bio-fungicide. In the first mode the Trichoderma fungus 
stimulates microbial activity around a plants root system, which has a positive effect on plant 
growth. In the second mode, as a bio-fungicide, Trichoderma protects the roots from harmful 
deceases by stimulating protective chemicals on the root surface. 
 
Table 4.11  Benefits from the use of Trichodermaa 
Crop Application Benefit 
Beetroot Trichopel R applied into the 
furrow of at seeding 
69% increase in net yield 
Propagation 
media 
Trichodry in a series of replicated 
pots sown with Pea seeds 
48% control of Pythium compared to 16% in 
untreated media 
Tomato plants 
in glasshouse 
Trichoflow treatment in entire 
glasshouse 
Increased yield by 103% compared to control 
and 69% compared to alternative treatment 
Grapevine Nursery grown vines treated with 
Trichoprotection products 
Bacteria present in roots and rootstock 
decreased by 32-36% 
Fungal present in the roots decreased by 29%
Black goo fungi decreased by 40% 
Mean root mass increased by 42% 
Turf Trichopel-Turf raked into the 
surface layer of the seed-bed 
Significant decrease in mean disease scores 
a Source: Agrimm Technologies Limited. 
Several products based on Trichoderma have been developed. They have been successfully 
applied on many different crops; field crops as well as for indoor crops. Table 4.11 above 
indicates some benefits from the use of Trichoderma. 
 
Although the Trichoderma range of products has proved to be effective in a number of crops, 
the uptake appears limited. Information collected in the present research suggested that the 
economic contribution of Trichoderma products to the New Zealand primary sector is below 
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the level of materiality. This value is approximate, because information on exact impacts on 
the different cropping systems using Trichoderma products were unavailable. 
 
4.3.2.3  ToxoVax 
 
AgVax was formed to commercialise vaccines developed by AgResearch. They have three 
main products: AndroVax, CampyVax, and ToxoVax. This research estimated the economic 
contribution of one vaccine, ToxoVax. Estimates of the value of the other two main products 
are not provided here. AndroVax increases ewe fertility and lambing percentages. Because it 
is a fertility regulator and not an agent that controls a disease or pest, it is not included in the 
estimates calculated here. CampyVax is a vaccine against Campylobacter fetus fetus, which is 
considered the leading bacterial cause of abortions in sheep in New Zealand (Fenwick et al., 
2000). From the literature, the overall extent of losses due to this organism is unclear; for 
example, estimates of the number of ovine abortion per year or the per cent of abortions that 
were bacterial in origin were unavailable. Significantly, Orr (1996) reported that ‘[s]heep in 
New Zealand are remarkably disease free’ (p. 105). It is also of importance to this valuation 
of the impact of biotechnology that an earlier vaccine had been available in New Zealand 
since 1980 (Fenwick et al., 2000), and it would have been the result of older technology. The 
contribution of CampyVax is thus the difference between control provided by the earlier 
vaccine (the counterfactual situation) and the improved control that CampyVax seems to 
offer. The information necessary to calculate the economic contribution of this difference was 
unavailable, but the presence of an alternative, though less effective, vaccine suggested that 
the contribution of biotechnology in this instance was fairly low. 
 
Key informants at AgVax were very obliging and provided very useful information on the 
effects of ToxoVax and the history of its development. The company’s Website notes that 
field trials show an average national increase in lambing of three per cent for vaccinated 
flocks. The key informants estimate that a large percentage of replacement ewes are 
vaccinated with ToxoVax. The financial information provided was analysed for consistency 
with secondary data sources and then used to estimate the contribution that ToxoVax makes 
to the primary sector. Using financial information from Burtt (2004) and the information from 
AgVax, both from key informants and the company’s Website, the vaccine is estimated to 
contribute $33,372,000 annually to sheep farmers’ gross margins after costs.  
 
4.3.2.4  Ballance 
 
The Ballance Bioshield Grassgrub uses natural soil bacteria to break the population growth 
cycle for grass grubs. It was developed in a joint venture between Ballance Agri-Nutrients 
and Celentis. 
 
The product eliminates the need to use chemical pesticides. The product is drilled into the 
soil, which costs $70-$100 per hectare. Chemical spray methods have an application cost of 
$70 per hectare. The control agent is active in the soil for up to five years, during which time 
it introduces bacteria that interfere with the life cycle of grass grubs by causing the grub to 
stop eating.  
 
The technology has been on the market for ten years (previously under the name Invade) and 
is currently applied on 2000-3000 hectares per year. 
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Information on the economic costs and benefits of Bioshield was unavailable for this research. 
In addition, secondary sources were insufficient to be used for estimations. This product is 
thus noted as an example of biotechnology but no value for it was estimated. 
 
4.3.2.5  Bt 
 
The bacterium Bacillus thuringiensis (Bt) attacks agriculturally important pests, with different 
subspecies targeting different families of insects. Commercial preparations of Bt are 
particularly important in integrated pest management (IPM) systems, for organic agriculture, 
and in MAF’s eradication programmes for several exotic moths. Bt products are widely 
available and commonly used in New Zealand and overseas. 
 
The value of Bt products derives from essentially two sources: in the first place, they allow 
agricultural production without use of chemical pesticides. This may allow producers to 
achieve a premium price in the market, such as a premium price for organic produce. The 
second source of value is the damage to production that is avoided by using the product. In 
New Zealand’s case, this includes the agricultural production that may be saved because 
MAF’s eradication programmes prevent exotic pests from establishing themselves here. 
 
By far, the largest user of Bt in New Zealand is MAF. MAF’s own economic impact 
assessments of the eradication programmes indicate that the value of production that has been 
saved up to the present by using Bt is quite small. The population models that underlie MAF’s 
reports have very small growths in pest populations in the first years of infestation. It is not 
until several years after the first appearance of pest species that they begin to have 
economically significant populations. In addition, the different exotic insects have different 
impacts on horticulture and forestry. New Zealand forests are not particularly good hosts for 
several exotic species, so potential economic damages are limited. Some horticultural crops 
are good hosts to some species, but account for only a percentage of total damages. The net 
result is that the value of currently avoided damages through the use of Bt is rather small, in 
the hundreds of thousands of dollars. It should be emphasised, however, that this use of 
MAF’s economic impact assessment does not in any way address the calculations of present 
value of future damages. Such calculations are outside the scope of the present research. 
 
The rest of the Bt use in New Zealand can be attributed to the organic and IPM producers, 
who use it throughout horticultural production. Data on its use and impact are unavailable, 
however. The specific impacts are related to the target insect pests and the crops on which Bt 
is used, so that its impacts need to be assessed on a crop-by-crop basis over several years. 
Furthermore, its net impact for organic and IPM producers is related to the potential premium 
that producers received as well as the cost structure of organic production. This net impact 
thus also needs to be assessed in the context of both prices and total production costs; 
unfortunately, data were not available to do this. The economic impact of Bt use in organic 
agriculture was also deemed economically immaterial in the context of this report because of 
the relatively small size of the organic sector and the fraction of that production that could be 
attributed to Bt. 
 
In sum, while Bt is likely to be important both in particular cases and as a preventative 
measure, its current contribution to New Zealand primary production is likely to be less than 
one million dollars in total. 
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4.3.2.6  Ryegrass endophytes 
 
Endophytes are fungi that live within ryegrass plants. Wild-type endophytes that occur 
naturally in New Zealand pastures have been shown to have harmful effects on grazing 
animals. The most significant of these effects is the condition called ‘ryegrass staggers’. 
 
As a result of research on the connection between endophytes and ryegrass staggers, 
AgResearch identified alternative beneficial endophytes and developed technology for 
inoculating ryegrass cultivars with this novel endophyte. Seed companies currently use this 
technology to produce AR1 lines of pasture seeds, which now accounts for a significant 
portion of their seed sales. In the three years since commercial release of this endophyte, 
annual sales have gone from 800 tonnes to 2,000 tonnes of seed. 
 
Key informants provided good information about the impact of the AR1 endophyte on 
pastoral production in New Zealand. Although specific estimates varied, the novel endophyte 
increases production by about $200 per hectare on sheep farms and by $200 to $400 on dairy 
farms, with the lower figure the more consistent estimate. The increased cost of the seed is 
about $25 per hectare and a single planting lasts five to ten years. The seed is sown at 20 kg 
per hectare, so the amount of pasture sown to AR1 ryegrass is 200,000 hectares. Using these 
figures, Table 4.12 calculates the increased production in dairy and sheep production and the 
impacts on gross margins. For this calculation, the counterfactual situation was the absence of 
improved endophytes and the presence of wild-type endophytes. The entire amount of the 
increased production was thus attributed to this biotechnology. In total, AR1 endophyte seeds 
are estimated to increase farmers’ gross margins by $25,351,000. 
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Table 4.12  Economic contribution of AR1 novel endophyte to pastoral production 
Product Revenue
a 
($000’s) 
Number of 
AR1 hectaresb
Impact of AR1 
($/hectare) 
Increased 
production 
($000’s) 
Gross margina 
($ per $ of 
revenue) 
Cost of AR1 seed 
at $25/hectare 
($000’s) 
Value of AR1 
($000’s)c 
Dairy 5,312,500 130,600 $200 26,120 0.79 3,265 17,370 
Sheep farming 2,824,090 69,400 $200 13,880 0.70 1,735 7,981 
Total 8,136,590 200,000  40,000   25,351 
a See Table 4.9 for calculations and sources. 
b AR1 hectares are apportioned to the two subsectors as a function of their revenue. 
c Value of AR1 is equal to (Increased production * Gross margin) – Cost of AR1 seed. 
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4.3.2.7  Summary: Biocontrol agents 
 
This review of biocontrol agents in the primary sector has examined the economic impact of 
several specific products, all of which have impacts on more than one subsector. Interviews 
with key informant and research on the economic impacts of these biocontrol agents indicate 
that these estimates include the economically significant examples of biocontrol agents in 
New Zealand. Given the constraints of time and information, this research did not estimate 
specific economic impacts for every product identified, but their impacts do not rise to the 
level of materiality. 
 
Table 4.13  Summary of economic contributions of biocontrol agents 
Subsector 
Value of biocontrol agents 
($000’s) 
Dairy 19,893 
Beef and veal 772 
Sheep (meat and wool) 41,353 
Forestry nil 
Horticulture and 
floriculture small value 
Arable crops nil 
Seafood nil 
Total 62,018 
 
4.3.3 Direct impacts: Enzyme manipulation 
Enzyme manipulation has wide use in food processing, turning products from the farm and 
sea into the products on supermarket shelves. They have much less use, however, in getting 
products to the farmgate. Most enzyme use was thus excluded by the focus of this project on 
the primary sector. There may be significant benefits from this technology but their 
assessment was beyond scope of the project. 
 
This research examined enzyme manipulation in three areas: a product that inhibits 
nitrification by enzymes in pastures, enzymes in wine production and enzyme use in 
producing dairy products. The use of enzyme manipulation for these products will be 
discussed in turn. 
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4.3.3.1 Eco-n 
 
Dicyandiamide (DCD) is a nitrification inhibitor that slows down the conversion of 
ammonium to nitrate. It is marketed in New Zealand as ‘eco-n’ by Ravensdown and under a 
different product name by Ballance. DCD reduces the leaching of nitrates from grazed 
pastures and also significantly increases pasture production by improving soil nutrient cycles 
in grazed dairy pastures. Eco-n is a joint development project between Lincoln University and 
Ravensdown. 
 
Eco-n is applied as a suspension spray in April-May and again in August-September. This 
covers the periods when most soil drainage (leaching) occurs. Trial results show that eco-n 
can give a 60 per cent reduction in nitrate leaching, 50 per cent reduction in potassium, 
calcium and magnesium leaching, and 75 per cent reduction in greenhouse gas emission 
(nitrous oxide), in addition to a 15 per cent increase in pasture production (Cameron, Di, 
Moir, Christie, & Pellow, 2005; Di & Cameron, 2004; Ravensdown). 
 
Cameron et al. (2005) provided the following figures which indicate the economic benefits of 
eco-n application on grazed dairy pastures. 
 
Table 4.14  Per-hectare benefits of eco-n 
 10% increase in pasture 
production 
15% increase in pasture 
production 
Increased pasture 
production 
1300 kgDM/ha/yr 1950 kgDM/ha/yr 
Additional milksolids 87 kgMS/ha/yr 130 kgMS/ha/yr 
Total Gross return  $347 /ha/yr $520 /ha/yr 
Net return $223 /ha/yr $396 /ha/yr 
 Source: Cameron et al. (2005) 
The calculations were based on a payout of $4.00 per kilogram of milksolids, a conversion 
rate of 15 kilograms of drymatter per kilogram of milksolids, and a base production of 13,000 
kilograms of drymatter per hectare and year. 
 
Dairy farmers with production of 13,000-15,000 kilograms of drymatter per hectare per year 
can expect results from eco-n application as detailed in Table 4.14. High input farmers, i.e. 
around 200 kilograms of nitrogen application per hectare and year, will experience a different 
result as they probably would not be able to increase drymatter production. Instead, they 
should be able to apply eco-n, reduce their nitrogen inputs and still experience the same level 
of production (Ravensdown). Thus, it is prudent to use a ten per cent increase in pasture 
production as an average increase when calculating the benefits to New Zealand, although 
most scientific results indicate a 15 per cent average production increase (Cameron et al., 
2005). 
 
In the summer of 2004, eco-n was applied to approximately 17,000 hectares. With a net return 
of $223 per hectare and year, the total net return to the industry is $3,791 million. Information 
on the DCD product marketed by Ballance was unavailable. 
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4.3.3.2  Dairy enzymes 
 
This research has not estimated a value for enzyme use in the dairy industry. It was clear that 
enzymes, including ones improved through biotechnology, are used in processing raw milk 
into dairy products, such as cheese and cheese flavouring. These products amount to billions 
of dollars of exports for New Zealand per year. 
 
While it was possible to find information about the products in which enzymes are used and 
somewhat less information about what those enzymes are, it was not possible to obtain 
economic information on enzyme use. There was an unwillingness on the part of the dairy 
industry to demonstrate any economic benefit from improved enzymes or any benefit from 
research into improved methods of processing. There are naturally-occurring enzymes that 
can be used to produce dairy foods, so the question of economic interest is the benefit that this 
industry derives from using the products of biotechnology. 
 
The dairy industry is a good candidate for future research, for several reasons. First, it is an 
important contributor to New Zealand’s primary production and exports. Secondly, there are 
clear alternative methods of production, some that use biotechnological innovations and 
others that do not. The assessment of the contribution of these innovations should be 
relatively straightforward. Thirdly, the dairy sector controls millions of dollars of research 
spending; some of these funds are privately generated while others are from public sources. 
Further research would therefore have an interest in assessing the value of publicly funded 
research. 
 
4.3.3.3  Wine enzymes 
 
Enzymes are used in a number of ways in producing wine. They increase the amount of juice 
extract from pulp and increase the clarity of the wine, amongst other impacts. Information 
from a key informant suggested the use of enzymes increase the production of wine from 
grapes by ten per cent over that which could be achieved without enzymes. Notably, one of 
the enzymes used in beverage processing is itself a product of biotechnology. This is C-fine, a 
product of the seafood industry (Boase, 2002, 12 April). 
 
The economic valuation of the impact of enzymes assumed that the impact of enzymes was to 
increase effective wine grape production by ten per cent without increasing the costs of 
production. That is, using enzymes was like having ten per cent more grapes to crush from the 
same acreage, without incurring higher cultivation or harvest costs. The following analysis 
was based on the estimate of a ten per cent of the value of production. 
 
Table 4.15  Value of enzymes to wine grape production 
Grapes crusheda 166,000 tonnes 
Price of bulk wine grapesb $600 per tonne 
Impact of enzymes at 10% of production $9,960,000 
a SONZAF 2004  
b Burtt (2004)  
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4.3.3.4  Forestry 
 
Enzymes do not appear to have commercial application in the forest and logging business but 
can be used successfully in the pulp and paper industry. Enzyme technology has the potential 
to increase the quality and quantity of feedstocks for pulp and paper processes, reduce 
manufacturing costs, and create high-value products. The technologies can also reduce 
environmental issues related to the industry. 
 
As the pulp and paper industry is very capital-intensive with facilities specific to the tasks, 
new technology must have significant benefits or fit easily into the existing manufacturing 
processes. Although many enzymatic applications have been proposed in the scientific 
literature, commercialised technologies tend to change existing industrial processes as little as 
possible. Commercial applications include xylanases in prebleaching kraft pulps and various 
enzymes in recycling paper. 
 
The decision to use enzyme in the production process depends on process economics, and as 
of writing this report no such situation exists in New Zealand. Consequently, there exists no 
current commercial application of enzyme technology in the New Zealand pulp and paper 
industry. However, it is more than likely that we will see some application within 
approximately the next five years as some processing facilities will reach capacity limits and 
most likely will include enzyme applications in their expansion plans. 
 
4.3.3.5  Summary: Enzyme manipulation 
 
The following table presents total results from commercial applications of enzyme 
manipulation. They do exclude the use of biotechnological enzyme in processing dairy foods. 
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Table 4.16  Summary of economic contributions of  
enzyme manipulation 
Subsector 
Value of enzyme manipulations 
($000’s) 
Dairy 3,791 
Beef and veal nil 
Sheep (meat and wool) nil 
Forestry nil 
Horticulture and 
floriculture 9,960 
Arable crops nil 
Seafood nil 
Total 13,751 
 
4.3.4 Direct impacts: Marker assisted selection/breeding 
 
In the course of this research, interviews regarding marker-assisted selection/breeding (MAS) 
were conducted with people in universities, CRIs, and private firms across all sectors. The 
general message was that it has led to few commercial products to date. In horticulture, MAS 
is used in the basic science, but it is not clear that it has led to new commercially-available 
cultivars. The basic science is still quite new and the cost-benefit ratio of using markers is 
conditional on the quality of the marker, the kind of trait under investigation and the cost of 
testing. The same is largely true in arable crops and pasture plant breeding. MAS continues to 
be of interest, but again not commercial. 
 
One innovation produced through MAS was a field pea cultivar. The biotechnology was used 
to produce the cultivar and definitely led to an improvement. Sales of the seed overseas are 
apparently yielding a revenue stream for Crop and Food Research. However, the contribution 
to the primary sector did not appear large enough to warrant more thorough investigation, 
given that the exact data were not readily available. 
 
4.3.4.1  Livestock 
 
Two commercial products are available in New Zealand: tests for the Inverdale gene and for 
the footrot gene. Other markers are scientifically established, but not yet commercially 
available. The Inverdale gene in the ram leads to more-fertile ewes, thus a benefit in the 
progeny of rams that have been tested. As the test was commercially released only this year, 
the primary sector will start to see the benefits after two breeding cycles (one for the more-
fertile ewes to be born, and a second cycle in which farmers should see greater production). 
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The footrot gene-marker test is used for selecting footrot-tolerant sheep to breed. Its use 
results in a reduction of other input costs, such as vaccinations, antibiotics, foot-paring and 
foot bathing, which are used for the control and prevention of footrot. As it reduces the use of 
chemicals, the technology may also benefit New Zealand’s ‘clean and green’ image, as well 
impact positively on market access issues. 
 
A thorough study by Greer (2005) assesses the benefits to the wool industry from adopting 
the footrot gene-marker test. The study surveyed all commercial merino and mid-micron 
farmers, and from that the benefits realised in 2003/04 were calculated at $770,000. The 
report also provides an estimation of future benefits of between four and 6.3 million dollars. 
 
4.3.4.2  Summary: marker-assisted breeding 
 
Marker assisted breeding and selection has been researched for many years, but is only now 
producing some commercial products. The only product that is now contributing materially to 
primary production in New Zealand is the test for the footrot gene marker. The only other 
commercial product appears to be the test for the Inverdale gene, which should begin yielding 
commercial value in primary production in a year or so. 
 
Table 4.17  Summary of economic contributions of marker  
assisted selection 
Subsector 
Value of marker assisted selection 
($000’s) 
Dairy nil 
Beef and veal nil 
Sheep (meat and wool) 770 
Forestry nil 
Horticulture and 
floriculture nil 
Arable crops nil 
Seafood nil 
Total 770 
 
4.3.5 Summary: Direct impacts of four biotechnologies 
 
This research fully investigated the primary sector in New Zealand to produce a list of the 
innovations produced using the four biotechnologies that are the subject of this report. Each 
innovation was examined in detail to determine its exact impacts on production and how 
production would be different in the absence of the innovation. Some innovations were 
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critical to the modern configuration of the industry, while others boosted productivity without 
changing productive processes. Those innovations adopted by large industries tended to have 
large absolute impacts, but were not necessarily the most significant as a percentage of output. 
Finally, this analysis accounted for the opportunity costs of resources used in production by 
relying on calculations of farmers’ gross margins (where appropriate). Table 4.18 provides a 
summary of impacts. 
 
Table 4.18  Summary of direct impacts of four biotechnologies 
 
4.4 Non-marketed benefits 
 
The benefits to the primary sector from using biotechnology are not limited to price and 
profitability impacts. Some impacts of biotechnology are ‘public goods’. This term refers to 
goods that are non-rival and non-excludable. A good is non-rival if one person’s use of them 
does not diminish another person’s use. A good is non-excludable if access to the benefits 
cannot be limited or rationed. Public goods are not bought or sold in private markets, so the 
value of these goods cannot be determined by examining prices for the goods and quantities 
traded. 
 
The basic tasks in researching non-marketed benefits are similar to evaluating direct 
economic benefits. The first step is to identify the specific impacts and estimate the 
magnitudes of the impacts. These estimates require the expertise of scientists who can provide 
information about air, water and soil quality impacts and about biological and ecological 
effects. After those impacts have been quantified, their value can be determined. 
 
Subsector 
Value of clonal 
propagation/cell 
manipulation 
($000’s) 
Value of 
biocontrol 
agents 
($000’s) 
Value of 
enzyme 
manipulations 
($000’s) 
Value of 
marker 
assisted 
selection 
($000’s) 
Total 
($000’s) 
Dairy 74,914 19,893 3,791 nil 98,598 
Beef and veal 20,890 772 nil nil 21,662 
Sheep (meat 
and wool) 35,287 41,353 nil 770 77,410 
Forestry 16,976 nil nil nil 16,976 
Horticulture and 
floriculture 32,995 small value 9,960 nil 42,955 
Arable crops 8,220 nil nil nil 8,220 
Seafood nil nil nil nil 0 
Total 189,282 62,018 13,751 770 265,821 
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The value of non-marketed benefits can be determined in a number of ways. If there is a good 
that can serve as a proxy for the non-marketed benefit, then price information on the proxy 
good can be used. In cases in which the non-marketed benefit can be shown to be bundled 
with other attributes in a marketed good, then the hedonic pricing method can obtain values 
for the non-marketed good. This is the case in which lack of air pollution effects housing 
prices, so that the willingness to pay to avoid air pollution is reflected in a price differential 
between areas with and without air pollution (Smith & Huang, 1995). For some impacts, 
cleaner production now averts clean-up costs later. Thus, the value of a benefit now can be 
measured by later expenditures that are averted. Other benefits, such as recreational values, 
can be determined by the travel cost method. This valuation method determines willingness to 
pay for the benefits of recreational amenities by looking at the extra costs that people are 
willing to incur in order to enjoy them (Devlin, Corbett, & Peebles, 1995). Finally, various 
survey-based methods, such as contingent valuation and choice modelling, determine the 
value of non-marketed benefits by examining the stated preferences of survey respondents 
(Bateman et al., 2002). These methods can be used to calculated values for essentially any 
impacts that can be sufficiently defined and described. 
 
As an example, the possible ways to measure the value of water resources are shown in Table 
4.19. The quality and availability of water resources are affected by agricultural production, 
and can be affected by the use of biotechnology. The appropriate method for determining the 
value of water resources depends on which aspect of water resources is being valued. Several 
studies have estimated values for different types of values and different groups of people, as 
shown in Table 4.20. These studies have used different techniques to estimate the values for 
non-marketed benefits. Similar research has been done for air quality to determine the 
willingness to pay for reductions in particulate matter. Studies using the hedonic method are 
summarised in Smith & Huang (1995). 
 
Table 4.19  Methods for valuing water resources 
Issue Suggested Method 
What is the value of irrigation water to agriculture? Production function 
Hedonic pricing 
What is the value of potable water? Averting expenditure 
Contingent Valuation 
What is the recreational value of surface water? Travel Cost 
Contingent Valuation 
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Table 4.20  Previous studies estimating the monetary value of water resources 
Author Method Type of Value Existing Estimatea 
Lynch and Weber, 
1992 
Contingent 
Valuation 
In-stream Water Values, 
Ashburton Anglers 
$50-$161/household/year 
(NZ$1991) 
Lynch and Weber, 
1992 
Contingent 
Valuation 
In-stream Water Values, 
Ashburton 
Non-anglers 
$28-$95/ 
household/year(NZ$1991) 
Lynch and Weber, 
1992 
Contingent 
Valuation 
In-stream Water Values, 
Ashburton 
Non-Ashburton 
$15-$63/ 
household/year(NZ$1991) 
Sheppard et al., 
1992 ; 1993 
Contingent 
Valuation 
Improved Water Quality, 
Lower Waimakariri River
$93-$133/household/year 
Faux and Perry, 1999 Hedonic Pricing Irrigation Water Value, 
Malheur County, Oregon
$514-$2551/acre depending 
on class of land (US$1999) 
Torell, Libbin & 
Miller, 1990 
Hedonic Pricing Irrigation Water Value, 
Ogallala Aquifer, USA 
$9.05 acre/foot (1983 US$)- 
$1.09 acre/foot (1986 US$) 
Kerr, Leathers & 
Sharp, 1983 
Travel Cost Rakaia River Salmon 
Angling 
$20 angler/visit ($NZ 1983)
Fraser, 1989 Travel Cost Wanganui River 
Recreation 
$104/person/visit ($NZ 1989)
Sanders, Walsh and 
Loomis, 1990 
Comparison 
Between Travel 
Cost and 
Contingent 
Valuation 
Protection of Rivers 
Rocky Mountains 
Colorado 
Travel cost: $23 ($US 1990)
Contingent Valuation: $21-
$24 ($US 1990) 
Source: adapted from (Devlin et al., 1995). 
a These values are current and in national currencies. The values can be converted to New Zealand currency with
the relevant exchange rate at the time the original study was conducted. To be strictly comparable, the values 
should be further adjusted for relative purchasing power across the countries concerned. 
 
To determine the value of non-marketed benefits in the present research, the best practice 
would be to identify specific impacts of a biotechnological innovation and describe the extent 
and magnitude of each impact. Depending on the impact, one of the above methods would be 
chosen as the appropriate method for determining the value of the impact. The value of that 
specific impact would then be accurately and appropriately measured. That value would then 
be applied to the impact as measured by scientists working on the specific biotechnological 
innovation. 
 
For nearly all of the innovations described above, very few data on non-marketed benefits 
were available. The impacts were insufficiently identified or described, the magnitudes of the 
impacts had not been measured, and appropriate valuations of those impacts were in any 
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event unavailable. The following discussion describes the potential impacts that should be 
considered and provides one example of an estimated economic value. However, a full picture 
of non-marketed values awaits further detailed research. 
 
4.4.1 Non-marketed impacts from biotechnology 
 
The biotechnological innovations reviewed above have changed primary production in one of 
two ways. Many of the innovations have made production more efficient. They have allowed 
primary producers to have more output per unit of input. A stark example of this increased 
efficiency is that ‘30 million ewes in the national flock now produce the weight of lamb meat 
each year that 70 million produced in the mid-1980s’ (Stringleman, 2005). Another example 
is the change in harvest index in arable crops. While the biomass of arable crops has remained 
largely constant, more of that biomass is in the grain and less of it is in the stem. Thus, more 
grain is harvested per hectare. The other type of change has been a shift to less-toxic methods 
of production. The use of clonal propagation in potatoes or Bt spray for controlling moth pests 
has replaced other methods of production or control that were more toxic in the environment 
or to non-target species. 
 
These general categories of changes have had the potential to have several specific impacts. 
One such potential impact is that environmental pressures from increased production could be 
less than they might have been. For example, if per-hectare production had not increased, then 
more area might have been brought into production, including increasing amounts of 
environmentally sensitive acreage. These environments could have been degraded, with an 
overall decline in environmental resilience and sustainability. 
 
A biotechnological innovation might also reduce agricultural chemical use. In the case of 
potatoes, clonal propagation has allowed the production of pathogen-tested, virus-free 
potatoes. According to key informants, the alternative methods of production rely on 
agricultural chemical with high toxicity. Plant breeding in other crops has focused on 
breeding for resistance to pests and diseases, again reducing the amount of pesticide use. 
Other innovations may have reduced the need for chemical fertilisers. 
 
The follow-up from such changes could be increased biodiversity. Through both a reduction 
in chemical pesticide use and changes to biocontrol agents, agricultural production could have 
reduced impacts on non-target species. These species may thus have been able to continue to 
survive even while agriculture has controlled pest species. 
 
Finally, air, soil and water pollution might have been reduced due to the use of biotechnology. 
With fewer hectares in production and more efficient use of water and agriculture chemicals, 
an innovation would have the potential to reduce pollution. 
 
4.4.2 The value of non-marketed benefits 
 
The value of non-marketed benefit from the biological innovations identified in the present 
research is uncertain. This uncertainty stems from a lack of information in two areas. First, the 
specific non-market benefits of the innovations were, in many cases, not specified by key 
informants. Data that would allow calculation of per-hectare reductions in pollution or 
measured changes to water quality were generally not available. The second source of 
uncertainty was the value to assign to specific changes even when they were identified. 
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Clearly, this is an area of future research. The approach to valuing non-marketed benefits 
needs to be inter-disciplinary, because it requires the expertise of physical scientists to 
identify and quantify impacts and the expertise of social scientists to determine the values of 
the impacts to the general public. 
 
An example of how this research might proceed can be provided here. Lincoln University 
researchers have analysed the specific impacts of eco-n, a product that Ravensdown has 
commercialised. They have determined that eco-n leads to a 60 per cent reduction in nitrate 
leaching, a 50 per cent reduction in potassium, calcium and magnesium leaching, and a 75 per 
cent reduction in emission of the greenhouse gas nitrous oxide (Cameron et al., 2005). The 
nitrous oxide emission reduction can be evaluated directly as the carbon dioxide equivalent 
value in carbon credits. One tonne of nitrous oxide has the global warming potential of 310 
tonnes of carbon dioxide (IPCC, 2001). The New Zealand government has decided to cap 
charges at $25 per tonne of carbon dioxide equivalent (New Zealand Climate Change Office, 
2002). Nitrous oxide can thus be valued at $7,750 per tonne. Once the impact of eco-n on 
emissions from a hectare of pasture is calculated, the dollar value of that emission can be 
calculated. Reduction in nitrate leaching has two impacts: it increases the availability of 
nitrogen to the pasture plants and it reduces nitrate pollution of water. The availability of 
nitrogen, once quantified, can be valued at the equivalent cost of urea fertiliser. Next, the 
impacts of nitrate leaching need to be described, e.g., impacts on the quality of drinking water 
and impacts on waterways. The value of these impacts can then be determined by using one 
or more of the valuation methods described above. The impacts of reduced potassium, 
calcium and magnesium leaching need to be similarly described and valued. With this 
information on the specific impacts and the values attached to them, the aggregate impact of 
eco-n could be determined. 
 
It is unfortunate that data were unavailable that would allow the valuation of non-marketed 
benefits. Key informants were able to provide general descriptions of the sorts of benefits that 
biotechnological innovations provide. However, measurements of specific benefits were 
generally unavailable. Where they were available, the benefits were not necessarily specified 
in a way that could be easily valued. Finally, data on the potential value of properly specified 
benefits were largely unobtainable. 
 
4.5 Conclusion 
 
This chapter has presented detailed calculations of the direct costs and benefits of 
commercialised biotechnological innovations in the primary sector. Through the discussions 
with key informants, this research was able to identify all innovations of commercial 
importance that rely on any of the four biotechnologies, clonal propagation/cell manipulation, 
biocontrol agents, enzyme manipulations and marker-assisted selection. Using primary and 
secondary data sources, the analysis estimated the direct economic value of each innovation to 
each subsector of the primary sector. 
 
The total estimated net benefit of these innovations to the primary sector was $266 million per 
year, assuming constant prices. Clonal propagation/cell manipulation represented the largest 
contributor to that total, by virtual of its widespread and relatively long-term use. Biocontrol 
agents had a smaller economic impact, and the impact of enzyme manipulation was smaller 
still. The least-commercialised biotechnology was marker-assisted selection, with only one 
innovation currently contributing to the economic performance of the primary sector at a 
value of less than one million dollars. 
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The contribution of these biotechnologies to the different subsectors is also apparent in these 
calculations. Dairy production benefited the most from these innovations, even without 
calculations of the contributions from enzymes used in dairy processing. This result is not 
surprising, given that dairy production is the largest of the subsectors. Other pastoral 
agriculture also benefited, with impacts on sheep production larger than those on beef and 
veal production. The horticulture subsector showed significant benefits, with some crops 
heavily reliant on biotechnology and other barely affected. The dollar value of impacts in 
arable crops was relatively small, but this was a function of the size of the subsector. Finally, 
impacts were relatively small for forestry as only one of the biotechnologies had commercial 
application, and they were nil for seafood production. 
 
Additional information related to these estimates is provided in Appendix 3 and Appendix 4. 
Appendix 3 provides a list of the specific innovations identified in this research, with a brief 
description of each. Appendix 4 provides additional calculations of the economic impacts of 
biotechnology. This research found that some innovations have had a range of impacts. In this 
chapter, those ranges are reduced to point estimates. Appendix 4 calculates the impacts based 
on the ranges identified. 
 
Estimates of the non-economic impacts were not possible. This research found that non-
economic benefits have in general not been specified or measured. While there were 
suggestions in the literature and in discussions with key informants about possible non-
economic benefits, such as environmental improvements, there is essentially no information 
about the exact impacts. Without this information, there can be no measurement of the value 
of these possible impacts. If non-economic benefits are considered an important contribution 
of biotechnology, then this is clearly a significant gap in the research. 
 
In addition to providing the above dollar estimates, this research has developed and 
demonstrated a robust method for identifying innovations and determining their economic 
contribution. This method can be applied in future research examining the impacts of other 
biotechnologies or the contributions to other parts of the economy, resulting in directly 
comparable value estimates. 
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Chapter 5  
Trade Impacts of Biotechnologies 
 
5.1 Introduction 
The above estimate of the direct economic impacts of four biotechnologies contains an 
important assumption. It was assumed for that analysis that the changes in production had no 
impact on farmgate prices. Biotechnology was shown to increase the production of several 
important commodities, but no adjustment was made for possible price impacts. This chapter 
estimates those price impacts. 
 
This trade modelling is an important contribution to the literature on biotechnology. Most 
research on the trade impacts of biotechnology has had to rely on ad hoc assumptions 
regarding productivity impact due to lack of data. The present research has estimated actual 
productivity impacts of commercialised biotechnology products. These impacts are then 
incorporated into a model of international trade. This analysis of trade impacts thus has a 
stronger factual basis than prior research. 
 
5.2 Theory 
 
Economic theory explains the relationship between market prices and quantities produced. 
For those commodities considered ‘normal’ goods, an increase in the amount produced leads 
to a reduction of the market price, assuming that preferences for the commodity are 
unchanged1. An important empirical question for this research is whether the increased 
quantities from New Zealand’s primary sector are sufficient to produce a price change. If the 
quantity that New Zealand produces is small in relation to the world market, then New 
Zealand is a ‘price taker’ – it can sell as much or as little as it produces without the market 
price changing. On the other hand, if New Zealand is a significant producer in relation to the 
world market, changes in New Zealand production could affect the market price. 
 
The effects of a change in productivity on revenue in New Zealand’s primary sector are 
shown in Figure 5.1. In this figure, the line S1 indicates current production using 
biotechnology. The line S2 indicates production in the absence of biotechnology. This is a 
backward shift or a shift to the left for the supply line, because production would be more 
expensive without biotechnology. Demand is indicated by the line D. The intersection of S1 
and D at point A indicates the present market situation, with price PA and quantity QA. Point B 
is the intersection of a price level at PA and line S2, production without biotechnology. The 
economic impact calculated in Chapter 4 assumed a constant price at PA but an increase in 
production from QB to QA. Implicitly, this assumed that New Zealand could not affect 
international prices. An increase in productivity would therefore inevitably lead to an increase 
in producer returns. 
 
The results modelled in this chapter are based on a different assumption, which is that New 
Zealand may be able to affect world prices. A model of international trade was used to model  
                                                 
1 This study assumes that preferences for the products of the primary sector are unaffected by the use of 
biotechnology. The innovations identified in this research did not appear to affect consumers’ preferences or 
willingness to pay. Previous research has demonstrated that effects on consumer preferences are an important 
consideration when evaluating the potential commercial impacts of certain types of biotechnology (Kaye-Blake, 
Saunders, & Fairweather, 2004; Saunders & Cagatay, 2003; Saunders, Kaye-Blake, & Cagatay, 2003). 
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Figure 5.1 Impacts of change in productivity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the market situation represented by the intersection of line S2 and line D at point C. This 
modelling recognised that changes in the quantity produced and exported can affect prices of 
primary products. The price level would not be expected to remain at PA, but would be 
expected to find a new equilibrium, represented by PC. The net contribution of biotechnology 
is the difference in areas of the rectangles PA A QAO and PC C QCO. Each of these rectangles 
indicates total revenue to the primary sector, either with biotechnology (PA A QAO) or without 
(PC C QCO). The difference can be expressed in percentage terms and combined with Chapter 
4 calculations to produce a price-adjusted estimate of the impacts of biotechnology. An 
important consideration with the price-adjusted estimate is that the impact of biotechnology 
could theoretically be either positive or negative. 
Economists distinguish between elastic and inelastic demand for goods. The price elasticity of 
demand is a measure of the percentage change in price expected from a percentage change in 
marketed quantities. If demand for a good is price elastic, then a change in the quantity 
produced leads to a comparatively small change in price. If demand is price-inelastic, then the 
price change is comparatively large. In general, demand for agricultural commodities is price-
inelastic: increasing the quantity supplied has a relatively large impact on the market price. 
The aggregate impact from increasing the supply of a price-inelastic good is a reduction in 
total revenues (price multiplied by quantity). This characteristic of some goods has important 
implications for the New Zealand primary sector, because it means that an increase in 
productivity can actually cause producer returns to fall. 
 
The basic facts about New Zealand’s primary sector suggest that international price impacts 
need to be analysed. New Zealand is an open economy, so the shifts in international 
commodity prices are transmitted directly to the farmgate (Kaye-Blake et al., 2003; Ministry 
of Agriculture and Forestry (MAF), 2004c). Much of New Zealand’s primary production is 
exported, again suggesting that international commodity prices are significant for farmgate 
prices. Finally, New Zealand represents a significant portion of world trade in some 
agricultural commodities, so that exporters of those commodities tend to face markets that are 
relatively price-inelastic. To summarise, the New Zealand primary sector depends to a large 
QB QC QA Quantity 
Price 
PA 
PC 
C 
B A 
D 
S2 
(without biotechnology) 
O 
S1 
(with biotechnology) 
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extent on exports of price-inelastic commodity products and has little buffer from 
international price changes. An analysis of trade impacts is therefore important. 
 
5.3 Literature review 
 
There have been several reviews of the literature on biotechnology and international trade, 
including those in Campbell, et al. (2000); Kaye-Blake, et al (2003); Kaye-Blake & Saunders 
(2003); Saunders & Cagatay (2003); and Stone, et al. (2002). Trade analyses and these 
reviews have focused largely on genetically modified crops, and in particular on specific 
crops rather than the value of the underlying horizontal enabling biotechnologies. They are 
valuable to the extent that they review findings regarding impacts of productivity gains and 
consumer willingness to pay for enhanced agricultural products. They also provide indications 
of robust methodologies for estimating trade impacts. 
 
Trade analysis has found that changes to agricultural productivity have quite different impacts 
to changes in consumer demand for primary products. Increasing productivity results in 
greater total social welfare, split between innovators, consumers, and producers. Innovators 
generally capture significant returns through appropriate licensing and pricing of 
biotechnological innovations. Consumers usually benefit from increased production: they 
have more food, fibre, and wood for lower prices. There are exceptions to this generalisation 
that arise from consumer reactions to genetic modification, but these exceptions are not 
germane to this research. Producers may or may not benefit from technology that increases 
agricultural efficiency. The exact impacts depend on the type of technology, its cost, and the 
final price level after adoption of the technology. By contrast, innovations that create primary 
products with enhanced consumer-oriented qualities lead to benefits across the board. 
Innovators can capture returns from the premium products, consumers gain by having better 
products, and producers benefit from higher prices. 
 
One method for analysing trade impacts is to use a partial equilibrium (PE) model. PE 
frameworks are ideal for quantifying the effects of changes in agricultural production. This is 
due to a number of factors, including the level of commodity disaggregation, the ease of 
traceability of interactions, the transparency of the results, the relatively small size of the 
models, and the low number of behavioural parameters and the methods used to obtain those 
parameters (Francois & Hall, 1997; Gaisford & Kerr, 2000; Roningen, 1997; van Beers & van 
den Bergh, 1996). An extensive programme of trade analysis for New Zealand has been 
conducted with the Lincoln Trade and Environment Model (LTEM). The LTEM was initially 
used to simulate various scenarios relating to adoption of GM crops in NZ, including reduced 
costs of production, premiums for and against GM and bans for GM products in key markets 
Japan and the EU (Saunders & Cagatay, 2001, 2003). Further modelling work has found that 
for biotechnology to have positive impacts on revenues to the primary sector, New Zealand 
must be able to keep productivity benefits for itself and/or the GM product must attract a 
higher price in world markets (Saunders et al., 2003). 
 
Another method for analysing trade impacts is to use a computable general equilibrium 
(CGE) model. These models, which can be much larger and more complex, quantify linkages 
between different parts of the economy. An international trade model would do this for all the 
sectors and countries in the model. There have been some CGE modelling activities in the 
Australian context that have relevance to New Zealand. A Productivity Commission Report 
(Stone et al., 2002) used the GTAP (Global Trade Analysis Project) model to examine 
potential impacts of GM technology on Australia’s trade in non-wheat grains and oilseeds. 
The results of the three scenarios in this report demonstrated that very small absolute changes 
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would occur in Australia’s import and export flows. Rather, regions with currently significant 
GM sectors (such as North America) received the most substantial impacts to trade and 
income. An assumptions critical to their findings is that incompletely-adopting countries 
(Australia, New Zealand, the EU) have an added regulatory burden that increases supply 
costs, whereas North America does not. In the present research, the innovations identified 
have not created any additional regulatory burden on the products of the primary sector. The 
negative impacts modelled in the Productivity Commission report are therefore not of concern 
to the present research. Those prior results thus suggest that the price impacts from the 
biotechnology innovations identified in the present research should be quite small. 
 
For the present research, the preferred method of analysis is a PE model. The ability to 
considered commodities at a very disaggregated level is a key consideration for modelling the 
impacts of the biotechnologies in this report. Furthermore, the relative ease and transparency 
of the modelling make the final impacts easy to understand and interpret. Linkages beyond 
the agricultural sector are quantified in supplemental ways, with the cost benefit analysis in 
Chapter 4 and the macro-economic analysis in Chapter 6. 
 
5.4 The trade model 
 
The trade modelling framework is the Lincoln Trade and Environment Model (LTEM); an 
agricultural multi-country, multi-commodity trade model that uses a PE framework to analyse 
the impact of changes in agricultural productivity and domestic agricultural and trade policies. 
The model is based on VORSIM, which evolved from SWOPSIM and its associated trade-
database used to conduct analyses during the Uruguay Round of General Agreement on Trade 
and Tariffs (GATT) negotiations (Roningen, 1986; Roningen, Dixit, Sullivan, & Hart, 1991). 
It has been used to analyse trade policies, climate change policies, and markets for organically 
grown, genetically modified, or otherwise differentiated products. 
 
The LTEM embodies all the advantages of PE trade models. An additional strength of the 
LTEM is its explicit modelling of the dairy sector at a disaggregated level. Because dairy 
markets are under the influence of various domestic and border policies, explicit modelling of 
supply and demand behaviour is essential in order to quantify the impacts of productivity 
changes. 
 
The LTEM includes 19 agricultural commodities (seven crop and 12 livestock products) and 
17 countries. The linkages of the agricultural sector with other industries and factor markets 
are not considered. The commodities included in the model are treated as homogeneous with 
respect to the country of origin and destination, and with respect to the physical 
characteristics of the product. Therefore commodities are assumed to be perfect substitutes in 
consumption in international markets. Importers and exporters are assumed to be indifferent 
about their trade partners. The nature of the innovations identified and described in Chapter 4 
suggests that assuming homogenous products is generally appropriate. The primary products 
that had quality enhancements through biotechnology are not commodities included in the 
LTEM. 
 
The LTEM is a synthetic model whose parameters are adopted from the relevant literature. 
Interdependencies between primary and processed products and/or between substitute/ 
complementary products are reflected by cross-price elasticities. The model is then used to 
quantify the price, supply, demand and net trade effects of various policy changes.  The model 
is used to derive the medium- to long-term policy impact in a comparative static fashion. The 
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base year the model works from is 2000. The present research models impacts up to 2005 to 
determine present price effects. 
 
In the general LTEM framework, there are seven endogenous variables in the structural-form 
of the equation set for a commodity under each country, made up of six behavioural equations 
and one economic identity. There are four exogenously determined variables, but the number 
of exogenous variables in the structural-form equation set for a commodity varies based on 
cross-price and cross-commodity relationships. The behavioural equations are: (i) domestic 
supply, (ii) demand, (iii) stocks, (iv) domestic producer price, (v) consumer price, and (vi) 
trade price. The economic identity is a net trade equation, which is equal to excess supply or 
demand in the domestic economy. For some products, the number of behavioural equations 
may change as the total demand is disaggregated into food, feed, and processing industry 
demand. This is determined endogenously. The equations in the LTEM are presented in 
Appendix 5. 
 
The results from the quantitative analysis of data from the interviews conducted in the course 
of this research serve as inputs to the model. They are used to generate estimates of the trade 
impacts of the biotechnological innovations. The equations and variables in the model are 
described in an appendix to this report. The next section discusses the model inputs generated 
for the present analysis. 
 
5.5 Model inputs 
 
The LTEM is used to model different scenarios in the primary sector in New Zealand. These 
scenarios are described with key inputs, whose values are modified to reflect different 
situations in the primary sector. The key inputs into the trade model are: the uptake rates of 
new technologies, the productivity impacts, and the willingness to pay for the products of the 
primary sector. These are each discussed in turn. 
 
5.5.1 Uptake of biotechnology 
 
One of the major factors affecting the aggregate impacts of an innovation on the primary 
sector is the proportion of producers who have adopted it. Adoption rates or portion of 
production using specific biotechnologies were detailed in Chapter 4. Adoption rates were not 
uniform across innovations or across subsectors. This variability in adoption rates creates 
difficulties in defining an overall adoption rate for biotechnology. 
 
In the LTEM, the commodities produced are assumed to be homogenous. As a result, it is 
possible to express the aggregate impact of a biotechnology as a percentage of production. In 
effect, the increases in production detailed in Chapter 4 are summed and a single shift in 
production is modelled for each commodity. Because of commodity homogeneity, the 
production impact is the same regardless of whether they are modelled as technology uptake 
by specific producers or simple commodity-wide productivity shifts. 
 
This method of modelling biotechnology’s impacts does not address the issue of uneven gains 
in the primary sector from uneven adoption of innovations. However, it would be relatively 
straightforward to extend the analysis in future research to include these effects. 
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5.5.2 Productivity increase 
 
The effects of biotechnology on the productivity of the primary sector are simulated with 
three alternative scenarios. The first scenario is the base case, primary production as it 
currently happens. This is modelled by using the base data for 2000 and modelling expected 
production up to 2005. No shifts in productivity are modelled in the first scenario.  
 
The other two scenarios model production in New Zealand in the absence of the 
biotechnological innovations described in Chapter 4. This absence is modelled as a reduction 
in primary sector productivity, proportional to the direct impacts quantified above. That is, 
productivity without biotechnology (S2 in Figure 5.1) would be less than productivity with 
biotechnology (S1 in Figure 5.1). The results from Chapter 4 provided an estimate of the 
reduction in productivity. The exact production shifts are given in Table 5.1. In this table, the 
negative signs indicate that production would be lower without biotechnology; this is 
equivalent to saying that biotechnology has increased production. Demand and supply 
equations in the LTEM are assumed to have constant elasticity functional form and 
exogenous shocks to this model arising from biotechnology are assumed to shift demand and 
supply by a constant percentage of price for all levels of production; in other words, pivotal 
shifts are assumed. These are similar to the shifts described in Frisvold et al. (2003) in their 
work on returns to technological advancements. 
 
The two alternative scenarios have one key difference. For the first one, the innovations are 
removed from the primary sectors of all countries in the model. This scenario examines the 
impact of an absence of biotechnology with the assumption that all countries have benefited 
equally from these innovations. For the second scenario, several of the innovations are 
removed from the primary sector only in New Zealand. This scenario is considered because of 
the New Zealand-specific application of some innovations. For example, the AR1 endophyte 
has been extensively adopted in New Zealand, but less extensively adopted elsewhere. 
 
Table 5.1  Trade model scenario inputs 
Trade commodity Change in productivity 
Scenario 1 
Production systems 
affected 
Scenario 2 
Production systems 
affected 
Wheat - 5.1% All countries All countries 
Coarse grains - 5.1% All countries All countries 
Beef, veal - 1.9% All pastoral NZ only 
Sheepmeat - 3.9% All pastoral NZ only 
Wool - 3.9% All pastoral NZ only 
Milk, raw - 2.3% All pastoral NZ only 
Apples nil n/a n/a 
Kiwifruit nil n/a n/a 
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Detailed modelling of the dairy complex is a key strength of the LTEM. In particular, the 
model separates production into extensive (e.g., pastoral) systems and intensive (e.g., feedlot) 
systems. This is an important distinction when modelling biotechnological innovations, 
because several innovations affected only pastoral systems. Feedlot production would not be 
improved by innovations in pasture quality. In order to reflect the differences among raw milk 
physical production systems in terms of the differences in nitrogen fertilizer and feed 
concentrates use, the countries Australia, EU, New Zealand and USA were separated into 
three regions and supply responses in these regions were modelled explicitly. 
 
The major dairy producing trading blocs were each sub-divided into regions (defined as in 
Table 5.2) to better reflect internal heterogeneity with respect to dairy production systems and 
environmental conditions. These divisions were based on observed variation in, for example, 
yields, stocking rates and drainage characteristics as well as the nitrogen fertilizer and feed 
concentrate use. The divisions are incorporated into the LTEM through the regional domestic 
raw milk supply equations. Data on production systems were taken from a number of sources, 
including farm advisory recommendations, census and survey reports, and field trials. 
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Table 5.2  Heterogeneity in the dairy production system amongst regions 
Region Production per cow (litres) 
Average 
stocking rate 
(per ha) 
Area 
(000ha) 
EU (15) :    
   West EU 5310 2.4 3174.8 
   East EU 4680 1.8 6639.6 
   Other EU 4991 2.3 3302.2 
Australia:    
   Victoria 4715 1.0 1267.9 
   NSW 4972 0.5 504.0 
   Rest of Australia 4608 0.5 1046.0 
USA: 7238   
   California 8439 10.0 149.2 
   WI, MI, MN, PA, NY 7182 3.0 1251.2 
   Rest of USA 6770 2.7 1727.8 
New Zealand:    
   Auckland 3278 2.8 494.6 
   South Island 3874 2.6 274.8 
   Rest of NZ 3300 2.0 570.4 
 
5.5.3 Willingness to pay for enhanced products 
 
The LTEM can simulate different willingness to pay for segmented commodity products. For 
example, an enzyme biotechnology that produces superior meat characteristics should lead to 
higher export prices for adopting producers. The trade model can incorporate data on the price 
premium received for the higher-quality meat and determine its impact on the revenues of the 
adopting producers and the sector as a whole. The modelling of such premiums is similar to 
the modelling of production impacts. 
 
This capability of the LTEM was not used for the modelling. For several commodities, there 
were no biotechnological innovations that altered product qualities and led to premium prices. 
For horticultural products, the interviews with key informants did identify some premium 
products; however, these products are not included in the LTEM. The main horticultural 
products in the LTEM, apples and kiwifruit, were not affected by quality-enhancing 
biotechnologies. Finally, this research did find some evidence of quality improvements in 
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arable crops. Data were not available on the specific changes or their price impacts. Due to 
lack of data, price premiums could not be modelled for arable crops. Thus, either because 
there were no enhanced products to model or because data were unavailable, no demand shifts 
were modelled. This would be an important area for future research, especially once specific 
quality enhancements could be identified in the primary sector. 
 
5.6 Modelling results 
 
Trade models by their nature produce a range of outputs: consumer and producer prices, 
quantities produced, quantities traded, and more. The information of importance here is the 
price change for each commodity as a result of lower production. For each commodity in the 
model whose production was affected by biotechnology, the difference between the producer 
price with biotechnology and the producer price in the absence of biotechnology was 
calculated. These calculations were made for both scenarios. The percentage changes in 
producer prices are presented in Table 5.3. 
 
Table 5.3  Impacts of productivity shifts 
Scenario 1 
World-wide impacts 
Scenario 2 
Some NZ-only impacts 
Trade 
commodity 
Change in 
productivity Change in NZ 
producer price 
(%) 
Change in 
NZ producer 
returns (%)
Change in NZ 
producer price 
(%) 
Change in 
NZ producer 
returns (%) 
Wheat - 5.1% 5.4 3.6 5.5 0.2 
Coarse grains - 5.1% 4.1 1.6 4.3 0.2 
Beef, veal - 1.9% 2.6 0.6 1.0 -2.0 
Sheepmeat - 3.9% 4.6 1.9 1.0 -6.3 
Wool - 3.9% 3.1 -0.6 1.0 -4.1 
Milk, raw - 2.3% 1.8 -1.2 1.1 -1.4 
 
The results in Table 5.3 conform to expectations. Scenario 1 considers the impact of 
worldwide adoption of biotechnology on the same scale as seen in New Zealand. As the 
results in Chapter 4 show, if New Zealand producers had not had access to the four 
biotechnologies, then primary production would currently be lower. When the impact of a 
worldwide reduction in productivity in the primary sector is modelled, market prices adjust 
upward in response to the reduction in supply. Trade also adapts to account for the change in 
productivity. As a result, the net change in producer returns for New Zealand is positive for 
wheat, coarse grains, beef and veal, and sheepmeat, and negative for wool and dairy. 
 
For Scenario 2, the price impacts are smaller for several commodities, those outside the arable 
crop subsector. These commodities were modelled as having improvements that applied only 
to the New Zealand primary sector, so that production in other countries was unaffected. 
Thus, the absence of biotechnology in New Zealand alone has smaller price impacts on 
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international commodity markets. The net impact on producer returns is essentially nil for 
wheat and coarse grains and negative for all other commodities. 
 
To calculate the dollar value of net direct impacts, gross impacts from Chapter 4 were 
adjusted by the changes in producer returns in Table 5.3. The gross margins were then 
calculated to make the results comparable to those in Chapter 4. Table 5.4 presents the results 
for Scenario 1, and Table 5.5 presents those for Scenario 2. For these calculations, changes to 
forestry and horticulture were not included, as they are not included in the trade model. 
 
Table 5.4  Scenario 1: impact of absence of biotechnologies 
Subsector 
Revenues with 
biotechnology 
($000’s) 
Change in 
producer 
returns  
(%) 
Change in 
producer returns
($000’s) 
Gross margin 
($ per dollar of 
revenue)a 
Net impact of 
absence of 
biotechnology 
($000’s) 
Dairy 5,312,500 -1.2 -64,169 0.79 -50,694 
Beef and veal 1,300,320 0.6 7,539 0.90 6,785 
Sheep (meat and 
wool) b 2,824,090 1.1 29,827 0.70 20,879 
Forestry  n/a   n/a 
Horticulture and 
floriculture  n/a   n/a 
Arable crops c 364,187 2.2 7,856 0.45 3,535 
Seafood  n/a   nil 
Total     -19,494 
a Gross margins are taken from various tables in Chapter 4. 
b The change in producer returns is calculated as the average of the Sheepmeat and Wool impacts in Table 5.3, 
weighted by the amount of revenue in Lamb, Mutton and Wool in Table 4.8: (1.9% * 1,644,860 + 1.9% * 226,000 +   
(-0.6%) * 953,230 ) ÷ 2,824,090 = 1.1%. 
c Vegetable seeds are not included. The change in producer returns is calculated as the average of the Wheat and 
Coarse grains change in producer returns in Table 5.3, weighted by the amount of revenue for each arable crop as 
shown in Table 4.1. The weighted average is equal to 2.2%. 
 
The net, price-adjusted direct economic impact as calculated in Table 5.4 is the reduction in 
producer returns after variable costs of production that arises from an absence of 
biotechnologies. This is the reverse view of the situation assessed in Chapter 4. This result 
suggests that by using the biotechnological innovations identified in this research, and 
assuming that all other countries had access to the same technology, the New Zealand primary 
sector had a direct economic benefit of $19 million dollars, excluding forestry and 
horticulture. By contrast, the direct economic benefit for these subsectors was calculated in 
Chapter 4 to be $206 million. 
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Table 5.5  Scenario 2: impact of absence of NZ biotechnologies 
Subsector 
Revenues with 
biotechnology 
($000’s) 
Change in 
producer 
returns  
(%) 
Change in 
producer returns
($000’s) 
Gross margin 
($ per dollar of 
revenue)a 
Net impact of 
absence of 
biotechnology 
($000’s) 
Dairy 5,312,500 -1.4 -73,774 0.79 -58,281 
Beef and veal 1,300,320 -2.0 -25,911 0.9 -23,320 
Sheep (meat and 
wool) b 2,824,090 -5.5 -156,377 0.7 -109,464 
Forestry  n/a    
Horticulture and 
floriculture  n/a    
Arable cropsc 364,187 0.2 707 0.45 318 
Seafood  n/a   nil 
Total     -190,747 
a Gross margins are taken from various tables in Chapter 4. 
b The change in producer returns is calculated as the average of the Sheepmeat and Wool impacts in Table 5.3, 
weighted by the amount of revenue in Lamb, Mutton and Wool in Table 4.8: ((-6.3%) * 1,644,860 + (-6.3%) * 
226,000 + (-4.1%) * 953,230 ) ÷ 2,824,090 = -5.5%. 
c Vegetable seeds are not included. The change in producer returns is calculated as the average of the Wheat and 
Coarse grains change in producer returns in Table 5.3, weighted by the amount of revenue for each arable crop as 
shown in Table 4.1. The weighted average is equal to 0.2%. 
 
The value calculated in Table 5.5 indicates how much lower direct economic impacts in the 
primary sector would be in the absence of specific biotechnologies. These are New Zealand-
specific biotechnologies that increase the productivity of the pasture-based parts of the 
primary sector. In this scenario, some biotechnologies, such as those in arable crops, were 
simply not available worldwide. Other biotechnologies were removed only from New Zealand 
commodity production. These were biotechnological innovations in dairy, meat and wool 
production. The reduction in direct impacts was $191 million, not including forestry and 
horticulture. This was very nearly identical to the direct economic benefit for these subsectors 
in Chapter 4, $206 million. 
 
5.7 Discussion of modelling results 
 
The results from the trade analysis provide important information regarding the impacts of 
biotechnology. The two scenarios modelled present two different pictures of biotechnology in 
New Zealand. The first scenario models the primary sector without the innovations identified 
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earlier in this report. Many of these applications of biotechnology, particularly clonal and cell 
technologies, are widely used. If these biotechnologies had not been developed, then they 
would not have affected production anywhere in the world. The difference between the world 
with biotechnology, or the base case, and the world without the identified innovations, is 
measured by Scenario 1. Considering those sectors that are included in the LTEM, the 
combination of price and quantity effects, the difference between using and not using 
biotechnology in New Zealand is $19 million in direct economic impacts. 
 
The second scenario is slightly different. For this modelling, dairy, meat and wool 
productivity were reduced only in New Zealand (arable crop productivity was reduced for all 
countries). The second scenario considers a world in which biotechnological innovations with 
application specifically to New Zealand environments had not been developed. Without these 
innovations boosting New Zealand production, the primary sector would lose direct economic 
impacts of $191 million. 
 
The difference between the final figure in Scenario 2, $191 million, and the final figure in 
Table 4.18, $266 million, stems from two sources. First, only those commodities included in 
the trade model have trade-adjusted impacts. If forestry and horticulture are removed, the 
direct impacts in Chapter 4 are $206 million. Secondly, increased production in Chapter 4 
assumes that there is no price effect. In the trade analysis, the impact of increased production 
on world commodity prices is explicitly modelled to determine the net impact on producer 
returns. For the Beef and veal subsector, the impact in the two different analyses is nearly 
identical. For the Sheep subsector, the change in the trade analysis is greater than the change 
in the simple, fixed-price analysis. On the other hand, reducing dairy production in New 
Zealand does affect world prices in dairy commodities. As a result, the change in the dairy 
sector is lower in the trade analysis than in the fixed-price analysis. The net effect on the 
primary sector, taking international price movements into account, is quite small. Individual 
subsectors do show gains and losses, however. 
 
5.8 Conclusions from trade analysis 
 
The trade analysis demonstrates the net impact of changing productivity. The analysis in the 
preceding chapter assumed that the price elasticity of demand for agricultural commodities 
was practically infinite. The New Zealand primary sector was a price-taker on world 
commodity markets, too small to make a difference. The trade analysis makes some 
adjustment to this picture. By considering the impact that New Zealand can have on 
commodity markets, especially in dairy products, it calculated slightly smaller impacts and 
indicated differences amongst subsectors. 
 
Which of the two trade scenarios more accurately portrays the New Zealand situation is 
uncertain. Clearly, adopting biotechnology is important. It increases productivity, which 
either allows New Zealand to have a competitive advantage in certain commodities or keeps 
the country in line with its rivals. If the former is true, that is, if biotechnology research has 
produced innovations that preferentially benefit New Zealand, then the contribution of 
biotechnology is closer to the estimate in Scenario 2. If the latter is true, then the net impact 
on producer returns of using biotechnology, given that everyone else has adopted it, too, is 
closer to the estimate in Scenario 1. 
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Chapter 6  
Macroeconomic Impacts of Biotechnologies 
 
6.1 Introduction 
 
Chapters 4 and 5 have estimated the impact on New Zealand’s primary sector of the four core 
biotechnologies considered in this report. This chapter extends that analysis to the 
macroeconomic level in two steps. First, the chapter considers the contribution of the 
biotechnologies to the primary sector’s recent productivity performance that is recognised as 
impressive, both compared to the sector’s long-term trends and to the performance of other 
sectors in the economy. Second, the chapter uses the data of Chapters 4 and 5 to calculate 
indirect and induced impacts of the primary sector effects on the wider macroeconomy. 
 
Two previous analyses have assessed the macroeconomic impacts of biotechnology on the 
New Zealand economy. The first, submitted to the Royal Commission on Genetic 
Modification (RCGM) (Stroombergen, 2000), was an economy-wide model of the impacts of 
GM crops in New Zealand. The consulting firm Infometrics used a computable general 
equilibrium (CGE) model to simulate the effects of several scenarios. The model essentially 
calculated the multiplier effects of the given changes but provided little else. Nana (2000) 
reviewed this RCGM submission and noted that modelling the robustness of the effects or the 
impacts of closely related scenarios would have provided more useful results.  
 
The other main attempt at macroeconomic analysis was part of a research project for the 
Ministry for the Environment (MfE) by (Sanderson et al., 2003). The economic research firm 
Business and Economic Research Limited (BERL) used another CGE model to examine the 
impact of genetically modified crops on New Zealand. They found that the overall effect on 
GDP from commercial use of GM organisms in agriculture could be either negative or 
positive, depending on how consumer reactions affect actual trade and how GM technology 
affects actual production. 
 
An important lesson from the above research is the importance of accurate and transparent 
assumptions for modelling. In addition, aggregated macro-economic models are generally 
insensitive to small-scale changes in primary sector productivity and are insufficiently 
disaggregated to generate impacts from the biotechnology sectors. With these lessons in mind, 
the chapter relies on standard multipliers to estimate the macroeconomic impacts of the 
biotechnology products, which are shown to be relatively small. To provide a context for the 
multiplier analysis, the following section presents New Zealand Treasury data that highlight 
the impressive productivity performance of the country’s primary sector in the second half of 
the 1990s. 
 
6.2 Productivity in the Primary Sector 
 
In June 2003, the New Zealand Treasury published a working paper examining productivity 
in New Zealand between 1988 and 2002 (Black, Guy, & McLellan, 2003). That working 
paper included analysis at the industry level, noting that important sector trends can be hidden 
by an aggregate analysis (p. 12, see also Buckle, Haugh, & Thomson, 2001). Their data are 
presented below in Table 6.1. 
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Table 6.1  Average multifactor productivity growth by industry 
March Years 1988 to 1993 (%) 
1993 to 2002 
(%) 
1988 to 2002 
(%) 
Primary -0.52 2.45 1.38 
Mining and Quarrying -1.91 0.72 -0.23 
Construction -4.59 0.25 -1.51 
Manufacturing 0.29 -0.16 0.00 
Electricity, Gas & Water 1.11 -0.93 -0.21 
Transport & Communications 6.75 5.52 5.96 
Business & Property Services -2.54 0.74 -0.44 
Personal & Community Services 0.82 1.48 1.24 
Retail & Wholesale Trade -0.38 1.40 0.76 
Total 0.09 1.32 0.88 
Source: Black, Guy and McLellan (2003), Table 1, p. 8, and Table 4, p. 14. 
 
As the Treasury authors observe, ‘over the 1988 to 2002 period, the productivity growth of 
two industries stands out: the Transport, storage and communications industry (average 
growth of 6.0 per cent per annum) and the Primary industry (average growth of 1.38 per cent 
per annum)’ (Black, et al., 2003, p. 15). In the case of the primary sector, the impressive 
performance was even more pronounced during the later period of 1993 to 2002, when its 
annual productivity growth rate of 2.45 per cent was nearly twice as high as the national 
average (1.32 per cent). 
 
Figure 6.1 and Figure 6.2 on the next page present some preliminary data on long-term trends 
in the agriculture sector, based on research currently being undertaken within the New 
Zealand Treasury. We are grateful to Grant Scobie (personal communication, 11 April 2005) 
for providing these data for this report.  
 
The preliminary dataset contains data for gross agriculture output (defined as gross farming 
income divided by a farm output price index) from 1926/27 to 2002/03. The last observation 
showed a very large increase, and so this report has truncated the sample at 2001/02 to avoid 
this having a disproportionate affect on the Hodrick-Prescott filter used to obtain long-term 
trends. The dataset also includes a series for the same period on aggregate agriculture inputs, 
defined as the sum of the farm wage bill, capital services and non-factor inputs. Both series 
are measured in 1949/50 prices. 
 
In this study, the authors used the Hodrick-Prescott filter (λ = 7, as is appropriate for annual 
data) to obtain long-term trend series for gross output and inputs (Hodrick & Prescott, 1997). 
These trend series are shown in Figure 6.1. Figure 6.2 shows the implied long-term 
productivity series, obtained by dividing gross output by inputs, rebased so that 1949/50=100. 
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Figure 6.1  Trend output and inputs in agriculture, 1929/30 – 2001/02 
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Figure 6.2  Trend multifactor productivity in agriculture, 1929/30 – 2001/02 
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Figure 6.2 confirms the impressive productivity growth that took place in agriculture in the 
second half of the 1990s, comparable to the surge in the late 1950s. This observation would 
have been further reinforced if the large rise in output recorded for 2002/03 was included in 
the analysis (so that it is too early to say whether there has been a fall off in trend productivity 
after the 1998/99 peak shown in Figure 6.2). 
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Thus the available industry-level productivity data suggest that the primary sector has 
performed particularly well in recent years, both compared to its long-term trends and to the 
performance in other sectors of the economy. It is therefore sensible to ask what role 
biotechnology has played in this recent performance. The value of production calculated for 
each subsector and presented in Table 1.2, though only representative of the exact output, 
gives some indication. For example, the dairy output at the farmgate is estimated in Table 1.2 
to be $5.3 billion per year. With a gross margin of $0.79 per revenue dollar, the value of total 
gross margin in dairy is approximately $4.2 billion. The contribution of the four 
biotechnologies is calculated in Chapter 4 to be $99 million, making the contribution from 
biotechnology about 2.4 per cent of the gross margin. Similar calculations can be made for 
beef and veal and for sheep subsectors. They suggest that the contributions of the four 
biotechnologies to gross margins are 1.9 per cent and 3.9 per cent, respectively. Valuing the 
contribution of biotechnology to the horticultural subsector generally would be misleading, 
because it has been key for some crops and relatively unimportant for others. The contribution 
to forestry would need to be valued in terms of the capital value of all of New Zealand’s 
forests, information that was unavailable for this report. The performance of the arable 
subsector is directly linked to improvements in plant breeding, which were calculated in 
Chapter 4 to have led to a 5.1 per cent increase in productivity. Finally, the seafood subsector 
does not seem to have been affected yet by these biotechnologies. 
 
During the decade 1991/92 to 2001/02, Treasury’s preliminary data in Figure 6.1 suggest that 
trend output in agriculture increased by 14.52 per cent. The contributions of the four 
biotechnologies to gross margins were no more than about five per cent (leaving aside a few 
horticultural crops). In this context of the trend output figure, the contributions calculated 
above suggest that the four biotechnologies considered in this report have played a positive, 
but not dominant, role in the sector.  
 
6.3 Wider macroeconomic impacts of the direct effects of biotechnology 
 
Chapters 4 and 5 of this report estimated the direct impact of the four biotechnologies on the 
primary sector. This direct impact is only part of the total contribution to the New Zealand 
economy; there are also indirect and induced contributions. The three types of impacts are as 
follows: 
 
1. Direct contributions: the result of direct finance and employment injected into the 
primary sector by the biotechnology innovations; 
2. Indirect contributions: the result of upstream and downstream finance and employment 
created to service the larger output from the primary sector; and 
3. Induced contributions: the result of the above two contributions affecting further 
household spending, which generates finance and employment such as increases in the 
purchases of consumption goods and services.  
 
The analysis in this section of the report calculates the indirect and induced contributions to 
assess the total impact of the biotechnologies on the economy. To estimate the indirect 
impacts (for both output and employment), it is usual to include two levels of upstream and 
downstream effects. The first level is from those who supply the primary sector directly. An 
important element in this first level of impacts is the activity of firms supplying the 
biotechnological innovations. Ideally this should be estimated from primary data. The second 
level is the output and employment effect generated by these firms supplying the primary 
sector directly. The second level includes the economic impacts of the biotechnology firms. 
 77 
 
The interviews with key informants did include questions in an attempt to elicit this first level 
of indirect impact for output/expenditure. Key informants were asked about the inputs to 
production and how those were affected by innovations. However, data were not generally 
available so secondary sources of data have been used as described below.  
 
The second level of indirect impact – that is the upstream and downstream expenditure of 
those firms directly servicing the primary sector – was estimated using secondary sources of 
data. The secondary sources of data used were the output and value added input/output tables 
for New Zealand. These tables show the flows in and out of an economy by sector, allowing 
multipliers to be calculated representing the average upstream and downstream effects by 
sector, for both output and value added (Butcher, 1999). Finally, the induced impact on output 
and value added was calculated, again using input/ output tables (Butcher, 1999), and added 
to the direct and indirect impacts to obtain the total contribution of the biotechnological 
innovations.  
 
The results of this analysis are presented in subsections 6.3.1 and 6.3.2 based on the 
assumptions in chapters 4 and 5 respectively. 
 
6.3.1 Constant price analysis 
 
The analysis of Chapter 4 assumed that changes in production had no impact on farmgate 
prices. The total direct impact of the four biotechnologies on the primary sector was estimated 
at $265.8 million in current year prices. Table 6.2 presents the multiplied effects of this direct 
impact as a result of indirect and induced effects as explained above. The total annual 
contribution of the biotechnologies to the New Zealand macroeconomy under the assumption 
of no changes in farmgate prices is $453.2 million, with just under two-thirds of this 
contribution coming from the dairy and sheep subsectors.  
 
Table 6.2  Total annual value-added contribution of the four biotechnologies 
to the New Zealand economy (current year) 
Subsector Direct impacts ($000’s) 
Direct + Indirect 
impacts  
($000’s) 
Direct + Indirect + 
Induced impacts  
($000’s) 
Dairy 98,598 135,079 167,617 
Beef and veal 21,662 30,327 36,392 
Sheep (meat and wool) 77,410 110,696 131,597 
Forestry 16,976 26,482 29,878 
Horticulture 42,955 58,848 73,454 
Arable 8,221 12,003 14,305 
Total 265,822 373,435 453,243 
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6.3.2 Trade model analysis 
 
Chapter 5 used the Lincoln Trade and Environment Model (LTEM) to analyse the 
consequences if changes in productivity led to changes in output prices (see Figure 5.1). The 
chapter modelled two scenarios. In Scenario 1, it was assumed that the modelled 
biotechnology innovations were adopted by all countries. In Scenario 2, it was assumed that 
several of the innovations affected production in New Zealand only. Table 6.3 below presents 
the calculations associated with Scenario 1, with worldwide absence of the biotechnological 
innovations. The last row of the table provides the impact without a change in international 
commodity prices, based on the analysis in chapter 4, excluding the impact of forestry and 
horticulture that were unable to be modelled in chapter 5. Table 6.4 presents the same 
calculations for Scenario 2. Recall also that Chapter 5 analysed what would happen in the 
absence of the biotechnologies, so that a minus sign in Tables 6.3 and 6.4 indicates a positive 
effect of biotechnology. 
 
As would be expected, the total macroeconomic impacts under these assumptions are less 
than under the assumptions of Chapter 4. The difference is considerable in the case of 
Scenario 1 (where all countries adopt the biotechnology innovations), reducing the 
contribution from $349.9 million to $33.1 million. In contrast, if other countries do not adopt 
the innovations, the effect on New Zealand is relatively small – a drop from $349.9 million to 
$323.8 million. 
 
Table 6.3  Total annual value-added impact: Scenario 1 
Direct impacts Direct + Indirect impacts 
Direct + Indirect 
+ Induced impactsSubsector 
($000’s) ($000’s) ($000’s) 
Dairy -50,694 -69,450 -86,179 
Beef and veal 6,785 9,500 11,399 
Sheep (meat and wool) 20,879 29,857 35,494 
Forestry n/a n/a n/a 
Horticulture n/a n/a n/a 
Arable 3,535 5,161 6,151 
Total -19,494 -24,933 -33,135 
Total at constant prices -205,891 -288,105 -349,911 
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Table 6.4  Total annual value-added impact: Scenario 2 
Direct impacts Direct + Indirect impacts 
Direct + Indirect 
+ Induced impactsSubsector 
($000’s) ($000’s) ($000’s) 
Dairy -58,281 -79,845 -99,079 
Beef and veal -23,320 -32,648 -39,177 
Sheep (meat and wool) -109,464 -156,533 -186,089 
Forestry n/a n/a n/a 
Horticulture n/a n/a n/a 
Arable 318 464 553 
Total -190,747 -268,562 -323,791 
Total at constant prices -205,891 -288,105 -349,911 
 
6.4 Conclusion 
 
This chapter’s macroeconomic analysis relying on multipliers and known flow-on effects has 
provided a reasonable first estimate of the indirect and induced effects of biotechnology 
products. Future research could develop a general equilibrium model on the New Zealand 
economy purpose-built for close examination of the impacts of biotechnological products. In 
particular, such a model would need a disaggregated agricultural sector and separate sectors 
for biotechnological research and product development. A large econometric exercise of this 
type was not possible within the time and resources available for the current project. 
 
The tables in section 6.3 provided estimates of the total macroeconomic impact of the four 
core biotechnologies ranging from $33.1 million to $453.2 million, depending on assumptions 
about world trade and the agriculture subsectors included. These figures can be compared to 
the level of Gross Domestic Product for the year ending March 2004 of $137.8 billion. Thus 
the largest estimate in this chapter amounts to just under one-third of one per cent of GDP. 
 
The analysis of this chapter contains an important message, however, that should not be 
overlooked. Comparing the results of Tables 6.3 and 6.4 reveals the large difference that can 
occur if a biotechnology innovation is not adopted worldwide. This was a frequent comment 
in interviews for this project: adopting biotechnology innovations in New Zealand has been 
essential for keeping up with (or ahead of) competing producers in the rest of the world.  
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Chapter 7  
Conclusion 
 
This research assesses the economic impact of the current commercial use in the primary 
sector of four specific biotechnologies: clonal propagation/cell manipulation, biocontrol 
agents, enzyme manipulations and marker-assisted selection. By choosing four specific 
technologies and assessing only commercialised innovations, this research makes two 
contributions to previous studies of biotechnology use within the primary industries. The first 
contribution is to calculate actual realised benefits, rather than to make projections about 
possible future benefits. Secondly, the focus on commercially released technologies meant 
that issues with regards to possible public perception and potential foreign market access did 
not cloud the analysis. 
 
The information on the contribution of these four technologies in the primary industries is not 
readily available in official statistics or from other studies. Thus, to obtain information on 
current biotechnology use, an extensive survey of scientists and industry people was 
undertaken. The survey revealed that much biotechnology research has yet to result in 
commercial products that contribute economic value to primary production in New Zealand. 
Some parts of the primary sector are essentially unaffected by these biotechnologies. 
However, there are successful products with a substantial contribution to the sector, as well as 
a number of commercialised products with more modest impacts.  
 
The detailed cost benefit analysis reveals that the highest contributions come from clonal 
propagation/cellular manipulation. This specific biotechnology has been commercially used in 
plant research and breeding for decades, and is a good example of a horizontal enabling 
technology, a technology with wide application across many industries and innovations. The 
contribution to the primary sector was estimated to be $189 million; a large part of this value 
comes from improvements of plant species used in dairy, sheep and beef pastoral agriculture. 
 
Biocontrol agents have a number of products that are applied in a number of different 
subsectors. Many of these, although successfully used, have yet to reach substantial volumes 
and materiality in their economic contribution. The total contribution of biocontrol agents was 
calculated to be $62 million, of which ryegrass endophytes and the ToxoVax vaccine 
accounted for almost 95 per cent. 
 
Enzyme manipulation had a current contribution of $14 million, excluding the use of 
biotechnological enzymes in processing dairy foods. The low value reflects this research’s 
focus on the primary industries, thus excluding downstream processing where the main 
application of enzyme biotechnologies can be found. 
 
Marker-assisted breeding and selection has been researched for many years, but is only now 
producing some commercial products. The only product that appears to be contributing to 
primary production in New Zealand is the test for the footrot gene marker, with an estimated 
contribution of $770,000. The only other commercial product appears to be the test for the 
Inverdale gene, which should begin yielding commercial value in primary production in a 
year or so. 
 
The impact of changes in farm gate prices was not accounted for in the analysis of direct 
impacts. An increase in the amount produced can lead to a reduction of the market price, and 
an important question is whether the increased quantities from New Zealand’s primary sector 
are sufficient to produce a price change. If the quantity that New Zealand produces is small in 
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relation to the world market, then New Zealand is a ‘price taker’ – it can sell as much or as 
little as it produces without the market price changing. On the other hand, if New Zealand is a 
significant producer in relation to the world market, changes in New Zealand production 
could affect the market price. 
 
The effect on prices and thus on the net contribution to the NZ economy were assessed with 
the Lincoln Trade and Environment Model (LTEM). Two basic scenarios were run; the first 
one has the innovations modelled as adopted by all countries in the model; the second 
scenario has several innovations modelled as affecting production only in New Zealand. The 
results indicate a lower contribution by the four technologies than that estimated in the fixed 
price calculations. In the first scenario the net impact of absence of biotechnology was 
calculated to be -$19 million; for the second scenario the result was -$191 million. The 
relevant figure from the fixed-price analysis is $206 million, which excludes subsectors not 
included in the trade analysis. Thus, the first scenario reduces the direct economic impacts to 
about one-tenth of the original estimate. In the second scenario, the direct economic impacts 
were again reduced, but were still 90 per cent of the original estimate. 
 
Which of the two trade scenarios more accurately portrays the New Zealand situation is 
uncertain. Clearly, adopting biotechnology is important. It increases productivity, which 
either allows New Zealand to have a competitive advantage in certain commodities or keeps 
the country in line with rival producers. The results do suggest, however, that biotechnologies 
adopted globally may increase production but may not greatly increase producer returns in the 
primary sector. 
 
The macroeconomic impact was estimated by calculating the indirect and induced impacts on 
the New Zealand economy, using the direct impacts described above. Thus the total annual 
value-added contribution of the four biotechnologies as applied in the primary sector (current 
year), was calculated to be $453 million, based on the constant price estimate. The two trade 
scenarios led to estimates of the macroeconomic impact of the absence of biotechnology of 
$33 million (Scenario 1) and $324 million (Scenario 2), compared to a constant price analysis 
calculation of $350 million (number reduced by contribution from subsectors not included in 
the trade analysis).  
 
Analysis of the agricultural sector revealed that the sector has seen significant increases in 
multifactor productivity over the last ten to 15 years. The productivity increases were much 
larger than the estimated impacts of the four biotechnologies. In this context of the trend 
output figure, the impacts of the four biotechnologies considered in this report have had a 
positive, but not dominant, role in the primary sector. 
 
It is important to recognise the bounds of this research. The research discussed in this report 
focused specifically on the impacts of four selected biotechnologies on the primary sector. It 
is difficult to extrapolate from those biotechnologies and sectors to broader conclusions about 
other biotechnologies or other sectors. Without research specifically examining these other 
biotechnologies or sectors, the extent of their economic contribution is unknown. 
 
This research does point to areas that would benefit from further investigation. One such area 
is a survey of biotechnologies and their uses across the whole New Zealand economy. Such a 
survey would help address the issue of the overall economic impact of biotechnology and the 
economic impact analysed in the present research relative to the total impact. Some 
groundwork for such research has been laid here. In addition, existing surveys of 
biotechnological activity in New Zealand (Miller, 2003; Pink, 2001) and catalogues of 
biotechnology (e.g., Zaid et al., 1999) would be useful resources for framing future research. 
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It should also be mentioned that the dairy industry be a good candidate for future research. It 
is an important industry for New Zealand, and the present research was unable to account 
fully for the uses and impacts of biotechnology in this industry. The estimates calculated here 
and further estimates of the impacts of biotechnology could be improved with a better 
understanding of economic impacts in dairy production. In addition, millions of dollars of 
research spending, including public monies, are spent on dairy research. It would be 
interesting to assess the economic benefits from such publicly funded research. 
 
One topic that was found to be little-researched was the non-marketed impacts of 
biotechnology. The interviews and the literature both suggested that biotechnology could 
provide numerous non-marketed benefits, especially by reducing the negative environmental 
impacts of primary sector activities. What appear to be needed are estimates of specific non-
marketed impacts, the specific benefits of those impacts, and valuation of those benefits. This 
lack of information has important policy implications. If biotechnology produces non-
marketable benefits, such as pollution reduction that benefits the wider population, then 
fostering such benefits through public funding is economically appropriate. Without knowing 
the value of the benefits, however, the appropriate level of funding is unknown. 
 
Another topic that the present research did not include was proprietary control of technology 
or Intellectual Property Rights (IPRs). There already exists a significant and complex body of 
literature considering IPRs, and they are an important consideration when assessing economic 
impacts of biotechnology. It would be valuable to consider the New Zealand situation in light 
of existing knowledge regarding intellectual property and to investigate potential 
improvements. 
 
It has been said that to understand the economy, it is sometimes necessary to go and look. The 
research reported here has taken the ‘go and look’ approach to understanding the economic 
contribution of biotechnology to New Zealand’s primary sector. The findings are unique, a 
first attempt to estimate economic impacts in this way, and should thus prove a helpful 
contribution to understanding the use and development of biotechnology.  
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Appendix 1 
List of Key Informants 
 
Name Organisation 
Jeremy Absolom Rissington Breedline Genetics 
Jock Allison Abacus Biotech Limited 
Tony Arthur Ovita Ltd 
Ron Beatson HortResearch 
Bruce Belgrave Grasslanz 
Don Bell Process Developments Ltd 
Rod Bennett Institute of Food Nutrition and Human Health, Massey University
Roy Bickerstaffe Lincoln University 
Andrew Broadwell BioDiscovery New Zealand Ltd 
Mike Butcher Pipfruit NZ 
Keith Cameron Lincoln University 
Garth Carnaby Canesis (formerly) 
John Chang Canterprise 
Andrew Clarke A2 Corporation 
Tony Conner Crop & Food Research 
Matthew Cromey Crop & Food Research 
Rex Dolby Agro Science Consultancy Services 
Sue Finderup Westland Dairy 
Lester Fletcher AgResearch 
Ian Gear Ministry of Agriculture and Forestry 
David Glen ICPbio Ltd 
Stephen Goldson AgResearch 
Warrick Green Wrightson Research 
Jon Hickford Lincoln University 
Lloyd Hickman Alex McDonald (Merchants) Ltd 
Diane Hill Global Technologies (NZ) Ltd 
Kerry Hughes Alex McDonald (Merchants) Ltd 
John S Hunt Agrimm Technologies Ltd 
Trevor Jackson AgResearch 
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List of Key Informants (continued) 
Name Organisation 
Henry Kaspar Cawthron Institute 
Peter Kettle Ministry of Agriculture and Forestry 
Bruce Kirk Scios Ltd 
Geoffrey Langford HortResearch 
Nigel Larsen Crop & Food Research 
Andrew MacPherson AgVax Developments Ltd 
Sue Marshall Crop & Food Research 
Alan Marshall Tectra 
Morgan McArthur Ancare NZ Ltd 
John McKenzie Agricom NZ Ltd 
Steve McNeil Canesis 
Mike Mensis Forest Research 
Bill Montgomerie Livestock Improvement Corporation 
Ron Pellow Ravensdown Fertiliser Co-operative Limited 
Russel Priest Meat & Wool 
Mike Rockell Institute of Food Nutrition and Human Health, Massey University
William Rolleston South Pacific Sera Ltd 
Gavin Ross AgriGenesis Bioscience Ltd 
Adrian Russell Plant Research NZ Ltd 
John Scandrett Botry-Zen Ltd 
Alan Seal HortResearch 
Sandra Simpson Multiflora Labs, Ltd 
Charles Sorenson Horizon2 
Richard Spelman Livestock Improvement Corporation 
John Stewart Grasslanz 
Gail Timmerman-Vaughan Crop & Food Research 
Wei Young Wang P.F. Olsen 
Alan White HortResearch 
Phillip Wilcox Forest Research 
Ken Wong Forest Research 
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Appendix 2 
Survey Instrument 
 
 
This project is assessing the current contribution of biotechnology to the primary sector in
New Zealand. We are interviewing people in biotechnology firms and primary industries to
gather information. 
The biotechnologies of interest for this project are: 
• Marker-assisted selection / breeding 
• Bio-control agents 
• Enzyme manipulations 
• Clonal propagation / cell manipulation 
We are collecting examples of these biotechnologies from across the primary sector,
including:  
• Dairy 
• Meat and wool 
• Forestry 
• Horticulture 
• Arable crops 
• Seafood 
• New industries, e.g., biofuels, biomaterials 
We appreciate your participation in this project. 
This is a joint project of the Agribusiness and Economics Research Unit (AERU), the
Commerce Division, and the National Centre for Advanced Bio-Protection Technologies at
Lincoln University. It is funded by the Ministry of Research, Science and Technology
(MoRST). 
Economics of Biotechnology in Primary Production 
Questionnaire for semi-structured interviews of key informants
April - May 2005 
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Section 1 
Identification of key informant 
1. Name: __________________________________________________________________
2. Organisation: ____________________________________________________________
3. Prior organisation (if relevant): ______________________________________________
4. Contact information: ______________________________________________________
___________________________________________________________________________
___________________________________________________________________________
 
 
Section 2 
Overview of technology use 
5. How is biotechnology used in general in your industry or subsector? [If informant needs
prompting, suggest: How has biotechnology affected the methods of production? How has
biotechnology affected the products of your industry?] ___________________________
___________________________________________________________________________
___________________________________________________________________________
6. What role does biotechnology play in your firm’s activities? _______________________
___________________________________________________________________________
 
 
Section 3 
Specific examples 
7. Could we discuss each use of biotechnology in detail? We are looking for examples of
production inputs and outputs, processes, services, methods, or environmental impacts
from the four biotechnologies. [Use the ‘Specific example of biotechnology’ sheet to
record.]  
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Section 3, Question 7: Specific example of biotechnology 
 
Example:    
Impact 
(tick one or more) 
Biotechnology 
(tick one or more) 
? input 
? output 
? process 
 
? service 
? method 
? environmental 
impact 
? Marker-assisted selection 
? Bio-control agents 
? Enzyme manipulations 
? Clonal propagation/cell 
manipulation 
? Benefits 
   
Cost savings:  
Output price 
change:  
Yield increase:  Other:  
? Costs 
   
Technology fee:  Labour costs:  
Machinery costs:  
Other (finance, 
land):  
? Other changes   
Labour use:  
Changes to 
other inputs:  
Timing changes:  Other changes:  
? Uptake rates 
  
% of producers: % w/ impacts:
% of production:  
Potential 
uptake?:
? Other info:    
    
 
Key informant: _________________________     Example ____ of ____ 
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Appendix 3 
List of Innovations Identified 
 
Innovation Type of biotechnology Description 
Plant breeding, arable 
crops 
Clonal propagation/cell 
manipulation 
Studies imply a crop genetic improvement figure of 0.5% per year in yield. It was assumed that 
one-half the crop genetic improvement can be attributed to clonal propagation/cell 
manipulation. 
Floriculture, contract 
tissue culture 
Clonal propagation/cell 
manipulation 
Tissue culture allows for quicker propagation and better form resulting in larger tubers and 
earlier flowers, resulting in premium prices for growers. 
Forestry, clonal 
propagation 
Clonal propagation/cell 
manipulation 
Tissue culture (organogenesis) and somatic embroyogenesis are used increasingly in 
commercial radiata pine forests. 
Hops Clonal propagation/cell 
manipulation 
The entire hops industry in New Zealand is based on triploid hops with good agronomic and 
brewing qualities. 
Potatoes Clonal propagation/cell 
manipulation 
Tissue culture is used after heat treatment to propagate the initial generations of plants, which 
are then used to produce seed potatoes. Most of New Zealand’s seed potatoes are produced by 
this process, which produces virus-free, uniform seed potatoes and does so more quickly than 
older methods of propagation. 
Plant breeding, 
horticulture 
Clonal propagation/cell 
manipulation 
These techniques are widely used in plant breeding. The exact impact on the horticultural 
subsector is difficult to determine. This research calculates the impact from gross margins for 
vegetable crops and the rate of crop genetic improvement found in arable crops. 
Plant breeding, 
pasture plants 
Clonal propagation/cell 
manipulation 
The use of tissue culture, protoplast fusion, and other cellular techniques in pasture plant 
breeding goes back to the 1970s, but with increased uptake in the 1980s. This application of 
biotechnology has improved forage quality through changes to digestibility, intake rate, and 
metabolisable energy content 
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List of Innovations Identified (continued) 
 
Innovation Type of biotechnology Description 
BVDV vaccines Biocontrol agents The potential effects of Bovine virus diarrhoea virus (BVDV) are abortions, poor foetal 
development, and failure to thrive. Estimated economic impacts in other national herds are 
US$2 million to US$57 million per million calvings, with most estimates falling in the range of 
US$10 million to US$40 million. 
Trichoderma 
products 
Biocontrol agents Trichoderma is a beneficial, naturally occurring fungus. It has two basic modes of operation; as 
a bio-fertiliser and/or as a bio-fungicide. 
ToxoVax (AgVax) Biocontrol agents This is a vaccine against toxoplasmosis, which causes abortions in sheep. Field trials show an 
average national increase in lambing of 3% for vaccinated flocks. 
Bioshield Grassgrub 
(Balance) 
Biocontrol agents The Ballance Bioshield Grassgrub uses natural soil bacteria to break the population growth 
cycle for grass grubs. The product eliminates the need to use chemical pesticides. 
Bt preparations Biocontrol agents The bacterium Bacillus thuringiensis (Bt) attacks agriculturally important pests. Commercial 
preparations of Bt are particularly important in integrated pest management (IPM) systems, for 
organic agriculture, and in MAF’s eradication programmes for several exotic moths. 
Ryegrass endophytes Biocontrol agents Wild-type endophytes in New Zealand pastures have been shown to have harmful effects on 
grazing animals. AgResearch identified alternative beneficial endophytes and developed 
technology for inoculating ryegrass cultivars with this novel endophyte. 
eco-n (Ravensdown) Enzyme manipulation eco-n is made from DCD, a nitrification inhibitor that slows down the conversion of ammonium 
to nitrate. Both Ballance and Ravensdown have commercial DCD products. DCD reduces the 
leaching of nitrates from grazed pastures and also significantly increases pasture production by 
improving soil nutrient cycles in grazed dairy pastures. 
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List of Innovations Identified (continued) 
 
Innovation Type of biotechnology Description 
Dairy enzymes Enzyme manipulation This research has not estimated a value for enzyme use in the dairy. It is clear that enzymes, 
including ones improved through biotechnology, are used in processing raw milk into dairy 
products, such as cheese and cheese flavouring. 
Wine enzymes Enzyme manipulation Enzymes are used in a number of ways in producing wine. They increase the amount of juice 
extract from pulp and increase the clarity of the wine, amongst other impacts. 
Forestry enzymes Enzyme manipulation Enzymes have no commercial application in the forest and logging business, but are used in 
other countries. Enzyme technology can increase the quality and quantity of feedstocks for pulp 
and paper processes, reduce manufacturing costs, and create high-value products. 
Footrot gene marker 
test 
Marker-assisted 
selection 
The footrot gene-marker test is used for selecting footrot-tolerant sheep to breed. Its use results 
in a reduction of other input costs, such as vaccinations, antibiotics, foot-paring and foot 
bathing. It also reduces the use of chemicals. 
Inverdale gene 
marker test 
Marker-assisted 
selection 
The Inverdale gene in the ram leads to more-fertile ewes, thus a benefit in the progeny of rams 
that have been tested. As the test was commercially released only this year, the primary sector 
will start to see the benefits after two breeding cycles. 
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Appendix 4 
Quantitative impacts: a range of values 
 
This appendix presents quantitative values based on the discussion and calculations in 
Chapter 4. The values presented here indicate a range of possible economic values of impacts 
from biotechnology innovation, whereas the earlier values represented the best point estimates 
of economic impacts. This appendix presents the direct economic impacts by subsector or 
innovation, as in Chapter 4. The indirect and induced impacts from the range of values are 
also presented. 
 
Detailed tables are provided only for those biotechnological innovations for which a range of 
values were indicated. For some of the innovations, there was little uncertainty about the 
value to be estimated. The values for those innovations were the same as in Chapter 4. The 
summary table in this appendix uses the point values in Chapter 4 or the range of values from 
this appendix, as appropriate. 
 
In the course of this research, it was suggested that the uncertainty of the economic impacts 
could be parameterised and modelled. Modelling impacts in this way would allow calculation 
of mean impacts and confidence intervals. This would be a valid approach to investigating the 
uncertainty of these estimates and a useful extension of this research. Due to time constraints, 
such a modelling exercise was not attempted. Beyond the simple mechanics of the work, 
modelling would require careful consideration of the parameters to use for describing the 
uncertain variables.  
 
Table A4.1 calculates a range of values for the impact of clonal propagation/cell manipulation 
in arable crops. The exact contribution of the biotechnology to crop productivity was 
uncertain. Several estimates of total productivity growth in agricultural were available, as 
discussed above. The contribution of crop genetic improvement (CGI) was somewhat 
uncertain, although the general figure of one-half of total productivity growth was cited 
(Rubenstein, Heisey, Shoemaker, Sullivan, & Frisvold, 2005). The extent to which genetic 
improvement relies on biotechnology was also uncertain, and did not appear to have been a 
topic of research in the published literature. The assumption in Chapter 4 was that 
approximately one-half of CGI depends on biotechnology. For this appendix, the economic 
impact was recalculated as a range, with the low end assuming that one-quarter of CGI 
depended on biotechnology and the high end replicating the Chapter 4 calculations. 
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Table A4.1. Economic contribution of clonal propagation/cell manipulation to the arable crop subsector 
Current production due to 
biotechnology (%) 
Increased production 
($000’s) 
Value of clonal 
propagation/cell manipulation 
($000’s) Arable crops 
Area 
(hectares) 
Revenue per 
hectarea ($)
Revenue 
($000) 
0.125% p.a. 0.25% p.a. 0.125% p.a. 0.25% p.a.
Gross 
margina   
($ per $ of 
revenue) 0.125% p.a. 0.25% p.a. 
Barleyb 64,700 1,725 111,608 2.5 5.1 2,790 5,692 0.45 1,256 2,561 
Field peasc 10,000 2,320 23,200 2.5 5.1 580 1,183 0.54 313.2 639 
Maized 14,166 3,497 49,539 2.5 5.1 1,238 2,526 0.36 445.851 910 
Small seedsc 33,000 2,376 78,408 2.5 5.1 1,960 3,999 0.42 823.284 1,679 
Veg seedsc 3,000  25,000 n/a n/a n/a n/a n/a n/a n/a 
Wheate 40,900 2,480 101,432 2.5 5.1 2,536 5,173 0.47 1,192 2,431 
Total arable     389,187     9,105 18,574   4,030 8,220 
a Burtt (2004). 
b Area data: Ministry of Agriculture and Forestry Website, Total Barley - Area Harvested and Quantity Produced (2003). 
c Area data: MAF (2004c). Gross margins for small seeds is the unweighted average of clover, ryegrass, and fescue gross margins. 
d Area data: Ministry of Agriculture and Forestry Website, Grain and Seed Crops by Farm Type (ANZSIC), (2002 
e Area data: Ministry of Agriculture and Forestry Website, Total Wheat - area harvested and quantity produced, (2004). 
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The exact impacts of clonal propagation in forestry were also uncertain. They were 
very sensitive to the variables used in calculating the unrealised capital gain. A range 
of possible values of clonal forests could be calculated using the extremes of 
uncertain and/or variable input variables. By varying rotation, initial investment, 
premium, and the discount rate as per table below, the value ranged from a loss of 
$20.5 million to a gain of $69 million. 
 
Table A4.2. Economic contribution of clonal propagation/cell 
manipulation to forestry 
 Minimum gain Maximum gain 
Rotation (years) 30 27 
Initial investment ($) 1 0.6 
Pre tax premium ($/m3) 0 20 
Discount rate (%) 9.5 7.0 
NPV of clonal forestry ($000) -20,507 69,031 
 
The impacts of clonal propagation/cell manipulation in horticulture were also likely to 
take a range of values. The estimate for hops is included here as a point estimate, as 
the information gathered in this research suggested that the entire industry depended 
on biotechnology. The estimate for potatoes took a range of values, as key informants 
could only estimate the possible impact of the loss of tissue culture on the industry. 
For other vegetables, a range of values was calculated using the same impacts 
estimated in the section on arable crops. The calculations are presented in Table A4.3. 
 
Table A4.4 presents similar calculations for pasture-based production. The 
calculations were based on the information in Chapter 4 and the range of 
biotechnology impacts discussed above in the context of arable crops. 
 
The impact of biocontrol agents was also the subject of some uncertainty. Table A4.5 
provides estimates for the range of impacts that have been observed with the AR1 
endophyte ryegrass. Although the information provided by key informants suggested 
that the $200 per hectare figure used in Chapter 4 was a consistent and robust value of 
the benefit, there were indications that benefits could be higher. These higher figures 
are included in Table A4.5. 
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Table A4.3. Economic contribution of clonal propagation/cell manipulation to the horticulture subsectora 
Current production due to 
biotechnology (%) 
Increased production 
($000’s) 
Value of clonal propagation/cell 
manipulation ($000’s) Horticultural 
crops 
Area 
(hectares) 
Revenue 
($000’s) 
Low High Low High 
Gross margin 
($ per 
hectare) 
Low High 
Hops        1,919 1,919 
Potatoes 10,600 141,000 66.7 75 94,000 141,000 1,438 10,162 11,432 
Other 
vegetables 36,973  2.5 5.1   2,081 1,924 3,924 
Total               14,005 17,275 
a Sources: see text and tables above. 
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Table A4.4. Economic contribution of clonal propagation/cell manipulation to pastoral production 
Current production 
due to 
biotechnology (%) 
Increased production
($000’s) 
Value of clonal 
propagation/cell 
manipulation  
($000’s) Product 
Amount of 
productiona 
Revenue 
per unitb 
Revenue  
($000’s) 
Production 
affected 
0.125% 
p.a. 
0.25% 
p.a. 
0.125% 
p.a. 
0.25% 
p.a. 
Gross 
marginc  ($ 
per $ of 
revenue) 
0.125% p.a. 0.25% p.a. 
Dairy 1,250,000 t 4250 5,312,500 0.35 2.5 5.1 46,484 94,828 0.79 36,723 74,914 
Beef and 
veal 4,644,000 hd 280 1,300,320 0.35 2.5 5.1 11,378 23,211 0.90 10,240 20,890 
Sheep farming           
     Lamb 434,000 t 3790 1,644,860 0.35 2.5 5.1 14,393 29,361    
     Mutton 113,000 t 2000 226,000 0.35 2.5 5.1 1,978 4,034    
     Wool 173,000 t 5510 953,230 0.35 2.5 5.1 8,341 17,015    
Total sheep farming  2,824,090    24,711 50,410 0.70 17,298 35,287 
Total pastoral production  9,436,910    82,573 168,449  64,260 131,091 
a MAF (2004c). Figures are from 2003 because some 2004 figures in the report are estimates. 
b For Dairy, this is the 2003/04 payout of $4.25 per kg. For Beef and veal, this is farm income per head of overwintered cattle (Burtt, 2004). For Lamb, Mutton and Wool, prices 
are average baseline prices (MAF, 2004c). 
c Burtt (2004). For Dairy and Beef and veal, gross margin is adjusted to account for the cost of winter feed. Sheep farming gross margins are the weighted average of three budgets 
(Burtt, 2004). Merino sheep numbers taken from Greer (2005). 
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Table A4.5. Economic contribution of AR1 novel endophyte to pastoral production 
Impact of AR1 
($/hectare) 
Increased production
($000’s) 
Value of AR1 
($000’s) 
Product Revenue
a 
($000’s) 
Percentage of 
AR1 hectaresb 
(%) 
Number of 
AR1 hectares
Low High Low High 
Gross 
margina 
($ per $ of 
revenue) Low High 
Dairy 5,312,500 65.3 130,600 $200 $400 26,120 52,240 0.79 20,635 41,270 
Sheep farming 2,824,090 34.7 69,400 $200 $220 13,880 15,268 0.70 9,716 10,688 
Total 8,136,590 100.0 200,000   40,000 67,508  30,351 51,958 
a See Table A4.4 for calculations and sources. 
b Percentage of AR1 hectares is calculated as the subsector revenue divided by total Dairy and Sheep farming revenue. 
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The economic value of Bovine virus diarrhoea virus (BVDV) was unknown because 
the exact losses due to the disease are uncertain. Houe (2003) provided values from a 
range of studies. The values clustered around the point estimate of US$10 million per 
million calvings, but Houe (2003) indicated that the range is US$10 million to $40 
million. Table A4.6 presents the results of calculations of the impact of BVDV 
vaccines. The underlying calculations are confidential, but were based on beef and 
dairy herd estimates from MAF (MAF, 2004c), losses per million calvings of $10 
million and $40 million (Houe, 2003), a NZ$/US$ exchange rate of 0.70, and a 
combined gross margin of 0.81 for beef and dairy farms. 
 
Table A4.6. Economic contribution of BVDV vaccines 
Revenue Value of BVDV vaccines ($000) Product 
($000’s) low high 
Dairy 5,312,500 2,523 16,118 
Beef and veal 1,300,320 772 4562 
Total 6,612,820 3,295 20,680 
 
The last biotechnological innovation for which a range of impacts was calculated is 
eco-n, the DCD nitrification inhibitor. As discussed in Chapter 4, scientific research 
suggested that the product could have a range of impacts. The point estimate above 
assumed the conservative value from the following table. However, the higher per-
hectare findings could also be used to generate a higher benefit estimate, as shown in 
Table A4.7. 
 
Table A4.7. Benefits of eco-n 
  10% increase in pasture production 
15% increase in pasture 
production 
Increased pasture production 1300 kgDM/ha/yr 1950 kgDM/ha/yr 
Additional milksolids 87 kgMS/ha/yr 130 kgMS/ha/yr 
Total Gross return $347 /ha/yr $520 /ha/yr 
Net return per hectare $223 /ha/yr $396 /ha/yr 
Number of hectares 17,000 ha 17,000 ha 
Total benefits $3,791,000 $6,732,000 
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The total range of benefits from the biotechnological innovations identified in this 
research is presented in Table A4.8. 
 
The final table in this appendix, Table A4.9, presents the range of direct, indirect and 
induced economic impacts from these biotechnologies. They were calculated as in 
Chapter 6, using the range of direct impacts presented in this appendix. These 
calculations suggested that the range of total economic impacts from the use of these 
innovations, including the upstream and downstream impacts, and changes to 
household income and employment, was from $261 million to $616 million. 
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Table A4.8. Summary of range of direct impacts of four biotechnologies 
Subsector 
Value of clonal 
propagation/cell 
manipulation 
($000’s) 
Value of biocontrol agents 
($000’s) 
Value of enzyme 
manipulations 
($000’s) 
Value of marker 
assisted selection 
($000’s) 
Total 
($000’s) 
Dairy 36,723 - 74,914 19,893 - 54,123 3,791 - 6,732 nil - nil 60,407 - 135,769 
Beef and veal 10,240 - 20,890 772 - 4,562 nil - nil nil - nil 11,012 - 25,452 
Sheep (meat and 
wool) 17,298 - 35,287 41,353 - 42,325 nil - nil 770 - 770 59,421 - 78,382 
Forestry -20,507 - 69,031 nil - nil nil - nil nil - nil -20,507 - 69,031 
Horticulture and 
floriculture 29,725 - 32,995 small value - small value 9,960 - 9,960 nil - nil 39,685 - 42,955 
Arable crops 4,030 - 8,220 nil - nil nil - nil nil - nil 4,030 - 8,220 
Seafood nil - nil nil - nil nil - nil nil - nil nil - nil 
Total 77,509 - 241,337 62,018 - 101,009 13,751 - 16,692 770 - 770 154,048 - 359,808 
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Table A4.9. Range of total annual value-added contribution of the four biotechnologies to the New Zealand 
economy (current year) 
Subsector Direct impacts ($000’s) 
Direct + Indirect impacts  
($000’s) 
Direct + Indirect + Induced 
impacts  
($000’s) 
Dairy 60,407 - 135,769 82,757 - 186,003 102,692 - 230,808 
Beef and veal 11,012 - 25,452 15,417 - 35,633 18,500 - 42,759 
Sheepmeat and wool 59,421 - 78,382 84,972 - 112,086 101,016 - 133,249 
Forestry -20,507 - 69,031 -31,991 - 107,687 -36,093 - 121,496 
Horticulture 39,685 - 42,955 54,368 - 58,848 67,862 - 73,454 
Arable 4,030 - 8,220 5,884 - 12,002 7,012 - 14,303 
Total 154,048 - 359,809 211,407 - 512,259 260,989 - 616,069 
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Appendix 5 
The Lincoln Trade and Environment Model 
 
This appendix provides a detailed description of the Lincoln Trade and Environment Model 
(LTEM). Included in this description are the equations in the model, the method of 
determining prices and quantities, and the parameters in the base data for the model. 
 
Behavioural Equations in the LTEM 
 
Each country in the LTEM has its own set of behavioural equations for each commodity. In 
general there are six behavioural equations and one economic identity for each commodity in 
each country, i.e. there are seven endogenous variables in the structural-form of the equation 
set. These behavioural equations are domestic supply, demand, stocks, domestic producer and 
consumer prices and a trade price equation. The economic identity is the net trade equation, 
representing the excess supply or demand in each country. There is some variation between 
countries and commodities based on the levels of disaggregation. The following section 
explains the functional form and variable specification for each of the behavioural equations.   
 
Domestic Supply 
The type of supply equation used in the LTEM is known as a directly estimated partial supply 
response model (Colman, 1983). The equation is a function of own- and cross-prices, with an 
ad hoc theoretical background. The equations use the Cobb-Douglas (CD) constant elasticity 
functional form, specified at the level of the variables. The supply equations for each of the 
types of commodities are presented below: 
 
Crops 
Wheat and Coarse Grains, Oils and Oilseeds, Sugar and Rice 
∏=
j
jtitit
jppppqs ααα 10
;   01 >α , 0<jα    1 
Livestock Products 
Meat: Beef and Veal, Sheepmeat, Pig Meat 
∏∏=
j k
ktjtitit
kj pcppppqs αααα 10
;  01 >α , 0<jα , 0<kα   2 
Dairy: Raw Milk 
∏∏=
j k
ktjtitit
kj pcppppqs αααα 10
;  01 >α , 0<jα , 0<kα   3 
 
Dairy: Liquid Milk, Butter, Cheese, Whole Milk Powder, Skim Milk Powder 
∏=
j
jtRMtitit
jRM ppqsppqs αααα 10
;  01 >α , 0>RMα , 0<jα   4 
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Poultry: Eggs and Poultry Meat 
∏∏=
j k
ktjtitit
kj pcppppqs αααα 10
;  01 >α , 0<jα , 0<kα   5 
 
Variables and Parameters: 
i:  own commodity 
j:  substitutes  
k:  feed products  
qs:  domestic supply  
pp:  producer price 
pc:  consumer price 
 
In the LTEM, the supply and demand responses in the dairy sector are modelled explicitly, as 
the sector is affected by various domestic and border policies in world markets.   
 
Domestic Demand 
Demand is simulated in the LTEM using a uniform CD aggregate domestic demand function, 
again for each country and commodity. The demand relationship is derived from the 
consumers’ utility maximisation behaviour under perfect competition assumption. Demand is 
therefore specified as a function of the own- and substitute prices, per capita income and the 
population growth rate. Income and population are exogenous to the model. The demand 
equations for the main groups of commodities are shown below: 
 
Crops 
Wheat and Coarse Grains 
j
j
jtttitfoti pcpoppincpcqd
βββββ ∏= 3210,
; 01 <β , 02 >β , 03 >β , 0>jβ  6 
qj
qt
j q
jtitfeti qspcpcqd
ββββ ∏∏= 10,
;  01 <β , 0>jβ , 0>qβ   7 
Oils and Oilseeds 
j
j
jtttitfoti pcpoppincpcqd
βββββ ∏= 3210,
; 01 <β , 02 >β , 03 >β , 0>jβ  8 
qj
qt
j q
jtitfeti qspcpcqd
ββββ ∏∏= 10,
;  01 <β , 0>jβ , 0>qβ   9 
rOS
r
rtOStprtOS pppcqd
βββ ∏= 0,
;  0<OSβ , 0>rβ    10 
Sugar and Rice 
321
0,
ββββ ttitfoti poppincpcqd = ;  01 <β , 02 >β , 03 >β   11 
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Livestock Products 
Meat: Beef and Veal, Sheepmeat, Pig Meat 
j
j
jttitit pcpoppincpcqd
βββββ ∏= 3210
; 01 <β , 02 >β , 03 >β , 0>jβ  12 
Dairy: Liquid Milk, Butter, Cheese, Skim Milk Powder, Whole Milk Powder 
j
j
jttitit pcpoppincpcqd
βββββ ∏= 3210
; 01 <β , 02 >β , 03 >β , 0>jβ  13 
Poultry: Eggs, Poultry Meat 
j
j
jttitit pcpoppincpcqd
βββββ ∏= 3210
; 01 <β , 02 >β , 03 >β , 0>jβ  14 
 
Variables and Parameters: 
i:  own commodity 
j:  substitutes  
pc:  consumer price 
pinc:  per capita income 
pop:  population 
ppr:  producer price of oilmeals and oil 
qdfe:  domestic feed demand 
qdfo:  domestic food demand 
qdOS:  domestic processing demand for oilseeds 
qsq:  domestic supply of meat, poultry products and raw milk 
 
Stocks 
Stocks are modelled using the theory of inventory demand (FAPRI, 1989). The main motive 
for the stock demand is transaction rather than speculation. The equations are shown below: 
 
Crops 
Wheat and Coarse Grains, Oils and Oilseeds, Sugar and Rice 
Livestock Products 
Meat, Dairy, Poultry 
1
0
ϕϕ itit qsqe = ;    01 >ϕ      15 
1ϕϕ itiit qdqe = ;    01 >ϕ      16 
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Variables and Parameters: 
i:  own commodity 
qd:  domestic demand (can be food, feed or processing) 
qe:  stocks 
qs:  domestic supply 
 
Net Trade 
As mentioned previously, net trade in the LTEM is an economic identity based on the 
difference between domestic supply and the sum of various demand amounts as well as 
stocks.  Stocks are incorporated as a change from the previous year.  The net trade equations 
are shown below: 
 
Crops 
Wheat and Coarse Grains, Oils and Oilseeds, Sugar and Rice 
Livestock Products 
Meat, Dairy, Poultry 
 
)()( ,,, itprtifetifotiitit qeqdqdqdqsqt Δ−++−=      17 
 
Variables and Parameters: 
i:  own commodity 
qdfe:  domestic feed demand 
qdfo:  domestic food demand 
qt:  quantity traded 
 
Raw milk is not traded as its supply is assumed to be completely exhausted in the production 
of the other dairy products.   
 
Prices 
Domestic consumer and producer prices in the LTEM are determined by the world trade 
prices for each commodity, as well as the domestic and border policies applied in each 
country.  Equations 19 and 20 illustrate this price transmission mechanism.  The trade price 
of a commodity is determined by the world market price of that commodity, as shown in 
equation 18.  Producer and consumer support and subsidy measures are incorporated into the 
price equations through the use of commodity based price wedge variables, which 
differentiate the domestic and trade prices of each commodity.  These variables may include 
per unit direct payments, inputs subsidies, general services expenditures and other market 
subsidy payments to producers, as well as a consumer market subsidy, as shown in equations 
21 and 22.  These policies are all calculated per tonne of production and consumption, 
following the concept of producer and consumer subsidy equivalents (PSE and CSEs) (Cahill 
& Legg, 1990). 
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Crops 
Wheat and Coarse Grains, Oils and Oilseeds, Sugar and Rice 
Livestock Products 
Meat, Dairy, Poultry 
 
τε
⎟⎠
⎞⎜⎝
⎛=
ex
WDppt itit
         18 
tititit tctpptpp ++=  ;   0=tc      19 
tititit tctcptpc ++=  ;   0=tc      20 
)( ititititititit smsgsisdtpptpp +++++=        21 
itititit cmtcptpc ++=          22 
 
Variables and Parameters: 
i:  own commodity 
cm:  consumer market subsidy 
ex:  exchange rate 
pc:  consumer price 
pp:  producer price 
pt:  trade price  
sd:  direct payments 
sg:  general services expenditure 
si:  input subsidy 
sm:  other producer market subsidy 
tci:  export subsidies 
tc:  transportation costs 
tpi:  import tariffs 
WDp:  world price 
 
The model works by simulating the commodity-based clearing price in world markets on the 
domestic quantities and prices, which may or may not be under the effect of policy changes, 
in each country. Excess domestic supply or demand in each country spills over onto the world 
market to determine world prices. The world market-clearing price is determined at the level 
that equilibrates the total excess demand and supply of each commodity in the world market, 
by using a non-linear optimisation algorithm (Newton’s global or search algorithm). 
 
All prices in the LTEM are in US dollars, removing any exchange rate effects. 
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Supply and Demand Side Parameters: 
 
Table A5.1. Supply Side Parameters: Own- and Cross-Price Elasticities 
 
Country Producer Price Consumer Price
Commodity Raw Milk Beef and Veal Sheepmeat Wool Wheat Coarse Grains Oil Seeds Oil Meals
Raw Milk
Australia 0.50 -0.04 -0.01 -0.01 -0.10 -0.13 -0.02
EU (15) 0.50 0.11 -0.11 -0.20 -0.09
New Zealand 0.80 0.06 -0.04 -0.52 -0.01 -0.09
USA 0.40 0.05 -0.01 -0.19 -0.01 -0.04
Country Producer Price
Commodity Liquid Milk Raw Milk Butter Cheese Skim Milk P. Whole Milk P.
Liquid Milk
Australia 0.50 -0.17 -0.03 -0.05 -0.03 -0.02
EU (15) 0.50 -0.12 -0.05 -0.10 -0.01 -0.02
New Zealand 0.50 -0.06 -0.08 -0.07 -0.08
USA 0.30 -0.04 -0.01 -0.03 -0.01
Butter
Australia -0.07 -0.24 0.80 -0.40 0.30 -0.19
EU (15) -0.07 -0.23 0.59 -0.12 0.06 -0.03
New Zealand -0.01 -0.03 0.15 0.10
USA -0.07 -0.25 0.74 -0.29 0.10 -0.03
Cheese
Australia -0.04 0.07 -0.12 0.44 -0.15
EU (15) -0.03 0.01 -0.03 0.29 -0.01 -0.02
New Zealand -0.01 0.05 -0.01 0.17
USA -0.02 0.06 -0.03 0.26 -0.04 -0.02
Skim Milk Powder
Australia -0.07 -0.24 0.80 -0.40 0.30 -0.19
EU (15) -0.07 -0.23 0.59 -0.12 0.06 -0.03
New Zealand -0.01 -0.03 0.15 0.10
USA -0.07 -0.25 0.74 -0.29 0.10 -0.03
Whole Milk Powder
Australia -0.08 -0.30 -0.25 -0.02 -0.07 0.91
EU (15) -0.14 -0.32 -0.12 -0.40 1.18
New Zealand -0.01 0.06 0.16
USA -0.22 -0.31 -1.54 2.29
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Table A5.2. Demand Side Parameters: Own-, Cross-Price and Income Elasticities 
  
Country Producer Price Income
Commodity Liquid Milk Butter Cheese Skim Milk P. Whole Milk P.
Liquid Milk
Australia -0.23 0.01 -0.03
EU (15) -0.50 0.01 0.05
New Zealand -0.20 0.09
USA -0.30 0.01 0.02 0.01 -0.01
Butter
Australia -0.45 0.05 0.01 0.24
EU (15) -0.48 0.05 0.01 0.30
New Zealand -0.45 0.01 0.19
USA 0.06 -0.70 0.01 0.01 0.10
Cheese
Australia 0.01 -0.40 0.31
EU (15) 0.01 -0.45 0.35
New Zealand 0.01 -0.45 0.42
USA 0.01 -0.55 0.40
Skim Milk Powder
Australia 0.02 0.01 -0.45 0.04 -0.04
EU (15) 0.02 0.03 0.02 -0.40 0.03 0.30
New Zealand -0.40 0.18
USA 0.03 0.01 0.03 -0.55 0.01 0.35
Whole Milk Powder
Australia 0.07 0.05 -0.45 -0.04
EU (15) 0.01 0.04 0.10 -0.50 0.30
New Zealand 0.05 0.02 -0.45 0.18
USA 0.08 0.15 -0.70 0.38
